FUKUOKA Kazuya

Researcher Information

Degree

• MD PhD（1990/10 Nara Medical University）

J-Global ID

• 200901095382789473

Research Interests

• 呼吸器内科学   癌化学療法   臨床腫瘍学   Medical Oncology   

Research Areas

• Life sciences / Tumor diagnostics and therapeutics
• Life sciences / Hematology and oncology
• Life sciences / Respiratory medicine

Academic & Professional Experience

• 2019/10 - Today  Kindai UniversityGenome Medical Center, Kindai University HospitalProfessor
• 2018/10 - Today  Kindai University近畿大学病院 臨床研究センターセンター長
• 2016/04 - Today  Kindai University近畿大学病院 臨床研究センター臨床教授
• 2018/10 - 2022/09  Kindai Universityライフサイエンス研究所副所長
• 2015/04 - 2016/03  Kindai University近畿大学病院 臨床研究センター准教授
• 2014/04 - 2015/03  Kindai University近畿大学医学部 堺病院 腫瘍内科准教授
• 2005/07 - 2013/03  兵庫医科大学内科学呼吸器・RCU科 胸部腫瘍学講座 がんセンター准教授
• 1998/07 - 2005/06  奈良県立医科大学内科学第二講座助教・講師
• 1995/04 - 1998/03  国立がんセンター研究所薬効試験部リサーチレジデント
• 1994/07 - 1995/03  奈良県立医科大学附属病院第二内科非常勤医
• 1990/07 - 1994/06  大阪府済生会吹田病院内科副医長

Education

• 1986/04 - 1990/03  Nara Medical University  医学研究科  内科学II
• 1980/04 - 1986/03  Nara Medical University  Medical Faculty  Medical Department
• 1977/04 - 1980/03  大阪星光学院高等学校

Association Memberships

• THE JAPANESE SOCIETY OF CLINICAL PHARMACOLOGY AND THERAPEUTICS   THE JAPAN LUNG CANCER SOCIETY   THE JAPAN SOCIETY FOR RESPIRATORY ENDOSCOPY   Japanese Society of Medical Oncology   American Society of Clinical Oncology   日本呼吸器学会   日本内科学会   International Association for the Study of Lung Cancer   American Association for Cancer Research   

Published Papers

• がん遺伝子パネル検査FoundationOneによる肺癌の遺伝子変異の測定

  米阪 仁雄; 高濱 隆幸; 黒崎 隆; 川中 雄介; 金村 宙昌; 磯本 晃佑; 鈴木 慎一郎; 三谷 誠一郎; 中川 和彦; 白石 直樹; 小田 いつき; 西郷 和真; 池川 敦子; 福岡 和也; 武田 真幸; 西尾 和人

  肺癌 (NPO)日本肺癌学会 62 (5) 439 - 439 0386-9628 2022/10
• がん遺伝子パネル検査FoundationOneによる肺癌の遺伝子変異の測定

  米阪 仁雄; 高濱 隆幸; 黒崎 隆; 川中 雄介; 金村 宙昌; 磯本 晃佑; 鈴木 慎一郎; 三谷 誠一郎; 中川 和彦; 白石 直樹; 小田 いつき; 西郷 和真; 池川 敦子; 福岡 和也; 武田 真幸; 西尾 和人

  肺癌 (NPO)日本肺癌学会 62 (5) 439 - 439 0386-9628 2022/10
• Current Status and Future Perspective of Precision Medicine in Oncology

  Takayuki Takahama; Kimio Yonesaka; Naoki Shiraishi; Itsuki Oda; Atsuko Ikegawa; Kazumasa Saigoh; Kazuya Fukuoka; Kazuhiko Nakagawa

  Medical Journal of Kindai University 近畿大学医学会 47 (1・2) 19 - 25 0385-8367 2022/06 [Refereed]
   

  近年、次世代シークエンサー(NGS)の臨床応用が進み、がんに生じた遺伝子変化を網羅的に解析することが可能となった。包括的がんゲノムプロファイリング(CGP)検査を実施することで、がん化に関わる原因遺伝子が明らかになると同時に、治療の選択肢が増え、恩恵を受ける症例が出てきている。近畿大学病院ゲノム医療センターでは、2019年に日本においてCGP検査が保険適応を受けて以降、がん関連遺伝子検査がスムーズに進むよう業務を行っている。エキスパートパネルの運営を通して、患者や主治医への適切な遺伝子解析結果を届けることを目標とし、また二次的所見への対応などを行ってきた。本稿では、CGP検査の現状について概説し、特に課題の多い出口戦略について、治療への到達率を高めるために必要なことは何か考察をしたい。(著者抄録)
  ダウンロード
• Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary.

  J Tanizaki; K Yonemori; K Akiyoshi; H Minami; H Ueda; Y Takiguchi; Y Miura; Y Segawa; S Takahashi; Y Iwamoto; Y Kidera; K Fukuoka; A Ito; Y Chiba; K Sakai; K Nishio; K Nakagawa; H Hayashi

  Annals of oncology : official journal of the European Society for Medical Oncology 33 (2) 216 - 226 2022/02 

  BACKGROUND: Cancer of unknown primary (CUP) has a poor prognosis. Given the recent approval of immune checkpoint inhibitors for several cancer types, we carried out a multicenter phase II study to assess the efficacy of nivolumab for patients with CUP. PATIENTS AND METHODS: Patients with CUP who were previously treated with at least one line of systemic chemotherapy constituted the principal study population. Previously untreated patients with CUP were also enrolled for exploratory analysis. Nivolumab (240 mg/body) was administered every 2 weeks for up to 52 cycles. The primary endpoint was objective response rate in previously treated patients as determined by blinded independent central review according to RECIST version 1.1. RESULTS: Fifty-six patients with CUP were enrolled in the trial. For the 45 previously treated patients, objective response rate was 22.2% [95% confidence interval (CI), 11.2% to 37.1%], with a median progression-free survival and overall survival of 4.0 months (95% CI, 1.9-5.8 months) and 15.9 months (95% CI, 8.4-21.5 months), respectively. Similar clinical benefits were also observed in the 11 previously untreated patients. Better clinical efficacy of nivolumab was apparent for tumors with a higher programmed death-ligand 1 expression level, for those with a higher tumor mutation burden, and for microsatellite instability-high tumors. In contrast, no differences in efficacy were apparent between tumor subgroups based on estimated tissue of origin. Adverse events were consistent with the known safety profile of nivolumab. No treatment-related death was observed. CONCLUSIONS: Our results demonstrate a clinical benefit of nivolumab for patients with CUP, suggesting that nivolumab is a potential additional therapeutic option for CUP.
  ダウンロード
• The Achievements for ”7-University Joint Project of Training Plan for Oncology Professionals”

  福岡和也; 中川和彦

  癌と化学療法 49 (6) 0385-0684 2022
• Recent topics in the development of anticancer drugs

  Hirase C Sano; K; Fukuoka K

  （Med J Kindai Univ 46 (1-2) 13 - 31 2021/06 [Refereed]
  
• Clinical application of the FoundationOne CDx Assay to therapeutic decision‐making for patients with advanced solid tumors

  Masayuki Takeda; Takayuki Takahama; Kazuko Sakai; Shigeki Shimizu; Satomi Watanabe; Hisato Kawakami; Kaoru Tanaka; Chihiro Sato; Hidetoshi Hayashi; Yoshikane Nonagase; Kimio Yonesaka; Naoki Takegawa; Tatsuya Okuno; Takeshi Yoshida; Soichi Fumita; Shinichiro Suzuki; Koji Haratani; Kazumasa Saigoh; Akihiko Ito; Tetsuya Mitsudomi; Hisashi Handa; Kazuya Fukuoka; Kazuhiko Nakagawa; Kazuto Nishio

  The Oncologist Wiley 26 (4) e588-e596  1083-7159 2021/04 

  BACKGROUND: Implementation of personalized medicine requires the accessibility of tumor molecular profiling in order to allow prioritization of appropriate targeted therapies for individual patients. Our aim was to study the role of comprehensive genomic profiling assays that may inform treatment recommendations for patients with solid tumors. MATERIALS AND METHODS: We performed a prospective study to evaluate the feasibility of application of the FoundationOne CDx panel-which detects substitutions, insertions and deletions, and copy number alterations in 324 genes, select gene rearrangements, and genomic signatures including microsatellite instability and tumor mutation burden (TMB)-to patients with advanced or recurrent solid tumors before its approval in Japan. RESULTS: A total of 181 samples were processed for genomic testing between September 2018 and June 2019, with data being successfully obtained for 175 of these samples, yielding a success rate of 96.7%. The median turnaround time was 41 days (range, 21-126 days). The most common known or likely pathogenic variants were TP53 mutations (n = 113), PIK3CA mutations (n = 33), APC mutations (n = 32), and KRAS mutations (n = 29). Among the 153 patients assessed for TMB, the median TMB was 4 mutations/Mb, and tumors with a high TMB (≥10 mutations/Mb) were more prevalent for lung cancer (11/32) than for other solid tumor types (9/121, Fisher's exact test p < .01). No clear trend toward increased efficacy for immune checkpoint inhibitor (ICI) monotherapy or ICI combination chemotherapy in patients with a high programmed cell death-ligand 1 tumor proportion score or a high TMB was apparent. Among the 174 patients found to harbor known or likely pathogenic actionable alterations, 24 individuals (14%) received matched targeted therapy. CONCLUSION: The FoundationOne CDx assay was performed with formalin-fixed, paraffin-embedded tumor specimens with a success rate of >95%. Such testing may inform the matching of patients with cancer with investigational or approved targeted drugs. IMPLICATIONS FOR PRACTICE: This prospective cohort study was initiated to investigate the feasibility and utility of clinical application of FoundationOne CDx. A total of 181 samples were processed for genomic testing between September 2018 and June 2019, with data being successfully obtained for 175 of these samples, yielding a success rate of 96.7%, and 24 individuals (14%) received matched targeted therapy.
• Mesothelin is useful biomarker and therapeutic target of malignant pleural mesothelioma

  FUKUOKA Kazuya

  Respiratory Medicine 36 (1) 69 - 74 2019/07 [Invited]
  
• New era for next-generation sequencing in Japan.

  Masayuki Takeda; Kazuko Sakai; Takayuki Takahama; Kazuya Fukuoka; Kazuhiko Nakagawa; Kazuto Nishio

  Cancers 11 (6) 2019/05 [Refereed]
   

  : Recent progress in understanding the molecular basis of cancer-including the discovery of cancer-associated genes such as oncogenes and tumor suppressor genes-has suggested that cancer can become a treatable disease. The identification of driver oncogenes such as EGFR, ALK, ROS1, BRAF and HER2 has already been successfully translated into clinical practice for individuals with solid tumor. Next-generation sequencing (NGS) technologies have led to the ability to test for multiple cancer-related genes at once with a small amount of cells and tissues. In Japan, several hospitals have started NGS-based mutational profiling screening in patients with solid tumor in order to guide patients to relevant clinical trials. The Ministry of Health, Labor, and Welfare of Japan has also approved several cancer gene panels for use in clinical practice. However, there is an urgent need to develop a medical curriculum of clinical variant interpretation and reporting. We review recent progress in the implementation of NGS in Japan.
• Trend of Cancer Genome Medicine in Japan

  FUKUOKA Kazuya

  Med J Kindai Univ 43 (1-2) 11 - 16 2018/06 [Refereed]
  
• Biomarkers for diagnosis of malignant mesothelioma focused on soluble mesothelin-related peptides

  FUKUOKA Kazuya

  医学のあゆみ 263 (13) 1145 - 1150 2017/12
• Institutional Base of Cancer Clinical Trials in Japan

  FUKUOKA Kazuya

  Med J Kindai Univ 42 (3-4) 91 - 97 2017/12 [Refereed]
  
• Recent Trend of Clinical Study in Japan

  FUKUOKA Kazuya

  Med J Kindai Univ 41 (3-4) 69 - 75 2016/12 [Refereed]
  
• Afatinib投与によって、原発巣にpathological CRが得られたEGFR遺伝子変異陽性(del.19)肺腺癌の1例

  岡田 あすか; 福岡 和也; 西尾 和人; 高橋 慶一; 片山 公実子; 小口 展生; 村上 伸介; 竹中 英昭; 長 澄人; 鈴木 啓史; 西村 元宏

  肺癌 (NPO)日本肺癌学会 56 (6) 856 - 856 0386-9628 2016/11
• Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial)

  Seiki Hasegawa; Morihito Okada; Fumihiro Tanaka; Takeharu Yamanaka; Toshinori Soejima; Norihiko Kamikonya; Tohru Tsujimura; Kazuya Fukuoka; Kohei Yokoi; Takashi Nakano

  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY SPRINGER JAPAN KK 21 (3) 523 - 530 1341-9625 2016/06 [Refereed]
   

  We conducted a prospective multi-institutional study to determine the feasibility of trimodality therapy (TMT) comprising induction chemotherapy followed by extrapleural pneumonectomy (EPP) and radiation therapy in Japanese patients with malignant pleural mesothelioma (MPM). Major eligibility criteria were histologically confirmed diagnosis of MPM, including clinical subtypes T0-3, N0-2, M0 disease; no prior treatment for the disease; age 20-75 years; Eastern Cooperative Oncology Group performance status 0 or 1; predicted postoperative forced expiratory volume > 1000 ml in 1 s; written informed consent. Treatment methods comprised induction chemotherapy using pemetrexed (500 mg/m(2)) plus cisplatin (60 mg/m(2)) for three cycles, followed by EPP and postoperative hemithoracic radiation therapy (54 Gy). Primary endpoints were macroscopic complete resection (MCR) rate for EPP and treatment-related mortality for TMT. Forty-two eligible patients were enrolled: median age 64.5 (range 43-74) years; M:F = 39:3, clinical stage I:II:III = 14:13:15; histological type epithelioid were sarcomatoid; biphasic; others = 28:1:9:4. Of 42 patients, 30 completed EPP with MCR and 17 completed TMT. The trial met the primary endpoints, with an MCR rate of 71 % (30/42) and treatment-related mortality of 9.5 % (4/42). Overall median survival time and 2-year survival rate for 42 registered patients were 19.9 months and 42.9 %, respectively. Two-year relapse-free survival rate of 30 patients who completed EPP with MCR was 37.0 %. This phase II study met the predefined primary endpoints, but its risk/benefit ratio was not satisfactory.
• A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors

  Toshio Shimizu; Kazuya Fukuoka; Masayuki Takeda; Tutomu Iwasa; Takeshi Yoshida; Joanna Horobin; Mitchell Keegan; Lou Vaickus; Ajit Chavan; Mahesh Padval; Kazuhiko Nakagawa

  CANCER CHEMOTHERAPY AND PHARMACOLOGY SPRINGER 77 (5) 997 - 1003 0344-5704 2016/05 [Refereed]
   

  Purpose VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and proline-rich tyrosine kinase-2. This phase 1 study evaluated the safety and tolerability, pharmacokinetics, and clinical activity of VS-6063 in Japanese subjects with advanced solid tumor malignancies in a first-in-Asian study setting. Methods VS-6063 was administered orally twice daily (b.i.d.) in 21-day cycles to cohorts of three subjects each with a standard 3 + 3 dose-escalation design until disease progression or unacceptable toxicity. Blood samples for pharmacokinetics were collected on Day 1 and 15. The assessments were performed using CTCAE v4.0 for adverse events (AEs), and the Response Evaluation Criteria In Solid Tumors, version v1.1 (RECIST v1.1) for tumor response. Results Nine patients were treated across three dose levels (200-600 mg BID). No dose-limiting toxicities were observed at any dose level. Most frequent treatment-related AEs were Grade 1/2 unconjugated hyperbilirubinemia, fatigue, decreased appetite, and diarrhea. Only one subject in the 200 mg BID cohort experienced reversible and transient Grade 3 unconjugated hyperbilirubinemia. PK analyses confirmed that the exposure at the recommended Phase 2 dose (RP2D) of 400 mg BID was comparable with exposures previously reported in non-Japanese subjects. Durable stable disease of approximately 24 weeks was confirmed in two subjects (malignant mesothelioma and rectal cancer). Conclusions VS-6063 was well tolerated at all dose levels investigated in this first-in-Asian study. These data support the administration of VS-6063 to Japanese subjects at the RP2D in clinical trials involving solid tumor malignancies.
• Small cell lung cancer with isolated unitonsillar metastasis successfully treated with chemotherapy.

  FUKUOKA Kazuya

  Arch Cancer Res. 4 (1) 62 - 65 2016/03 [Refereed]
  
• Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

  Lee M. Krug; Hedy L. Kindler; Hilary Calvert; Christian Manegold; Anne S. Tsao; Dean Fennell; Ronny Ohman; Ruth Plummer; Wilfried E. E. Eberhardt; Kazuya Fukuoka; Rabab M. Gaafar; Jean-Jacques Lafitte; Gunnar Hillerdal; Quincy Chu; Wieneke A. Buikhuisen; Gregory M. Lubiniecki; Xing Sun; Margaret Smith; Paul Baas

  LANCET ONCOLOGY ELSEVIER SCIENCE INC 16 (4) 447 - 456 1470-2045 2015/04 [Refereed]
   

  Background Vorinostat is a histone deacetylase inhibitor that changes gene expression and protein activity. On the basis of the clinical benefit reported in patients with malignant pleural mesothelioma treated in a phase 1 study of vorinostat, we designed this phase 3 trial to investigate whether vorinostat given as a second-line or third-line therapy improved patients' overall survival. Methods This double-blind, randomised, placebo-controlled trial was done in 90 international centres. Patients with measurable advanced malignant pleural mesothelioma and disease progression after one or two previous systemic regimens were eligible. After stratification for Karnofsky performance status, histology, and number of previous chemotherapy regimens, patients were randomly assigned (1: 1) by use of an interactive voice response system with a block size of four to either treatment with vorinostat or placebo. Patients received oral vorinostat 300 mg (or matching placebo) twice daily on days 1, 2, 3, 8, 9, 10, 15, 16, and 17 of a 21-day cycle. The primary endpoints were overall survival and safety and tolerability of vorinostat. The primary efficacy comparison was done in the intention-to-treat population, and safety and tolerability was assessed in the treated population. This trial is registered with ClinicalTrials.gov, number NCT00128102. Findings From July 12, 2005, to Feb 14, 2011, 661 patients were enrolled and randomly assigned to receive either vorinostat (n= 329) or placebo (n= 332) and included in the intention-to-treat analysis. Median overall survival for vorinostat was 30.7 weeks (95% CI 26.7-36.1) versus 27.1 weeks (23.1-31.9) for placebo (hazard ratio 0.98, 95% CI 0.83-1.17, p= 0.86). The most common grade 3 or worse adverse events for patients treated with vorinostat were fatigue or malaise (51 [16%] patients in the vorinostat group vs 25 [8%] in the placebo group]) and dyspnoea (35 [11%] vs 45 [14%]). Interpretation In this randomised trial, vorinostat given as a second-line or third-line therapy did not improve overall survival and cannot be recommended as a therapy for patients with advanced malignant pleural mesothelioma.
• Isolated metastases of hepatocellular carcinoma in the left atrium, unresponsive to treatment with sorafenib.

  Fukuoka K; Masachika E; Honda M; Tsukamoto Y; Nakano T

  Molecular and clinical oncology 3 (2) 397 - 399 2049-9450 2015/03 [Refereed]
  
• Biallelic germline and somatic mutations in malignant mesothelioma: Multiple mutations in transcription regulators including mSWI/SNF genes

  Yoshie Yoshikawa; Ayuko Sato; Tohru Tsujimura; Taiichiro Otsuki; Kazuya Fukuoka; Seiki Hasegawa; Takashi Nakano; Tomoko Hashimoto-Tamaoki

  INTERNATIONAL JOURNAL OF CANCER WILEY-BLACKWELL 136 (3) 560 - 571 0020-7136 2015/02 [Refereed]
   

  We detected low levels of acetylation for histone H3 tail lysines in malignant mesothelioma (MM) cell lines resistant to histone deacetylase inhibitors. To identify the possible genetic causes related to the low histone acetylation levels, whole-exome sequencing was conducted with MM cell lines established from eight patients. A mono-allelic variant of BRD1 was common to two MM cell lines with very low acetylation levels. We identified 318 homozygous protein-damaging variants/mutations (18-78 variants/mutations per patient); annotation analysis showed enrichment of the molecules associated with mammalian SWI/SNF (mSWI/SNF) chromatin remodeling complexes and co-activators that facilitate initiation of transcription. In seven of the patients, we detected a combination of variants in histone modifiers or transcription factors/co-factors, in addition to variants in mSWI/SNF. Direct sequencing showed that homozygous mutations in SMARCA4, PBRM1 and ARID2 were somatic. In one patient, homozygous germline variants were observed for SMARCC1 and SETD2 in chr3p22.1-3p14.2. These exhibited extended germline homozygosity and were in regions containing somatic mutations, leading to a loss of BAP1 and PBRM1 expression in MM cell line. Most protein-damaging variants were heterozygous in normal tissues. Heterozygous germline variants were often converted into hemizygous variants by mono-allelic deletion, and were rarely homozygous because of acquired uniparental disomy. Our findings imply that MM might develop through the somatic inactivation of mSWI/SNF complex subunits and/or histone modifiers, including BAP1, in subjects that have rare germline variants of these transcription regulators and/or transcription factors/co-factors, and in regions prone to mono-allelic deletion during oncogenesis. What's new? Malignant mesotheliomas (MM) are highly aggressive neoplasms largely arising from asbestos exposure. Here, the authors investigated possible genetic causes for the low histone acetylation levels observed in MM cell lines resistant to histone deacetylase inhibitors. Using whole-exome sequencing, they are the first to present MM cases without history of familial MM with germline variants/mutations and somatic inactivation in multiple genes including mSWI/SNF. The genes containing rare germline variants/mutations were not limited to common tumor suppressor genes, and the molecular functions of these genes were related to transcriptional regulation. Such germline variants/mutations could be used as markers for MM predisposition.
• Suppression of heme oxygenase-1 activity reduces airway hyperresponsiveness and inflammation in a mouse model of asthma

  Kozo Kuribayashi; Shin-ichiro Iida; Yasuhiro Nakajima; Norihiko Funaguchi; Chiharu Tabata; Kazuya Fukuoka; Yoshihiro Fujimori; Daizo Ihaku; Takashi Nakano

  JOURNAL OF ASTHMA TAYLOR & FRANCIS LTD 52 (7) 662 - 668 0277-0903 2015 [Refereed]
   

  Objective: Carbon monoxide (CO) levels in expired gas are higher in patients with bronchial asthma than in healthy individuals. Heme oxygenase-1 (HO-1) is a rate-limiting enzyme that catalyzes the degradation of heme to yield biliverdin, CO and free iron. Thus, HO-1 is implicated in the pathogenesis of bronchial asthma. However, whether HO-1 expression and activity in lung tissue are related to allergic airway inflammation remains unclear. We investigated whether expression of HO-1 is related to allergic airway inflammation in lungs and whether HO-1 could influence airway hyperresponsiveness and eosinophilia in mice sensitized to ovalbumin (OVA). Methods: C57BL/6 mice immunized with OVA were challenged thrice with an aerosol of OVA every second day for 8 days. HO-1-positive cells were identified by immunostaining in lung tissue, and zinc protoporphyrin (Zn-PP), a competitive inhibitor of HO-1, was administered intraperitoneally to OVA-immunized C57BL/6 mice on day 23 (day before inhalation of OVA) and immediately before inhalation on the subsequent 4 days (total five doses). Mice were analyzed for effects of HO-1 on AHR, inflammatory cell infiltration and cytokine levels in lung tissue. Ethical approval was obtained from the concerned institutional review board. Results: Number of HO-1-positive cells increased in the subepithelium of the bronchi after OVA challenge, and HO-1 localized to alveolar macrophages. Zn-PP clearly inhibited AHR, pulmonary eosinophilia and IL-5 and IL-13 expression in the lung tissue. Conclusion: Expression of HO-1 is induced in lung tissue during attacks of allergic bronchial asthma, and its activity likely amplifies and prolongs allergic airway inflammation.
• Functional Alteration of Natural Killer Cells and Cytotoxic T Lymphocytes upon Asbestos Exposure and in Malignant Mesothelioma Patients.

  Yasumitsu Nishimura; Naoko Kumagai-Takei; Hidenori Matsuzaki; Suni Lee; Megumi Maeda; Takumi Kishimoto; Kazuya Fukuoka; Takashi Nakano; Takemi Otsuki

  BioMed research international 2015 238431 - 238431 2314-6133 2015 [Refereed]
   

  Malignant mesothelioma is caused by exposure to asbestos, which is known to have carcinogenic effects. However, the development of mesothelioma takes a long period and results from a low or intermediate dose of exposure. These findings have motivated us to investigate the immunological effects of asbestos exposure and analyze immune functions of patients with mesothelioma and pleural plaque, a sign of exposure to asbestos. Here, we review our knowledge concerning natural killer (NK) cells and cytotoxic T lymphocytes (CTL). NK cells showed impaired cytotoxicity with altered expression of activating receptors upon exposure to asbestos, while induction of granzyme(+) cells in CD8(+) lymphocytes was suppressed by asbestos exposure. It is interesting that a decrease in NKp46, a representative activating receptor, is common between NK cells in PBMC culture with asbestos and those of mesothelioma patients. Moreover, it was observed that CD8(+) lymphocytes may be stimulated by some kind of "nonself" cells in plaque-positive individuals and in mesothelioma patients, whereas CTL in mesothelioma is impaired by poststimulation maintenance of cytotoxicity. These findings suggest that analysis of immunological parameters might contribute to the evaluation of health conditions of asbestos-exposed individuals and to a greater understanding of the pathology of malignant mesothelioma.
• Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM)

  Kazue Yoneda; Fumihiro Tanaka; Nobuyuki Kondo; Masaki Hashimoto; Teruhisa Takuwa; Seiji Matsumoto; Yoshitomo Okumura; Noriaki Tsubota; Ayuko Sato; Tohru Tsujimura; Kozo Kuribayashi; Kazuya Fukuoka; Chiharu Tabata; Takashi Nakano; Seiki Hasegawa

  ANNALS OF SURGICAL ONCOLOGY SPRINGER 21 S472 - S480 1068-9265 2014/12 [Refereed]
   

  Purpose. To investigate the diagnostic and prognostic value of circulating tumor cells (CTCs), a potential surrogate of micrometastasis, in malignant pleural mesothelioma (MPM). Methods. We prospectively evaluated CTCs in 7.5 mL of peripheral blood sampled from patients with a suspicion of MPM. A semiautomated system was used to capture CTCs with an antibody against the epithelial cell adhesion molecule. Results. Of 136 eligible patients, 32 were finally diagnosed with nonmalignant diseases (NM), and 104 had MPM. CTCs were detected in 32.7 % (34 of 104) of MPM patients but in only 9.4 % (3 of 32) of NM patients (P = 0.011). The CTC count was significantly higher in MPM patients than in NM patients (P = 0.007), and a receiver operating characteristic (ROC) curve analysis showed an insufficient capability of the CTC test in discrimination between MPM and NM, with an area under ROC curve of 0.623 (95 % confidence interval, 0.523-0.723; P = 0.036). Among MPM patients, CTCs were more frequently detected in patients with epithelioid subtype (39.7 %, 31 of 78) than in those with nonepithelioid subtypes (11.5 %, 3 of 26; P = 0.016). Positive CTCs (CTC count >= 1) were a significant factor to predict a poor prognosis among epithelioid patients (median overall survival, 22.3 months for positive CTCs vs. 12.6 months for negative CTCs; P = 0.004) and not in nonepithelioid patients (P = 0.649). A multivariate analysis showed that positive CTCs were a significant and independent factor to predict a poor prognosis (hazard ratio, 2.904; 95 % confidence interval, 1.530-5.511; P = 0.001) for epithelioid MPM patients. Conclusions. CTC was a promising marker in diagnosis and prediction of prognosis in MPM, especially in epithelioid MPM.
• Cell-Adhesion Molecule Expression and the Proliferation of Malignant Mesothelioma: A Post-Mortem Examination

  Kozo Kuribayashi; Hiroshi Hirano; Keiji Nakasho; Hideki Ohyama; Koji Yamanegi; Chiharu Tabata; Kazuya Fukuoka; Yoshihiro Fujimori; Takashi Nakano

  ANTICANCER RESEARCH INT INST ANTICANCER RESEARCH 34 (6) 3061 - 3065 0250-7005 2014/06 [Refereed]
   

  Aim: In order to determine if metastatic malignant mesothelioma cells are more aggressive than primary malignant mesothelioma cells, an analysis of the expression of the adhesion molecules E-cadherin and beta-catenin, concomitant with an assessment of the proliferative activity at primary and metastatic sites, was conducted in post-mortem samples. Materials and Methods: E-cadherin or beta-catenin expression was graded according to the percentage of positively-stained tumor cells. The proliferative activity was quantified by the Ki-67 labeling index. Results: Histologically, the majority of metastatic tumors matched the primary tumor. In the epithelioid component of primary tumors, E-cadherin and beta-catenin expression ranged from 1+ to 4+. Conclusion: Malignant mesothelioma cells acquire a higher proliferative potential after metastasis, without any significant changes in their histology, although metastasis produces no definite trend on the expression of E-cadherin or beta-catenin.
• Functional properties of CD8(+) lymphocytes in patients with pleural plaque and malignant mesothelioma.

  Naoko Kumagai-Takei; Yasumitsu Nishimura; Megumi Maeda; Hiroaki Hayashi; Hidenori Matsuzaki; Suni Lee; Takumi Kishimoto; Kazuya Fukuoka; Takashi Nakano; Takemi Otsuki

  Journal of immunology research 2014 670140 - 670140 2314-8861 2014 [Refereed]
   

  It is known that asbestos exposure can cause malignant mesothelioma (MM) and that CD8(+) T cells play a critical role in antitumor immunity. We examined the properties of peripheral blood CD8(+) lymphocytes from asbestos-exposed patients with pleural plaque (PL) and MM. The percentage of CD3(+)CD8(+) cells in PBMCs did not differ among the three groups, although the total numbers of PBMCs of the PL and MM groups were lower than those of the healthy volunteers (HV). The percentage of IFN-γ (+) and CD107a(+) cells in PMA/ionomycin-stimulated CD8(+) lymphocytes did not differ among the three groups. Percentages of perforin(+) cells and CD45RA(-) cells in fresh CD8(+) lymphocytes of PL and MM groups were higher than those of HV. Percentages of granzyme B(+) and perforin(+) cells in PMA/ionomycin-stimulated CD8(+) lymphocytes were higher in PL group compared with HV. The MM group showed a decrease of perforin level in CD8(+) lymphocytes after stimulation compared with patients with PL. These results indicate that MM patients have characteristics of impairment in stimulation-induced cytotoxicity of peripheral blood CD8(+) lymphocytes and that PL and MM patients have a common character of functional alteration in those lymphocytes, namely, an increase in memory cells, possibly related to exposure to asbestos.
• Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma.

  Fukuoka K; Kuribayashi K; Yamada S; Tamura K; Tabata C; Nakano T

  Molecular and clinical oncology 1 (6) 942 - 948 2049-9450 2013/11 [Refereed]
  
• Carboplatin plus Either Docetaxel or Paclitaxel for Japanese Patients with Advanced Non-small Cell Lung Cancer

  Masaaki Kawahara; Shinji Atagi; Kiyoshi Komuta; Hiroshige Yoshioka; Masayuki Kawasaki; Yuka Fujita; Toshiro Yonei; Fumitaka Ogushi; Kaoru Kubota; Naoyuki Nogami; Michiko Tsuchiya; Kazuhiko Shibata; Yoshio Tomizawa; Koichi Minato; Kazuya Fukuoka; Kazuhiro Asami; Takeharu Yamanaka

  ANTICANCER RESEARCH INT INST ANTICANCER RESEARCH 33 (10) 4631 - 4637 0250-7005 2013/10 [Refereed]
   

  Aim: Assessment of the efficacy of docetaxel plus carboplatin vs. paclitaxel plus carboplatin in Japanese patients with advanced non-small cell lung cancer (NSCLC). Patients and Methods: Chemotherapy-naive patients were randomly assigned at a ratio of 2 to 1 to receive six cycles of either docetaxel (60 mg/m(2)) plus carboplatin [area under the curve (AUC)=6 mg/ml min] or paclitaxel (200 mg/m(2)) plus carboplatin (same dose), on day 1 every 21 days. The primary end-point was progression-free survival (PFS). Results: A total of 90 patients were enrolled. Overall response rate, median PFS and median survival time in the docetaxel-plus-carboplatin group and the paclitaxel-plus-carboplatin group were 23% vs. 33%, 4.8 months vs. 5.1 months, and 17.6 months vs. 15.6 months, respectively. The docetaxel-plus-carboplatin group had a higher incidence of grade 3 or 4 neutropenia (88% vs. 60%). Conclusion: Both regimens were similarly effective in Japanese patients with advanced NSCLC.
• 2012年アンケート調査からみた日本におけるendobronchial ultrasound-guided transbronchial needle aspirationの実態．

  浅野文祐; 青江 基; 大崎能伸; 岡田克典; 笹田真滋; 佐藤滋樹; 鈴木栄一; 千場 博; 福岡和也; 藤野昇三; 大森一光

  気管支学 (NPO)日本呼吸器内視鏡学会 35 (35) 367 - 371 0287-2137 2013/07 [Refereed]
   

  目的.Endobronchial ultrasound-guided transbronchial needle aspiration(EBUS-TBNA)の実態を調査するために、日本呼吸器内視鏡学会が全国調査を行った。対象と方法.調査対象は2011年1月〜2012年6月までの1年半にコンベックス型超音波気管支鏡を使用して行ったEBUS-TBNA症例で、日本呼吸器内視鏡学会認定および認定関連施設520施設に質問用紙を郵送した。結果.回収率は87.5%で、調査期間内にEBUS-TBNAを施行したと回答した施設は47.6%であった。主たる施行医が気管支鏡専門医である施設は73.1%で、EBUS-TBNAの経験が20例未満の施設が64.2%であった。さらに28.0%の施設で主たる施行医がハンズオンに参加していなかった。ほぼ全例入院でEBUS-TBNAを施行している施設が73.5%、ほぼ全例静脈麻酔を併用している施設が61.9%であった。穿刺するリンパ節数が通常1個である施設が76.4%、1個のリンパ節に対する穿刺回数は2〜3回の施設が89.0%と多かった。結語.EBUS-TBNA症例経験数の少ない施設や施行医が多く、ハンズオンなどの教育、啓発活動が引き続き必要と思われる。(著者抄録)
• Methotrexate and gemcitabine combination chemotherapy for the treatment of malignant pleural mesothelioma.

  Kuribayashi K; Miyata S; Fukuoka K; Murakami A; Yamada S; Tamura K; Hirayama N; Terada T; Tabata C; Fujimori Y; Nakano T

  Molecular and clinical oncology 1 (4) 639 - 642 2049-9450 2013/07 [Refereed]
  
• Complications associated with endobronchial ultrasound-guided transbronchial needle aspiration: A nationwide survey by the Japan Society for Respiratory Endoscopy

  Fumihiro Asano; Motoi Aoe; Yoshinobu Ohsaki; Yoshinori Okada; Shinji Sasada; Shigeki Sato; Eiichi Suzuki; Hiroshi Semba; Kazuya Fukuoka; Shozo Fujino; Kazumitsu Ohmori

  Respiratory Research 14 (1) 50  1465-9921 2013/05 [Refereed]
   

  Background: With the recent widespread use of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), there have been occasional reports on complications associated with its use. Previous reviews on EBUS-TBNA have been limited to studies by skilled operators, thus the results may not always be applicable to recent clinical practice. To assess the safety of EBUS-TBNA for the staging and diagnosis of lung cancer in Japan, a nationwide survey on its current usage status and complications associated with its use was conducted by the Japan Society for Respiratory Endoscopy (JSRE).Methods: A questionnaire about EBUS-TBNA performed between January 2011 and June 2012 was mailed to 520 JSRE-accredited facilities.Results: Responses were obtained from 455 facilities (87.5%). During the study period, EBUS-TBNA was performed in 7,345 cases in 210 facilities (46.2%) using a convex probe ultrasound bronchoscope, for 6,836 mediastinal and hilar lesions and 275 lung parenchymal lesions. Ninety complications occurred in 32 facilities. The complication rate was 1.23% (95% confidence interval, 0.97%-1.48%), with hemorrhage being the most frequent complication (50 cases, 0.68%). Infectious complications developed in 14 cases (0.19%) (Mediastinitis, 7 pneumonia, 4 pericarditis, 1 cyst infection, 1 and sepsis, 1). Pneumothorax developed in 2 cases (0.03%), one of which required tube drainage. Regarding the outcome of the cases with complications, prolonged hospitalization was observed in 14 cases, life-threatening conditions in 4, and death in 1 (severe cerebral infarction) (mortality rate, 0.01%). Breakage of the ultrasound bronchoscope occurred in 98 cases (1.33%) in 67 facilities (31.9%), and that of the puncture needle in 15 cases (0.20%) in 8 facilities (3.8%).Conclusions: Although the complication rate associated with EBUS-TBNA was found to be low, severe complications, including infectious complications, were observed, and the incidence of device breakage was high. Since the use of EBUS-TBNA is rapidly expanding in Japan, an educational program for its safe performance should be immediately established. © 2013 Asano et al. licensee BioMed Central Ltd.
• A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma.

  Mototsugu Shimokawa; Seiki Hasegawa; Kazuya Fukuoka; Morihito Okada; Kohei Yokoi; Fumihiro Tanaka; Takeharu Yamanaka; Takashi Daimon; Takashi Nakano

  Japanese journal of clinical oncology 43 (5) 575 - 8 0368-2811 2013/05 [Refereed]
   

  A prospective multi-institutional study has been initiated in Japan to evaluate the feasibility of induction chemotherapy using pemetrexed plus cisplatin, followed by pleurectomy/decortication aimed at macroscopic complete resection in patients with resectable malignant pleural mesothelioma. The study was initiated on September 2012, for which 24 patients will be recruited over a period of 2 years. The primary endpoint is the macroscopic complete resection rate, regardless of the surgical technique employed (i.e. pleurectomy/decortication or extrapleural pneumonectomy). The secondary endpoints are the pleurectomy/decortication rate, macroscopic complete resection rate by pleurectomy/decortication, pulmonary function at 3 months after surgery, adverse events, treatment-related mortality, response rate to chemotherapy and 3-year overall survival rate.
• Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.

  Y Tsutani; T Takuwa; Y Miyata; K Fukuoka; S Hasegawa; T Nakano; M Okada

  Annals of oncology : official journal of the European Society for Medical Oncology 24 (4) 1005 - 10 2013/04 [Refereed]
   

  BACKGROUND: To select optimal candidates for extrapleural pneumonectomy (EPP), we retrospectively evaluated the usefulness of metabolic response by fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) after neoadjuvant chemotherapy to predict prognosis for patients with resectable malignant pleural mesothelioma (MPM) who underwent EPP in a multicenter study. PATIENTS AND METHODS: We carried out high-resolution CT (HRCT) and FDG-PET/CT before and after neoadjuvant platinum-based chemotherapy on 50 patients with clinical T1-3 N0-2 M0 MPM who underwent EPP ± postoperative hemithoracic radiotherapy. A decrease of ≥30% in the tumor maximum standardized uptake value (SUVmax) was defined as a metabolic responder. The radiologic response using the modified RECIST or metabolic response and surgical results were analyzed. RESULTS: The median overall survival (OS) from diagnosis was 20.5 months. Metabolic responders significantly correlated to OS with median OS for metabolic responders not reached versus 18.7 months for non-responders. No correlation was observed between OS and radiologic response with median OS for radiologic responders and non-responders. Based on the multivariate Cox analyses, decreased SUVmax and epithelioid subtype were significantly independent factors for OS. CONCLUSIONS: The metabolic response after neoadjuvant chemotherapy is an independent prognostic factor for patients with resectable MPM. Patients with metabolic responder or epithelioid subtype may be good candidates for EPP.
• Circulating Endothelial Cell (CEC) as a Diagnostic and Prognostic Marker in Malignant Pleural Mesothelioma (MPM)

  Kazue Yoneda; Fumihiro Tanaka; Nobuyuki Kondo; Hayato Orui; Masaki Hashimoto; Teruhisa Takuwa; Seiji Matsumoto; Yoshitomo Okumura; Noriaki Tsubota; Ayuko Sato; Tohru Tsujimura; Kozo Kuribayashi; Kazuya Fukuoka; Takashi Nakano; Seiki Hasegawa

  ANNALS OF SURGICAL ONCOLOGY SPRINGER 19 (13) 4229 - 4237 1068-9265 2012/12 [Refereed]
   

  The purpose of this study was to investigate the diagnostic and prognostic value of circulating endothelial cell (CEC), a potential surrogate of tumor angiogenesis, in malignant pleural mesothelioma (MPM). We prospectively evaluated CEC count in 4.0 mL of peripheral blood sampled from patients with a suspicion of MPM. An automated system was used to capture CECs with an anti-CD146 antibody. Of 109 eligible patients, 30 were finally diagnosed with non-malignant diseases, and 79 were with MPM. CEC count was significantly higher in MPM patients than in NM patients (mean CEC count, 120.3 and 39.9, respectively; P = 0.001), and a receiver operating characteristic (ROC) curve analysis showed that CEC provided a significant diagnostic performance in discrimination between MPM and nonmalignant diseases with an area under curve (AUC-ROC) of 0.700 (95 % confidence interval [95 % CI], 0.595-0.806; P = 0.001). Among MPM patients, CEC count was positively correlated with intratumoral microvessel density (MVD), a measurement of tumor angiogenesis (Spearman correlation coefficiency [r] = 0.444; P = 0.001). Higher CEC count (> 50) was significantly associated with a poor prognosis (median overall survival, 11.4 months [95 % CI, 7.6-15.2] for higher CEC count patients versus 20.1 months [95 % CI, 16.0-24.2] for lower CEC count patients; P = 0.028). A multivariate analysis showed that higher CEC count was a significant and independent factor to predict a poor prognosis (hazard ratio [HR], 2.24, [95 % CI, 1.24-4.43]; P = 0.009). CEC, as a surrogate of tumor angiogenesis, was a promising marker in diagnosis and prediction of prognosis in MPM.
• Gene Therapy Using Adenovirus Against Malignant Mesothelioma

  Akinobu Gotoh; Takeshi Kanno; Hisao Nagaya; Takashi Nakano; Chiharu Tabata; Kazuya Fukuoka; Masatoshi Tagawa; Tomoyuki Nishizaki

  ANTICANCER RESEARCH INT INST ANTICANCER RESEARCH 32 (9) 3743 - 3747 0250-7005 2012/09 [Refereed]
   

  Background: Adenovirus vectors have been utilized for cancer gene therapies. The present study examined the oncolytic effects of adenovirus type 5 (Ad5) and fiber-substituted conditionally replicating adenovirus (CRAD) Ad5/F35 vectors on the human malignant mesothelioma cells MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452 cells. Materials and Method: For the adenovirus, the first mRNA/protein to be made (similar to 1 h after infection) is E1A. Ad5F35 and Ad5 CRAD vectors containing the El gene controlled by the human midkine promoter (Ad5F351MKp-E1 and Ad5/MKp-E1, respectively) were constructed. Western blotting and cell viability assays were carried out in cells transfected with Ad5/MKp-E1 and Ad5F35/MKp-E1. Results: Coxsackie and adenovirus receptor (CAR), a cell surface target of Ad5, and CD46, a cell surface target of Ad35, were expressed in all the malignant mesothelioma cell lines examined here, as much as in HEK293 cells, with no significant differences in the expression levels among cells. Both Ad5/MKp-E1 and Ad5F35/MKp-E1 induced oncolysis of malignant mesothelioma cells in a viral particle-dependent manner, with similar efficacy. Conclusion: The results of the present study suggest that both Ad5/MKp-E1 and Ad5F35/MKp-E1 are useful for the gene therapy of human malignant mesothelioma.
• ネフローゼ症候群を来たした悪性胸膜中皮腫の2例

  平山 倫子; 岡田 あすか; 金村 晋吾; 柴田 英輔; 本田 実紀; 神谷 瞳; 大桑 久弥; 大搗 泰一郎; 前田 理沙; 寺田 貴普; 村上 亜紀; 山田 秀哉; 田村 邦宣; 田端 千春; 中野 孝司; 福岡 和也; 八尋 真名; 木田 有利; 中西 健; 羽尾 裕之; 塚本 吉胤; 廣田 誠一

  肺癌 (NPO)日本肺癌学会 52 (3) 351 - 351 0386-9628 2012/06
• Heme Oxygenase-1 Promoter Polymorphism is Associated with Risk of Malignant Mesothelioma

  Aki Murakami; Yoshihiro Fujimori; Yoshie Yoshikawa; Shusai Yamada; Kunihiro Tamura; Noriko Hirayama; Takayuki Terada; Kozo Kuribayashi; Chiharu Tabata; Kazuya Fukuoka; Tomoko Tamaoki; Takashi Nakano

  LUNG SPRINGER 190 (3) 333 - 337 0341-2040 2012/06 [Refereed]
   

  Malignant mesothelioma is an aggressive tumor of serosal surfaces that is closely associated with asbestos exposure which induces oxidative stress. Heme oxygenase (HO)-1, a rate-limiting enzyme of heme degradation, plays a protective role against oxidative stress. The HO-1 gene promoter carries (GT)n repeats whose number is inversely related to transcriptional activity of the HO-1 gene. To investigate the relationship between the length polymorphism of (GT)n repeats and mesothelioma susceptibility, we analyzed the HO-1 promoter in 44 asbestos-exposed subjects without mesothelioma and 78 asbestos-exposed subjects with mesothelioma using PCR-based genotyping. The number of repeats ranged from 16 to 38, with two peaks at 23 and 30 repeats. Polymorphisms of (GT)n repeats were grouped into two classes of alleles, short (S) (< 24) and long (L) (a parts per thousand yen24), and three genotypes: L/L, L/S, and S/S. The proportions of allele frequencies in class L as well as genotypic frequencies of L allele carriers (L/L and L/S) were significantly higher in the asbestos-exposed subjects with mesothelioma than in those without mesothelioma. The findings of this study suggest that long (GT)n repeats in the HO-1 gene promoter are associated with a higher risk of malignant mesothelioma in the Japanese population.
• Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma

  Yoshie Yoshikawa; Ayuko Sato; Tohru Tsujimura; Mitsuru Emi; Tomonori Morinaga; Kazuya Fukuoka; Shusai Yamada; Aki Murakami; Nobuyuki Kondo; Seiji Matsumoto; Yoshitomo Okumura; Fumihiro Tanaka; Seiki Hasegawa; Takashi Nakano; Tomoko Hashimoto-Tamaoki

  CANCER SCIENCE WILEY-BLACKWELL 103 (5) 868 - 874 1347-9032 2012/05 [Refereed]
   

  In the present study, we analyzed genomic alterations of BRCA1-associated protein 1 (BAP1) in 23 malignant mesotheliomas (MMs), 16 epithelioid and seven non-epithelioid, consisting of 18 clinical specimens and five established cell lines. In examining these samples for homozygous deletions and sequence-level mutations, we found biallelic BAP1 gene alterations in 14 of 23 MMs (61%). Seven of these 14 MMs had homozygous deletions of the partial or entire BAP1 gene, another five had sequence-level mutations, including small deletions, a nonsense mutation, and missense mutations with additional monoallelic deletions, and the remaining two had homozygous mutations without allelic loss. All but one of the 14 BAP1 gene mutations were found in the epithelioid-type MMs; BAP1 mutations were found in 13 of 16 epithelioid-type MMs, but in only one of seven non-epithelioid-type MMs (13/16 vs 1/7; P similar to=similar to 0.005). There was no BAP1 mRNA expression in MMs with biallelic deletion and repressed expression was confirmed in MM specimens with deletion/mutation as compared with Met5a, SV40-transformed normal mesothelial cells. Western blot showed that seven of eight epithelioid MMs analyzed were BAP1 negative. Immunostaining with anti-BAP1 antibody in normal lung tissues revealed clear nuclear staining of normal mesothelial cells. No nuclear staining was observed among BAP1 mutation-positive MM tumors, whereas nuclear staining was observed among BAP1 mutation-negative MM tumors. These results suggest that the lack of the tumor suppressor BAP1 may be more specifically involved in the pathogenesis of epithelioid MM rather than non-epithelioid MM, and would be useful for diagnosis of epithelioid-type MM. (Cancer Sci 2012; 103: 868874)
• Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy

  Seiki Hasegawa; Nobuyuki Kondo; Seiji Matsumoto; Teruhisa Takuwa; Masaki Hashimoto; Hayato Orui; Shunichi Fukuda; Kazue Yoneda; Yoshitomo Okumura; Noriaki Tsubota; Kazuya Fukuoka; Ikuko Torii; Tohru Tsujimura; Takashi Nakano

  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY SPRINGER JAPAN KK 17 (1) 33 - 39 1341-9625 2012/02 [Refereed]
   

  Malignant pleural mesothelioma (MPM) remains suffering poor prognosis in spite of recent diagnostic and therapeutic progress. Although there is currently no established evidence, early diagnosis and early intervention may play a key role to improve prognosis of MPM, similarly to other malignancies. As pleural effusion is usually the first clinical sign of MPM, pleural effusion cytology is often the first diagnostic examination to be carried out. Since the sensitivity of pleural effusion cytology is approximately 60%, however, false-negative diagnosis is given to almost half of true MPM patients at this clinical step. One practical way to reduce the number of misdiagnosed MPM is to encourage performing thoracoscopic pleural biopsy unless definitive diagnosis other than MPM is established. There still remain a considerable number of patients with radiological/thoracoscopic T0 MPM who are misdiagnosed with nonspecific pleuritis after a complete investigation including thoracoscopic biopsies. Such patients will turn out to be malignant during follow-up period, although they have the best opportunity for long-term survival if only early therapeutic intervention is given. Currently, we are performing diagnostic total parietal pleurectomy in highly selected patients, who are characterized with strong clinical suspicion, positive pleural effusion cytology but uncertain pathological diagnosis, excellent cardiopulmonary reserve, and with written informed consent for highly invasive diagnostic surgery for pathologically unproven disease.
• Pathological and molecular biological approaches to early mesothelioma

  Tohru Tsujimura; Ikuko Torii; Ayuko Sato; Misa Song; Kazuya Fukuoka; Seiki Hasegawa; Takashi Nakano

  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY SPRINGER JAPAN KK 17 (1) 40 - 47 1341-9625 2012/02 [Refereed]
   

  Malignant mesothelioma is an asbestos-related malignancy that arises primarily from mesothelial cells on the serosal surfaces of the pleural, peritoneal, and pericardial cavities. Malignant pleural mesothelioma (MPM) is most common, and its incidence is dramatically increasing worldwide as a result of widespread use of asbestos. Morphological discrimination between MPM and reactive mesothelial hyperplasia is difficult, and the most reliable pathological criterion for malignancy is mesothelial proliferation invading deeply into subpleural adipose tissues. To establish radical cure of MPM, it is crucial to find early-stage MPM of epithelial type, in which mesothelial proliferation is localized on the serosal surface of parietal pleura or limited within the submesothelial fibrous tissues of parietal pleura. The initial clinical presentation for patients with MPM is frequently dyspnea and/or chest pain due to large pleural effusion, and cytological analysis of pleural effusions is valuable to find patients with early-stage MPM of epithelial type. Recently, cytological features of MPM in pleural effusion, molecular markers for MPM, and genetic alternations of MPM have been reported. In this review, we discuss major issues on pathological and molecular biological approaches for diagnosis of early-stage MPM of epithelial type.
• 2010年全国アンケート調査からみた呼吸器内視鏡診療の実態(安全対策委員会,委員会報告,第35回日本呼吸器内視鏡学会学術集会)

  浅野 文祐; 青江 基; 大崎 能伸; 岡田 克典; 笹田 真滋; 佐藤 滋樹; 鈴木 栄一; 千場 博; 福岡 和也; 藤野 昇三; 大森 一光

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 34 S133  2012
• A Case Report of Epithelioid Malignant Pleural Mesothelioma Showing a Complete Response Treated with Non-pemetrexed Chemotherapy

  Tamura Kunihiro; Ohtsuki Tai-ichiro; Shibata Eisuke; Kanemura Shingo; Yasumitsu Akihiro; Tsukamoto Yoshitane; Komuta Kiyoshi; Tabata Chiharu; Fukuoka Kazuya; Nakano Takashi

  The Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 34 (3) 228 - 233 0287-2137 2012 

  Background. Malignant pleural mesothelioma (MPM) is a rapidly progressive malignancy with a median survival of 10 to 12 months. Mesothelioma usually shows a poor response to chemotherapy; complete response (CR) is rare. Case. A 74-year-old female patient presented with pleural effusion. She had worked as a baker for 30 years and had a history of asbestos exposure from the oven. She had experienced right chest pain since December 2005, and a chest X-ray revealed a right pleural effusion. Subsequently, she was referred to our hospital in February 2006. Thoracoscopic examination under local anesthesia with biopsies demonstrated multiple parietal pleura-based nodules and confirmed epithelioid malignant mesothelioma. She received 4 cycles of cisplatin + irinotecan + doxorubicin with radiologic CR which was maintained until October 2010. The patient is currently alive and has a good performance status (PS), although she shows signs of relapse. Conclusion. CR to chemotherapy is rare but could be possible for MPM with a number of good prognostic factors. This patient had (1) epithelioid subtype, (2) stage 1 disease on first presentation, (3) good PS, (4) female, (5) no thrombocytosis, (6) normal white blood cell count. Thoracoscopy under local anesthesia is a useful for diagnosis of early stage of MPM.
• 14."Miliary Mesothelioma"の1例(第90回 日本呼吸器内視鏡学会近畿支部会)

  大搗 泰一郎; 福岡 和也; 平山 倫子; 金村 晋吾; 柴田 英輔; 神谷 瞳; 本田 実紀; 大桑 久弥; 前田 理沙; 寺田 貴普; 岡田 あすか; 村上 亜紀; 山田 秀哉; 田村 邦宣; 田端 千春; 中野 孝司; 坪田 紀明; 木田 有利; 中西 健; 塚本 吉胤; 廣田 誠一

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 34 (1) 95 - 95 2012
• AMP Converted from Intracellularly Transported Adenosine Upregulates p53 Expression to Induce Malignant Pleural Mesothelioma Cell Apoptosis

  Yoshitaka Nogi; Takeshi Kanno; Takashi Nakano; Yumiko Fujita; Chiharu Tabata; Kazuya Fukuoka; Akinobu Gotoh; Tomoyuki Nishizaki

  CELLULAR PHYSIOLOGY AND BIOCHEMISTRY KARGER 30 (1) 61 - 74 1015-8987 2012 [Refereed]
   

  Background/Aims: The present study investigated adenosine-induced apoptosis in human malignant pleural mesothelioma cells. Methods: MTT assay, TUNEL staining, flow cytometry using propidium iodide and annexin V-FITC, real-time RT-PCR, Western blotting, and assay of caspase-3, -8, and -9 activities were carried out using malignant pleural mesothelioma cell lines such as NCI-H28, NCI-H2052, NCI-H2452, and MSTO-211H cells, and p53 or A(3) adenosine receptor was knocked-down by transfecting each siRNA into cells. Results: Adenosine induced apoptosis in all the malignant pleural mesothelioma cells used here, independently of caspase activation. The adenosine effect was prevented by the adenosine transporter inhibitor dipyridamole, the adenosine kinase inhibitor ABT-702, or the A(3) adenosine receptor inhibitor MRS1191. Adenosine upregulated expression of the p53 mRNA and protein, that is abolished by ABT-702, but not by knocking-down A(3) adenosine receptor. Adenosine-induced apoptosis in NCI-H28 cells was significantly inhibited by knocking-down p53 and in part by knocking-down A(3) adenosine receptor. Conclusion: The results of the present study show that AMP converted from intracellularly transported adenosine upregulates p53 expression to induce caspase-independent apoptosis in malignant pleural mesothelioma cells and that A(3) adenosine receptor also participates partially in the apoptosis by the different mechanism. Copyright (c) 2012 S. Karger AG, Basel
• A(3) Adenosine Receptor-Mediated p53-Dependent Apoptosis in Lu-65 Human Lung Cancer Cells

  Tai-ichiro Otsuki; Takeshi Kanno; Yumiko Fujita; Chiharu Tabata; Kazuya Fukuoka; Takashi Nakano; Akinobu Gotoh; Tomoyuki Nishizaki

  CELLULAR PHYSIOLOGY AND BIOCHEMISTRY KARGER 30 (1) 210 - 220 1015-8987 2012 [Refereed]
   

  Background/Aims: A(3) adenosine receptor mediates apoptosis in cancer cells via diverse signaling pathways. The present study examined A(3) adenosine receptor-mediated apoptosis in Lu-65 cells, a human giant cell lung carcinoma cell line. Methods: MTT assay, TUNEL staining, real-time RT-PCR, Western blotting, and assay of caspase-3, -8, and -9 activities were carried out in Lu-65 cells, and A(3) adenosine receptor or p53 was knocked-down by transfecting each siRNA into cells. Results: Extracellular adenosine induces Lu-65 cell apoptosis in a concentration (0.01-10 mM)-dependent manner, and the effect was inhibited by the A(3) adenosine receptor inhibitor MRS1191 or by knocking-down A(3) adenosine receptor or p53. Like adenosine, the A(3) adenosine receptor agonist 2-Cl-IB-MECA also induced Lu-65 cell apoptosis. Adenosine upregulated expression of p53 and Noxa mRNAs and activated caspase-3 and -9, but not caspase-8. Those adenosine effects were still inhibited by knocking-down A(3) adenosine receptor or p53. Conclusion: The results of the present study show that adenosine upregulates p53 expression via A(3) adenosine receptor, to promote p53-dependent Noxa gene transcription, causing activation of caspase-9 and the effector caspase-3 to induce Lu-65 cell apoptosis. Copyright (c) 2012 S. Karger AG, Basel
• Sphingosine Suppresses Mesothelioma Cell Proliferation by Inhibiting PKC-delta and Inducing Cell Cycle Arrest at the G(0)/G(1) Phase

  Hisaya Okuwa; Takeshi Kanno; Yumiko Fujita; Akinobu Gotoh; Chiharu Tabata; Kazuya Fukuoka; Takashi Nakano; Tomoyuki Nishizaki

  CELLULAR PHYSIOLOGY AND BIOCHEMISTRY KARGER 30 (4) 995 - 1004 1015-8987 2012 [Refereed]
   

  Background/Aims: Sphingosine regulates cellular differentiation, cell growth, and apoptosis. The present study aimed at understanding sphingosine-regulated mesothelioma cell proliferation. Methods: Human malignant mesothelioma cells such as NCI-H28, NCI-H2052, NCI-H2452, and MSTO-211H cells were cultured. The siRNA to silence the protein kinase C (PKC)-delta-targeted gene was constructed and transfected into cells. MTT assay, cell cycle analysis using a flow cytometry, and cell-free PKC-delta assay were carried out. Results: For all the cell types sphingosine inhibited cell growth in a concentration (1-100 mu M)-dependent manner. The sphingosine effect was not prevented by rottlerin, an inhibitor of protein kinase C-delta (PKC-delta); conversely, rottlerin further enhanced the sphingosine effect or rottlerin suppressed mesothelioma cell growth without sphingosine. In the cell-free PKC assay, sphingosine attenuated PKC-delta activity. Knocking-down PKC-delta induced cell cycle arrest at the G(0)/G(1) phase and inhibited cell growth. Conclusion: The results of the present study show that sphingosine suppressed mesothelioma cell proliferation by inhibiting PKC-delta, to induce cell cycle arrest at the G(0)/G(1) phase. Copyright (C) 2012 S. Karger AG, Basel
• Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells

  Yoshie Yoshikawa; Ayuko Sato; Tohru Tsujimura; Tomonori Morinaga; Kazuya Fukuoka; Shusai Yamada; Aki Murakami; Nobuyuki Kondo; Seiji Matsumoto; Yoshitomo Okumura; Fumihiro Tanaka; Seiki Hasegawa; Tomoko Hashimoto-Tamaoki; Takashi Nakano

  INTERNATIONAL JOURNAL OF ONCOLOGY SPANDIDOS PUBL LTD 39 (6) 1365 - 1374 1019-6439 2011/12 [Refereed]
   

  Array-based comparative genomic hybridization analysis was performed on 21 malignant mesothelioma (MM) samples (16 primary cell cultures and 5 cell lines) and two reactive mesothelial hyperplasia (RM) primary cell cultures. The RM samples did not have any genomic losses or gains. In MM samples, deletions in 1 p, 3p21, 4q, 9p21, 16p13 and 22q were detected frequently. We focused on 3p21 because this deletion was specific to the epithelioid type. Especially, a deletion in 3p21.1 region carrying seven genes including SEMA3G was found in 52% of MM samples (11 of 14 epithelioid samples). The allele loss of 3p21.1 might be a good marker for the epithelioid MM. A homozygous deletion in this region was detected in two MM primary cell cultures. A heterozygous deletion detected in nine samples contained the 3p21.I region and 3p21.31 one carrying the candidate tumor suppressor genes such as semaphorin 3F (SEMA3F), SEMA3B and Ras association (RalGDS/AF-6) domain family member I (RASSFIA). SEMA3B, 3F and 3G are class 3 semaphorins and inhibit growth by competing with vascular endothelial growth factor (VEGF) through binding to neuropil in. All MM samples downregulated the expression of more than one gene for SEMA38, 3F and 3G when compared with Met5a, a normal pleura-derived cell line. Moreover, in 12 of 14 epithelioid MM samples the expression level of SEMA3A was lower than that in Met5a and the two RM samples. An augmented expression of VEGFA was detected in half of the MM samples. The expression ratio of VEGFA/SEMA3A was significantly higher in the epithelioid MMs than in Met5a, RMs and the non-epithelioid MMs. Our data suggest that the downregulated expression of SEMA3A and several SEMA3s results in a loss of inhibitory activities in tumor angiogenesis and tumor growth of VEGFA; therefore, it may play an important role on the pathogenesis of the epithelioid type of MM.
• Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma

  Shusai Yamada; Chiharu Tabata; Rie Tabata; Kazuya Fukuoka; Takashi Nakano

  CLINICAL CHEMISTRY AND LABORATORY MEDICINE WALTER DE GRUYTER & CO 49 (10) 1721 - 1726 1434-6621 2011/10 [Refereed]
   

  Background: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure. MPM has a limited response to conventional chemotherapy and radiotherapy, so early diagnosis of MPM is very important. This study investigated the pleural effusion mesothelin levels in patients with MPM and compared them to those of a population with a non-malignant pleuritis or lung cancer involving malignant pleural effusion. Methods: The pleural effusion mesothelin concentrations were measured in 45 MPM patients and 53 non-MPM individuals (24 individuals with non-malignant pleural effusions and 29 individuals with lung cancer involving malignant pleural effusion). Results: This study demonstrated that patients with MPM had significantly higher pleural effusion mesothelin levels than a population with non-malignant pleuritis or lung cancer involving malignant pleural effusion. The difference in overall survival between the groups with pleural effusion mesothelin levels lower and higher than the assumed cut-off of 10 nM was significant. Conclusions: The data suggest that the pleural effusion mesothelin concentration could be useful as an aid for the diagnosis of MPM.
• 悪性中皮腫細胞における3p21.1領域の欠失およびセマフォリン3ファミリー遺伝子の発現抑制(Deletion of the 3p21.1 region and downregulated expression of semaphorin 3 family genes in malignant mesothelioma)

  吉川 良恵; 森永 伴法; 佐藤 鮎子; 福岡 和也; 長谷川 誠紀; 辻村 亨; 中野 孝司; 玉置 知子[橋本]

  日本癌学会総会記事 (一社)日本癌学会 70回 201 - 201 0546-0476 2011/09
• [Archives of "comprehensive approach on asbestos-related diseases" supported by the "special coordination funds for promoting science and technology (H18-1-3-3-1)"-- overview of group research project, care and specimen registration, cellular characteristics of mesothelioma and immunological effects of asbestos].

  Takemi Otsuki; Takashi Nakano; Seiki Hasegawa; Morihito Okada; Tohru Tsujimura; Yoshitaka Sekido; Shinya Toyokuni; Hiroshi Nishimoto; Kazuya Fukuoka; Fumihiro Tanaka; Naoko Kumagai; Megumi Maeda; Yasumitsu Nishimura

  Nihon eiseigaku zasshi. Japanese journal of hygiene 66 (3) 543 - 52 0021-5082 2011/05 [Refereed]
   

  The research project entitled "Comprehensive approach on asbestos-related diseases" supported by the "Special Coordination Funds for Promoting Science and Technology (H18-1-3-3-1)" began in 2006 and was completed at the end of the Japanese fiscal year of 2010. This project included four parts; (1) malignant mesothelioma (MM) cases and specimen registration, (2) development of procedures for the early diagnosis of MM, (3) commencement of clinical investigations including multimodal approaches, and (4) basic research comprising three components; (i) cellular and molecular characterization of mesothelioma cells, (ii) immunological effects of asbestos, and (iii) elucidation of asbestos-induced carcinogenesis using animal models. In this special issue of the Japanese Journal of Hygiene, we briefly introduce the achievements of our project. The second and third parts and the third component of the fourth part are described in other manuscripts written by Professors Fukuoka, Hasegawa, and Toyokuni. In this manuscript, we introduce a brief summary of the first part "MM cases and specimen registration", the first component of the fourth part "Cellular and molecular characterization of mesothelioma cells" and the second component of the fourth part "Immunological effects of asbestos". In addition, a previous special issue presented by the Study Group of Fibrous and Particulate Substances (SGFPS) (chaired by Professor Otsuki, Kawasaki Medical School, Japan) for the Japanese Society of Hygiene and published in Environmental Health and Preventive Medicine Volume 13, 2008, included reviews of the aforementioned first component of the fourth part of the project. Taken together, our project led medical investigations regarding asbestos and MM progress and contributed towards the care and examination of patients with asbestos-related diseases during these five years. Further investigations are required to facilitate the development of preventive measures and the cure of asbestos-related diseases, particularly in Japan, where asbestos-related diseases are predicted to increase in the next 10 to 20 years.
• [Exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma].

  Fukuoka K; Tanaka F; Tsujimura T; Hashimoto-Tamaoki T; Hasegawa S; Nakano T

  Nihon eiseigaku zasshi. Japanese journal of hygiene The Japanese Society for Hygiene 66 (3) 553 - 557 0021-5082 2011/05 [Refereed]
   

  Malignant mesothelioma (MM) is a highly aggressive, incurable neoplasm associated with asbestos exposure. Early detection of MM is not easy and radiological surveillance is imperfect. The use of blood-based biomarkers might solve this difficulty and allow detection of MM at an early stage when combined treatment involving surgery, chemotherapy and radiotherapy might be effective. In the research project entitled "Comprehensive approach on asbestos-related diseases" supported by the "Special Coordination Funds for Promoting Science and Technology (H18-1-3-3-1)", we conducted an exploratory study on the detection of markers for diagnosing early-stage MM.
  In this study, we have shown that serum soluble mesothelin-related peptide (SMRP) is a highly specific and moderately sensitive biomarker for diagnosing MM. SMRP levels in pleural effusion were elevated not only in advanced-stage malignant pleural mesothelioma (MPM), but also in early-stage disease. SMRP in pleural effusion can be an MPM-specific biomarker with greater sensitivity than in serum, especially for the early stage of the disease. Circulating tumor cells (CTCs) and circulating endothelial cells (CECs) were considered to be useful surrogate markers of disease progression in MPM, although the lack of sensitivity for early-stage disease remains to be improved. Cytological analysis with gene expression profiling has been more effective in detecting early-stage MPM with pleural effusion.
  In conclusion, blood or effusion-based biomarkers, possibly in combination with other new modalities, such as a thoracoscopy combined with the advanced imaging systems consisting of autofluorescence imaging (AFI) and narrow band imaging (NBI), will show some promise for curing MPM if the disease is detected at an early stage.
  
• [Current status and future direction of Japan's clinical trial for malignant pleural mesothelioma].

  Seiki Hasegawa; Fumihiro Tanaka; Morihito Okada; Takeharu Yamanaka; Norihiko Kamikonya; Toshinori Soejima; Tohru Tsujimura; Kazuya Fukuoka; Takashi Nakano

  Nihon eiseigaku zasshi. Japanese journal of hygiene 66 (3) 558 - 61 0021-5082 2011/05 [Refereed]
   

  The feasibility and efficacy of trimodality therapy for malignant pleural mesothelioma (MPM) are still controversial mainly due to the lack of clinical evidence. Although three major clinical trials on this therapy have been recently reported from North America and Europe, it remains unclear whether results in Caucasian populations may be directly applicable to Asian populations. In this context, as a project of the "Comprehensive approach on asbestos-related diseases" supported by the "Special Coordination Fund for Promoting Science and Technology of MEXT, Japan", a prospective multi-institutional study has been planned to evaluate the feasibility of induction chemotherapy using pemetrexed plus cisplatin, followed by extrapleural pneumonectomy (EPP) and postoperative hemithoracic radiation in patients with resectable MPM. Primary endpoints are macroscopic complete resection rate by EPP and treatment-related mortality for trimodality therapy. The study was initiated in May 2008 and patient enrollment was finished in November 2010.
• Evaluation of the safety profiles of pemetrexed in combination with cisplatin for malignant pleural mesothelioma in an outpatient clinic

  Kazuya Fukuoka; Kozo Kuribayashi; Yoshihiro Fujimori; Takashi Nakano

  Japanese Journal of Lung Cancer 51 (2) 109 - 112 0386-9628 2011/04 [Refereed]
   

  Objective. To evaluate the safety profile of combination therapy of pemetrexed plus cisplatin for malignant pleural mesothelioma (MPM) in an outpatient clinic. Methods. Patients received an intravenous infusion of 500 mg/m2 pemetrexed followed by an intravenous infusion of 60-75 mg/m2 cisplatin, on day 1 of every 21 days, concomitantly with vitamins. Results. We analyzed total of 105 patients who received combination therapy of pemetrexed plus cisplatin, after a histological diagnosis of MPM, but who had received no prior systemic chemotherapy, 77 (64 men, 13 women) of whom continued to receive this combination therapy as outpatients. The median age was 62.2 (range, 44 to 77). Epithelioid histology was present in 65 patients and 12 patients had non-epithelioid histology. There were 285 cycles administered in the outpatient setting, with a median cycle of 3 (range, 1 to 11). Hematological toxicities of grade ≥3 included leukopenia in 10 patients (13.0%), neutropenia in 15 patients (19.5%), and anemia in 8 patients (10.4%). Neither febrile neutropenia nor neutropenic infection was observed. Common non-hematological toxicities were gastrointestinal toxicities, such as nausea, constipation, anorexia, and vomiting, although toxicities of grade ≥3 were not observed. Other grade 3 adverse events were neurotoxicity and allergic reaction in 1 and 2 patients, respectively. The most common abnormal laboratory findings were increased creatinine levels in 21 patients (27.3%), followed by increased aminotransferase levels in 12 patients (15.6%). There were no treatment-related deaths. Conclusion. The safety of this combination therapy was confirmed in outpatients with MPM. © 2011 The Japan Lung Cancer Society.
• Arsenic Trioxide Induces Apoptosis Through JNK and ERK in Human Mesothelioma Cells

  Ryoji Eguchi; Yoshihiro Fujimori; Hiromi Takeda; Chiharu Tabata; Toshiro Ohta; Kouzo Kuribayashi; Kazuya Fukuoka; Takashi Nakano

  JOURNAL OF CELLULAR PHYSIOLOGY WILEY-BLACKWELL 226 (3) 762 - 768 0021-9541 2011/03 [Refereed]
   

  Malignant mesothelioma is an aggressive tumor of serosal surfaces, which is refractory to current treatment options. Arsenic trioxide (As2O3) is used clinically to treat acute promyelocytic leukemia, and also to inhibit proliferation of several solid tumors including hepatoma, esophageal, and gastric cancer in vitro. Here we found that As2O3 inhibited cell viability of a mesothelioma cell line, NCI-H2052. As2O3 induced apoptosis of NCI-H2052 cells, which was accompanied by activation of c-Jun NH2-terminal kinase (JNK) 1/2, extracellular signal-regulated kinase (ERK) 1/2, and caspase-3. zVAD-fmk, a broad-spectrum caspase inhibitor, inhibited As2O3-induced apoptosis and activation of caspase-3, but not that of JNK1/2 and ERK1/2. Small interfering RNAs (siRNAs) targeting JNK1/2 suppressed As2O3-induced caspase-3 activation and apoptosis, indicating that JNK1/2 regulate As2O3-induced apoptosis though caspase cascade. Furthermore, JNK1 siRNA abrogated As2O3-induced JNK2 phosphorylation and JNK2 siRNA abrogated As2O3-induced JNK1 phosphorylation, suggesting that JNK1 and JNK2 interact with each other. Moreover, JNK1 siRNA, but not JNK2 siRNA, abrogated As2O3-induced ERK1/2 phosphorylation. JNK2 siRNA together with PD98059, a specific MAPK/ERK kinase inhibitor, suppressed As2O3-induced apoptosis more significantly than JNK2 siRNA alone. These results indicated that As2O3 induces apoptosis of NCI-H2052 cells mainly through JNK1/2 activation, and that ERK1/2 is involved in As2O3-induced apoptosis when JNK1/2 are inactivated. J. Cell. Physiol. 226: 762-768, 2011. (C) 2010 Wiley-Liss, Inc.
• 2.EBUS-TBNAにて診断したサルコイドーシスの1例(第89回 日本呼吸器内視鏡学会近畿支部会)

  大搗 泰一郎; 福岡 和也; 金村 晋吾; 柴田 英輔; 政近江 利子; 神谷 瞳; 本田 実紀; 大桑 久弥; 前田 理沙; 平山 倫子; 寺田 貴普; 岡田 あすか; 村上 亜紀; 山田 秀哉; 田村 邦宣; 田端 千春; 中野 孝司; 芳川 浩男; 大類 隼人; 橋本 昌樹; 多久和 輝尚; 松本 成司; 近藤 展行; 長谷川 誠紀; 坪田 紀明; 塚本 吉胤; 廣田 誠一

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 33 (5) 382 - 382 2011
• W2-3 局所麻酔下胸腔鏡検査における胸腔内所見分類の試み(胸腔鏡所見分類作成をめざして,胸腔鏡手技・所見検討委員会企画,ワークショップ2,第34回日本呼吸器内視鏡学会学術集会)

  大搗 泰一郎; 福岡 和也; 政近 江利子; 大桑 久弥; 神谷 瞳; 本田 実紀; 安光 亮洋; 前田 理沙; 三上 浩司; 野木 佳孝; 平山 倫子; 寺田 貴普; 岡田 あすか; 村上 亜紀; 山田 秀哉; 田村 邦宣; 栗林 康造; 田端 千春; 坪田 紀明; 中野 孝司

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 33 S150  2011
• Recurrent Breast Cancer 15 Years After Radical Mastectomy in Which Respiratory Endoscopy Was Effective in the Diagnosis of Pleural and Pulmonary Metastasis

  Yamada Shusai; Fukuoka Kazuya; Tabata Chiharu; Yasumitsu Akihiro; Masachika Eriko; Maeda Risa; Okuwa Hisaya; Kamiya Hitomi; Honda Miki; Otsuki Taiichiro; Mikami Koji; Nogi Yoshitaka; Hirayama Noriko; Terada Takayuki; Okada Asuka; Murakami Aki; Tamura Kunihiro; Kuribayashi Kozo; Nakano Takashi

  The Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 33 (4) 250 - 255 0287-2137 2011 

  Background. Thoracoscopy under local anesthesia is useful in patients with retention of pleural fluid. Case. A 75-year-old woman had undergone a standard radical mastectomy followed by adjuvant chemotherapy for right breast cancer at the age of 60 in January 1995. Her subsequent progress was monitored by endocrine therapy with tamoxifen and fluorouracil for 2 years. She was referred to our hospital 15 years later for medical evaluation and treatment after right pleural effusion was detected on chest X-ray films taken during a regular medical checkup in October 2009. ^<18>F-fluorodeoxyglucose positron-emission tomography (^<18>FDG-PET) showed abnormal accumulation in the lower lobe of the patient's right lung, cervical vertebrae and thoracic vertebrae. Her serum CA15-3 level was elevated (30.9U/ml) and breast cancer with pulmonary metastasis and multiple bone metastasis were suspected. Examination of her pleural effusion obtained by thoracocentesis did not yield a definitive diagnosis, so thoracoscopy under local anesthesia and bronchoscopy were performed. Recurrent breast cancer with carcinomatous pleuritis, pulmonary metastasis, and multiple bone metastasis were diagnosed. Conclusion. Respiratory endoscopy was very useful in the diagnosis of recurrent breast cancer with carcinomatous pleuritis, pulmonary metastasis and also for the differentiation of the lung cancer lesion.
• 12.化学療法が奏効し,人工呼吸器から離脱し得た小細胞肺癌の1例(第88回 日本呼吸器内視鏡学会近畿支部会)

  本田 実紀; 大搗 泰一郎; 福岡 和也; 政近 江利子; 神谷 瞳; 大桑 久弥; 三上 浩司; 前田 理沙; 野木 佳孝; 平山 倫子; 寺田 貴普; 安光 亮洋; 岡田 あすか; 村上 亜紀; 山田 秀哉; 田村 邦宣; 栗林 康造; 田端 千春; 中野 孝司; 大類 隼人; 橋本 昌樹; 塩見 和; 松本 成司; 近藤 展行; 田中 文啓; 長谷川 誠紀; 坪田 紀明; 塚本 吉胤; 廣田 誠一

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 33 (2) 138 - 138 2011
• Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma

  Noriko Hirayama; Chiharu Tabata; Rie Tabata; Risa Maeda; Akihiro Yasumitsu; Shusai Yamada; Kozo Kuribayashi; Kazuya Fukuoka; Takashi Nakano

  RESPIRATORY MEDICINE W B SAUNDERS CO LTD 105 (1) 137 - 142 0954-6111 2011/01 [Refereed]
   

  Background: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure. MPM has a limited response to conventional chemotherapy and radiotherapy so early diagnosis of MPM is very important. Vascular endothelial growth factor (VEGF), a potent mitogen for the vascular endothelium, is also known to be an autocrine growth factor for MPM. Here, we investigated the pleural effusion VEGF levels in patients with MPM and compared them to those of a population with a non-malignant pleuritis or lung cancer involving malignant pleural effusion. Methods: The pleural effusion VEGF concentrations were measured in 46 MPM patients and 45 individuals with non-MPM individuals (25 individuals with non-malignant pleural effusions, and 20 individuals with lung cancer involving malignant pleural effusion). Results: We demonstrated that patients with MPM had significantly higher pleural effusion VEGF levels than a population with non-malignant pleuritis or lung cancer involving malignant pleural effusion, and the patients with advanced stage MPM showed higher levels of VEGF than the early stage MPM patients. The difference in overall survival between the groups with pleural effusion VEGF levels lower and higher than the assumed cut-off of 2000 pg/ml was significant. Conclusions: Our data suggest that the pleural effusion VEGF concentration could be useful as an aid for the diagnosis of MPM and as a prognostic factor. (C) 2010 Elsevier Ltd. All rights reserved.
• A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma

  C. Tabata; N. Hirayama; R. Tabata; A. Yasumitsu; S. Yamada; A. Murakami; S. Iida; K. Tamura; K. Fukuoka; K. Kuribayashi; T. Terada; T. Nakano

  European Respiratory Journal 36 (5) 1099 - 1105 0903-1936 2010/11 [Refereed]
   

  Malignant pleural mesothelioma (MPM) is an aggressive malignant tumour associated with asbestos exposure that has only a limited response to conventional therapy therefore, diagnosing MPM early is very important. We have previously reported that angiopoietin (Ang)-1 was correlated with bleomycin-induced pulmonary fibrosis. Here, we investigated the association of Ang-1 with the development of MPM cells, which originate from mesenchymal cells similar to lung fibroblasts, and demonstrated that Ang-1 stimulated the growth and migration of MPM cells in vitro. We also demonstrated that patients with MPM had significantly higher serum levels of Ang-1 in comparison to a population who had been exposed to asbestos but had not developed MPM. The patients with advanced-stage MPM showed higher levels of Ang-1 than the early-stage MPM patients and the Kaplan-Meier method revealed a significant correlation between serum Ang-1 levels and survival. We propose the possibility that Ang-1 plays an important role in MPM tumour growth and our data suggest that the serum concentration of Ang-1 could be useful as prognostic factor. Copyright©ERS 2010.
• 悪性中皮腫細胞におけるBAP1(BRCA1 associated protein 1)遺伝子の高頻度欠失(Frequent genome deletions of BAP1 (BRCA1-associated protein 1) in malignant mesothelioma cells)

  吉川 良恵; 森永 伴法; 佐藤 鮎子; 福岡 和也; 辻村 亨; 玉置 知子[橋本]; 中野 孝司

  日本癌学会総会記事 (一社)日本癌学会 69回 486 - 486 0546-0476 2010/08
• Clinical Significance of Serum Vascular Endothelial Growth Factor in Malignant Pleural Mesothelioma

  Akihiro Yasumitsu; Chiharu Tabata; Rie Tabata; Noriko Hirayama; Aki Murakami; Shusai Yamada; Takayuki Terada; Shinichiro Iida; Kunihiro Tamura; Kazuya Fukuoka; Kozo Kuribayashi; Takashi Nakano

  JOURNAL OF THORACIC ONCOLOGY LIPPINCOTT WILLIAMS & WILKINS 5 (4) 479 - 483 1556-0864 2010/04 [Refereed]
   

  Introduction: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure. MPM has a limited response to conventional chemotherapy and radiotherapy so diagnosing MPM early is very important. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for MPM. Here, we investigated the serum levels of VEGF in patients with MPM in comparison with a population that had been exposed to asbestos without developing MPM. Methods: Serum concentrations of VEGF were measured in 51 patients with MPM and 42 individuals with benign asbestos-related diseases (asbestosis or pleural plaques) or who were healthy despite asbestos exposure. Results: We demonstrated that patients with MPM had significantly higher serum levels of VEGF than a population who had been exposed to asbestos but had not developed MPM, and the patients with advanced stage MPM showed higher levels of VEGF than the early stage patients with MPM. The difference in overall survival between the groups with VEGF serum levels lower and higher than the assumed cutoff of 460 pg/ml was significant. Conclusions: Our data suggest that the VEGF serum concentration could be a useful marker for screening MPM among asbestos-exposed individuals and as a prognostic factor.
• Well-differentiated papillary mesothelioma with invasion to the chest wall

  Ikuko Torii; Masaki Hashimoto; Takayuki Terada; Nobuyuki Kondo; Hiroaki Fushimi; Kohki Shimazu; Shin-ichi Takeda; Teruhisa Takuwa; Yoshitomo Okumura; Ayuko Sato; Tadashi Yamamoto; Kazuya Fukuoka; Fumihiro Tanaka; Takashi Nishigami; Takashi Nakano; Seiki Hasegawa; Tohru Tsujimura

  LUNG CANCER ELSEVIER IRELAND LTD 67 (2) 244 - 247 0169-5002 2010/02 [Refereed]
   

  Well-differentiated papillary mesothelioma (WDPM) is an uncommon tumor with a papillary architecture, bland cytologic features, a tendency toward superficial spread without invasion, and good prognosis with prolonged survival. WDPM occurs primarily in the peritoneum of women, but also rarely in the pleura. We here report a case of 48-year-old woman who developed WDPM in the pleura with no history of asbestos exposure. Tumors were multifocal and widespread with a velvety appearance on the surface of parietal and visceral pleurae resected by extrapleural pneumonectomy (EPP). Tumors showed papillary structures with fibrovascular cores and lined by epithelioid cells. lmmunohistochemically, these epithelioid tumor cells were positive for epithelial membrane antigen (EMA), a marker of malignant mesothelioma, with more than 50% positive for p53. Tumor cells microinvaded into subpleural parenchyma of the lung and minimally spread to adipose tissues of the mediastinal lesion. In addition, tumor cells invaded into the chest wall with a trabecular or glandular architecture. Based on these findings, this case is pathologically considered as WDPM of the pleura with malignant potential. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
• W4-7 悪性胸膜中皮腫診断の胸腔鏡検査における画像強調観察法の有用性に関する検討(局所麻酔下胸腔鏡の標準化,ワークショップ4,第33回日本呼吸器内視鏡学会学術集会)

  安光 亮洋; 福岡 和也; 前田 理紗; 野木 佳孝; 三上 浩司; 寺田 貴普; 平山 倫子; 岡田 あすか; 村上 亜紀; 山田 秀哉; 田村 邦宣; 栗林 康造; 田端 千春; 坪田 紀明; 中野 孝司

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 32 S110  2010
• 3.呼吸器内視鏡検査にて診断し得た術後15年目の再発乳癌の1例(第87回 日本呼吸器内視鏡学会近畿支部会)

  山田 秀哉; 福岡 和也; 田端 千春; 栗林 康造; 田村 邦宣; 村上 亜紀; 岡田 あすか; 安光 亮洋; 寺田 貴普; 平山 倫子; 野木 佳孝; 三上 浩司; 大搗 泰一郎; 前田 理沙; 政近 江利子; 大桑 久弥; 本田 実紀; 神谷 瞳; 中野 孝司; 塚本 吉胤; 廣田 誠一

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 32 (5) 467 - 467 2010
• 13.左肺全摘術後17年目に再発を来した腺様嚢胞癌の1例(第86回 日本呼吸器内視鏡学会近畿支部会)

  安光 亮洋; 福岡 和也; 前田 理沙; 野木 佳孝; 三上 浩司; 寺田 貴普; 平山 倫子; 岡田 あすか; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 栗林 康造; 田端 千春; 中野 孝司; 坪田 紀明; 塚本 吉胤; 廣田 誠一; 宮本 良文

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 32 (1) 91 - 91 2010
• Clinical study of LY231514 (pemetrexed) in combination with cisplatin in patients with malignant pleural mesothelioma to determine safety

  Kazuya Fukuoka; Fumihiro Hommura; Hideo Kunitoh; Toyoaki Hida; Kazuhiko Nakagawa; Kenichi Gemba; Tetsu Shinkai; Yukito Ichinose; Yoshihiro Nambu; Takashi Nakano

  Japanese Journal of Lung Cancer 49 (7) 988 - 993 0386-9628 2009/12 [Refereed]
   

  Objective. To examine safety and efficacy of combination therapy with LY231514 (pemetrexed) plus cisplatin in malignant pleural mesothelioma. Methods. Patients aged between 20 and 75 years who were not candidates for surgery, who were given histological diagnoses of malignant pleural mesothelioma, had received no prior systemic chemotherapy, with a performance status (PS) of 0 or 1, and who had normal major organ function were enrolled. On day 1 of a 21-day cycle, patients received intravenous infusion of 500 mg/m2 pemetrexed, followed by intravenous infusion of 75 mg/m2 cisplatin, concomitantly with vitamin preparations. Results. Ten men and two women with a mean age of 63 years (range 50 to 73) were analyzed. The histological subtype was epithelioid in 8 patients, sarcomatoid in 2 patients, and biphasic in 2 patients. Ten patients had stage III/IV disease. Seven patients had a history of asbestos exposure. Hematological toxicities of grade 3 or more included decreased white blood cell count in 1 patient (8.3%) and decreased neutrophil count in 1 patient (8.3%), decreased lymphocyte count in 2 patients (16.7%) and decreased red blood cell count in 2 patients (16.7%), decreased hemoglobin in 4 patients (33.3%), and decreased platelet count in 2 patients (16.7%). Pneumonia was observed in 1 patient (8.3%). Common non-hematological toxicities included gastrointestinal toxicities, such as nausea, vomiting, and anorexia. The response rate was 25.0%. Conclusion. Safety of this combination therapy was confirmed in patients with malignant pleural mesothelioma. © 2009 The Japan Lung Cancer Society.
• All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice

  C. Tabata; R. Tabata; N. Hirayama; A. Yasumitsu; S. Yamada; A. Murakami; S. Iida; K. Tamura; T. Terada; K. Kuribayashi; K. Fukuoka; T. Nakano

  European Respiratory Journal 34 (5) 1159 - 1166 0903-1936 2009/11 [Refereed]
   

  Malignant pleural mesothelioma (MPM) is an aggressive malignant tumour of mesothelial origin associated with asbestos exposure. Because MPM has limited response to conventional chemotherapy and radiotherapy, the prognosis is very poor. Several researchers have reported that cytokines such as interleukin (IL)-6 play an important role in the growth of MPM. Previously, it was reported that all-trans-retinoic acid (ATRA) inhibited the production and function of IL-6 and transforming growth factor (TGF)-β1 in experiments using lung fibroblasts. We investigated whether ATRA had an inhibitory effect on the cell growth of MPM, the origin of which was mesenchymal cells similar to lung fibroblasts, using a subcutaneous xenograft mouse model. We estimated the tumour growth and performed quantitative measurements of IL-6, TGF-β1 and platelet-derived growth factor (PDGF) receptor (PDGFR)-β mRNA levels both of cultured MPM cells and cells grown in mice with or without the administration of ATRA. ATRA significantly inhibited MPM tumour growth. In vitro studies disclosed that the administration of ATRA reduced 1) mRNA levels of TGF-β1, TGF-β1 receptors and PDGFR-β, and 2) TGF-β1-dependent proliferation and PDGF-BB-dependent migration of MPM cells. These data may provide a rationale to explore the clinical use of ATRA for the treatment of MPM. Copyright©ERS Journals Ltd 2009.
• Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer

  Fumihiro Tanaka; Kazue Yoneda; Nobuyuki Kondo; Masaki Hashimoto; Teruhisa Takuwa; Seiji Matsumoto; Yoshitomo Okumura; Shakibur Rahman; Noriaki Tsubota; Tohru Tsujimura; Kozo Kuribayashi; Kazuya Fukuoka; Takashi Nakano; Seiki Hasegawa

  CLINICAL CANCER RESEARCH AMER ASSOC CANCER RESEARCH 15 (22) 6980 - 6986 1078-0432 2009/11 [Refereed]
   

  Purpose: To investigate the diagnostic performance of circulating tumor cells (CTC) in discrimination between primary lung cancer and nonmalignant diseases as well as in prediction of distant metastasis. Patients and Methods: We prospectively evaluated CTCs in 7.5-mL samples of peripheral blood sampled from patients with a suspicion or a diagnosis of primary lung cancer. A semiautomated system was used to capture CTCs with an antibody against epithelial cell adhesion molecule. Results: Of 150 eligible patients, 25 were finally diagnosed as having nonmalignant disease, and 125 were diagnosed as having primary lung cancer with (n = 31) or without (n = 94) distant metastasis. CTCs were detected in 30.6% of lung cancer patients and in 12.0% of nonmalignant patients. CTC count was significantly higher in lung cancer patients than in nonmalignant patients, but a receiver operating characteristic (ROC) curve analysis showed an insufficient capability of the CTC test in discrimination between lung cancer and nonmalignant diseases with an area under ROC curve of 0.598 (95% confidence interval, 0.488-0.708; P = 0.122). Among lung cancer patients, CTC count significantly increased along with tumor progression, especially with development of distant metastasis. The area under ROC curve for CTC count in prediction of distant metastasis was 0.783 (95% confidence interval, 0.679-0.886; P < 0.001). When patients with one or more CTCs were judged as having metastatic disease, sensitivity and specificity of the CTC test were 71.0% and 83.0%, respectively. Conclusions: CTC is a useful surrogate marker of distant metastasis in primary lung cancer. (Clin Cancer Res 2009;15(22):6980-6)
• 中皮腫細胞の形態を科学する 中皮腫細胞診断の現状と問題点 胸水細胞診から科学する早期中皮腫の病態と細胞像

  辻村 亨; 鳥井 郁子; 佐藤 鮎子; 片岡 竜貴; 西上 隆之; 山本 格士; 福岡 和也; 田中 文啓; 長谷川 誠紀; 中野 孝司

  日本臨床細胞学会雑誌 (公社)日本臨床細胞学会 48 (Suppl.2) 430 - 430 0387-1193 2009/09
• 早期悪性胸膜中皮腫 病理診断の問題点と対策

  辻村 亨; 佐藤 鮎子; 鳥井 郁子; 玉置 知子; 吉川 良恵; 福岡 和也; 田中 文啓; 長谷川 誠紀; 中野 孝司

  肺癌 (NPO)日本肺癌学会 49 (4) 376 - 379 0386-9628 2009/08 

  目的.早期中皮腫病変(EM)と反応性中皮過形成(RM)との鑑別は治療方針を決定する上で極めて重要であるが、これらの病変を形態的に鑑別することは難しい。我々は悪性胸膜中皮腫(MPM)ではp16INK4A遺伝子やNF2遺伝子が高頻度に欠失することに着目し、これらの遺伝子異常がEMとRMの鑑別に有用であるのかどうかを検討した。方法.形態的特徴に免疫組織化学染色を加えて評価し、MPM(16例)、RM(3例)、EM(2例)を選別した。これらの症例についてp16INK4A遺伝子とNF2遺伝子の欠失領域のプライマーを作製し、ゲノムDNAを鋳型にしたリアルタイムPCRにより遺伝子欠失の有無を検討した。結果.全てのRM症例でp16INK4A遺伝子とNF2遺伝子はともに保存されていたのに対して、MPMの全ての症例でp16INK4A遺伝子が欠失するとともにNF2遺伝子も高頻度に欠失していた。また、EMの2症例でp16INK4A遺伝子の欠失がみられ、その内の1例はNF2遺伝子も欠失していた。結論.p16INK4AとNF2の遺伝子診断は、EMとRMの鑑別に極めて有用であると考えられる。(著者抄録)
• 胸壁浸潤を示した高分化乳頭型悪性胸膜中皮腫の1例

  鳥井 郁子; 佐藤 鮎子; 西上 隆之; 辻村 亨; 寺田 貴普; 福岡 和也; 中野 孝司; 橋本 昌樹; 長谷川 誠紀

  肺癌 (NPO)日本肺癌学会 49 (4) 528 - 528 0386-9628 2009/08
• 肺原発のMucinous("colloid")adenocarcinomaの1切除例

  田村 邦宣; 福岡 和也; 三上 浩司; 前田 理沙; 野木 佳孝; 平山 倫子; 岡田 あすか; 寺田 貴普; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明; 田中 文啓; 長谷川 誠紀; 鳥井 郁子; 佐藤 鮎子; 辻村 亨

  肺癌 (NPO)日本肺癌学会 49 (4) 530 - 530 0386-9628 2009/08
• Osteopontin Modulates Malignant Pleural Mesothelioma Cell Functions In Vitro

  Rina Ohashi; Ken Tajima; Fumiyuki Takahashi; Ri Cui; Tao Gu; Kazue Shimizu; Kazuto Nishio; Kazuya Fukuoka; Takashi Nakano; Kazuhisa Takahashi

  ANTICANCER RESEARCH INT INST ANTICANCER RESEARCH 29 (6) 2205 - 2214 0250-7005 2009/06 [Refereed]
   

  Background: Although serum osteopontin (OPN) concentration is elevated in patients with malignant pleural mesothelioma (MPM), the role of OPN in the pathogenesis and development of MPM remains unknown. Materials and Methods: To determine the roles of OPN in MPM, immunohistochemical staining was performed to investigate the concentration of OPN in the pleural tumor of patients with mesothelioma; cell adhesion, proliferation and migration assays of H28 cells, an MPM cell line, were also carried out in vitro. Results: H28 cells cultured on OPN-coated plates revealed enhanced adhesion, proliferation, migration, cell survival and phosphorylated focal adhesion kinase activities. As expected, these enhancements were markedly suppressed with the addition of anti-alpha v beta 3 antibody or arginine-glycine-aspartic acid serine (RGDS) peptide to the medium. Conclusion: OPN is speculated to play an important role in the enhancement of adhesion, proliferation and migration activities of H28 cells, presumably by interacting with the alpha v beta 3 integrin.
• 悪性中皮腫における染色体構造異常の検討

  村上 亜紀; 福岡 和也; 平山 倫子; 寺田 貴普; 安光 亮洋; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明; 田中 文啓; 長谷川 誠紀; 吉川 良恵; 玉置 知子; 佐藤 鮎子; 辻村 亨

  日本呼吸器学会雑誌 (一社)日本呼吸器学会 47 (増刊) 237 - 237 1343-3490 2009/05
• 限局型悪性胸膜中皮腫の1例

  山田 秀哉; 福岡 和也; 栗林 康造; 田端 千春; 田村 邦宣; 飯田 慎一郎; 村上 亜紀; 安光 亮洋; 寺田 貴普; 平山 倫子; 中野 孝司; 坪田 紀明; 橋本 昌樹; 多久和 輝尚; 奥村 好邦; 近藤 展行; 田中 文啓; 長谷川 誠紀; 鳥井 郁子; 佐藤 鮎子; 辻村 亨

  肺癌 (NPO)日本肺癌学会 49 (2) 222 - 222 0386-9628 2009/04
• のう胞形成性脳転移をきたした悪性胸膜中皮腫の1例

  村上 亜紀; 寺田 貴普; 平山 倫子; 安光 亮洋; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 栗林 康造; 福岡 和也; 中野 孝司; 坪田 紀明; 田中 文啓; 長谷川 誠紀; 佐藤 鮎子; 鳥井 郁子; 辻村 亨

  肺癌 (NPO)日本肺癌学会 49 (2) 222 - 223 0386-9628 2009/04
• A Feasibility Study of Induction Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Postoperative Hemithoracic Radiation for Malignant Pleural Mesothelioma

  Takeharu Yamanaka; Fumihiro Tanaka; Seiki Hasegawa; Morihito Okada; Toshinori Soejima; Norihiko Kamikonya; Kazuya Fukuoka; Takashi Nakano

  JAPANESE JOURNAL OF CLINICAL ONCOLOGY OXFORD UNIV PRESS 39 (3) 186 - 188 0368-2811 2009/03 [Refereed]
   

  A prospective multi-institutional study has been commenced in Japan to evaluate the feasibility of induction chemotherapy using pemetrexed plus cisplatin, followed by extrapleural pneumonectomy (EPP) and postoperative hemithoracic radiation in patients with resectable malignant pleural mesothelioma. The study was initiated on May 2008 and 40 patients will be recruited over 3 years. Primary endpoints are macroscopic complete resection rate by EPP and treatment-related mortality for trimodality therapy. Secondary endpoints include treatment completion rate, adverse events, response rate by chemotherapy and 2-year overall and relapse-free survival.
• 11.集学的治療が奏効した早期悪性胸膜中皮腫の1例 : 胸腔鏡所見を中心に(第84回日本呼吸器内視鏡学会近畿支部会)

  田村 邦宣; 福岡 和也; 平山 倫子; 寺田 貴普; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明; 田中 文啓; 長谷川 誠紀; 辻村 亨

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 31 (2) 109 - 109 2009
• 1.気道異物の1症例(第85回日本呼吸器内視鏡学会近畿支部会)

  平山 倫子; 福岡 和也; 三上 浩司; 前田 理沙; 野木 佳孝; 寺田 貴普; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明; 多久和 輝尚; 田中 文啓; 長谷川 誠紀; 塚本 吉胤

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 31 (5) 334 - 334 2009
• OR11-4 胸腔鏡検査にてTlaと診断した悪性胸膜中皮腫症例の臨床病理学的検討(胸腔鏡2,一般口演11,第32回日本呼吸器内視鏡学会学術集会)

  平山 倫子; 福岡 和也; 三上 浩司; 前田 理沙; 野木 佳孝; 寺田 貴普; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明; 田中 文啓; 長谷川 誠紀; 辻村 亨

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 31 S109  2009
• OR24-4 悪性胸膜中皮腫診断におけるNarrow Band Imaging(NBI)を併用した局所麻酔下胸腔鏡の有用性についての検討(AFI・NBI,一般口演24,第32回日本呼吸器内視鏡学会学術集会)

  安光 亮洋; 福岡 和也; 寺田 貴普; 田村 邦宣; 平山 倫子; 三上 浩司; 前田 理沙; 野木 佳孝; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田端 千春; 栗林 康造; 坪田 紀明; 中野 孝司

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 31 S134  2009
• P2-2 悪性胸膜中皮腫の生検方法の選択 : 局麻下胸腔鏡と全麻VATSの適応(胸膜疾患の診断-開胸生検か局麻下胸腔鏡か,パネルディスカッション2,第32回日本呼吸器内視鏡学会学術集会)

  奥村 好邦; 橋本 昌樹; 多久和 輝尚; 近藤 展行; 田中 文啓; 長谷川 誠紀; 福岡 和也; 中野 孝司; 坪田 紀明

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 31 S83  2009
• Impairment in cytotoxicity and expression of NK cell-activating receptors on human NK cells following exposure to asbestos fibers

  Yasumitsu Nishimura; Y. Miura; M. Maeda; N. Kumagai; S. Murakami; H. Hayashi; K. Fukuoka; T. Nakano; T. Otsuki

  International Journal of Immunopathology and Pharmacology 22 (3) 579 - 590 0394-6320 2009 

  Asbestos is well-known for its tumorigenic activity, but its effect on anti-tumor immunity remains unclear. Therefore, we prepared a sub-line of YT-A1 human NK cells exposed to chrysotile B (CB) asbestos (YT-CB5) as an in vitro model to analyze the effect of asbestos exposure on NK cells, and examined cytotoxicity and expressions of its related molecules. The cytotoxicity of YT-CB5 against K562 cells decreased compared with the original line of YT-A1 (YT-Org). YT-CB5 exhibited significant decreases in expressions of cell surface NKG2D, 2B4 and intracellular granzyme A. YT-CB5 also exhibited a decrease in the 2B4-dependent cytotoxicity. In addition, the degranulations stimulated via cell surface NKG2D and 2B4 also decreased in YT-CB5. Therefore, peripheral blood NK cells in patients with malignant mesothelioma (MM) were examined and compared with healthy volunteers. NK cells in patients with MM also showed decreases in cytotoxicity against K562. Although the expressions of NKG2D and 2B4 did not decrease in NK cells of MM patients, the expression of cell surface NKp46 decreased. To confirm the effect of asbestos exposure on peripheral blood NK cells, PBMCs were cultured under exposure to CB. NK cells in PBMCs exposed to CB in vitro showed a significant decrease in the expression of NKp46, whereas NK cells in PBMCs exposed to glass wool did not show such a decrease. These results indicate that exposure to asbestos has the potential to impair the cytotoxicity of NK cells and alter the expression of NK cell-activating receptors including NKG2D, 2B4 and NKp46 and intracellular perforin/granzymes. Copyright © by BIOLIFE, s.a.s.
• CMV Infection Presenting as a Cavitary Lung Lesion in a Patient with Systemic Lupus Erythematosus Receiving Immunosuppressive Therapy

  Naoto Azuma; Naoaki Hashimoto; Akihiro Yasumitsu; Kazuya Fukuoka; Kazunori Yokoyama; Hisashi Sawada; Aki Nishioka; Masahiro Sekiguchi; Masayasu Kitano; Takanori Kuroiwa; Kiyoshi Matsui; Hajime Sano

  INTERNAL MEDICINE JAPAN SOC INTERNAL MEDICINE 48 (24) 2145 - 2149 0918-2918 2009 [Refereed]
   

  We report a case of cytomegalovirus (CMV) pneumonitis that presented as a cavitary lung lesion in a patient with systemic lupus erythematosus receiving immunosuppressive treatment. The lesion was confirmed by positive polymerase chain reaction (PCR) for CMV in bronchoalveolar lavage fluid (BALF) and CMV antigenemia. PCR for CMV in BALF was demonstrated to be useful for the diagnosis of CMV pneumonitis on the basis of high sensitivity and specificity. After initiating ganciclovir, the lesion gradually regressed. A cavitary lung lesion associated with CMV is extremely rare. This presentation suggests that the differential diagnosis of cavitary lung lesion in immunocompromised individuals should include CMV.
• 悪性胸膜中皮腫に対するシスプラチン・ペメトレキセド併用療法による術前導入化学療法の検討

  福岡 和也; 栗林 康造; 寺田 貴普; 平山 倫子; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 中野 孝司; 田中 文啓; 長谷川 誠紀; 佐藤 鮎子; 鳥井 郁子; 辻井 亨; 坪田 紀明

  肺癌 (NPO)日本肺癌学会 48 (5) 438 - 438 0386-9628 2008/10
• 悪性胸膜中皮腫におけるゲノムコピー数異常の検討

  村上 亜紀; 福岡 和也; 平山 倫子; 寺田 貴普; 安光 亮洋; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明; 田中 文啓; 長谷川 誠紀; 吉川 良恵; 玉置 知子; 佐藤 鮎子; 辻村 亨

  肺癌 (NPO)日本肺癌学会 48 (5) 509 - 509 0386-9628 2008/10
• 悪性中皮腫より樹立細胞株のアレイCGH解析(Array CGH analysis of cell lines established from malignant mesotheliomas)

  吉川 良恵; 佐藤 鮎子; 山田 秀哉; 福岡 和也; 辻村 亨; 家本 敦子; 長谷川 誠紀; 玉置 知子[橋本]; 中野 孝司

  日本癌学会総会記事 (一社)日本癌学会 67回 66 - 66 0546-0476 2008/09
• Photodynamic therapy using Light Emitting Diode (LED) for malignant mesothelioma

  IMAI Kentaro; USUDA Jitsuo; ICHINOSE Shuji; ISHIZUMI Taichiro; HIRATA Takeshi; INOUE Tatsuya; OHTANI Keishi; MAEHARA Sachio; KUBOTA Mitsuhiro; TSUNODA Yoshihiko; YAMADA Masae; KUROIWA Yukari; Tsutsui Hidemitsu; YAMADA Kimito; FURUKAWA Kinya; OKUNAKA Tetsuya; FUKUOKA Kazuya; NAKANO Takashi; KATO Harubumi

  JJSLSM Japan Society for Laser Surgery and Medicine 29 (1) 12 - 17 0288-6200 2008/04 

  Malignant pleural mesothelioma is an aggressive malignancy which can be associated with asbesto's exposure. There is no proven curative modality and the median survival ranges from 6-18 months. Recently, the multitargeted antifolate pemetrexed (ALIMTA^®) has been approved as the front-line agent in combination with cisplatin for the treatment of malignant mesothelioma. However, the overall outcome remains very poor despite current available therapies. In this study, we developed a new treatment strategy for malignant mesothelioma by photodynamic therapy (PDT) using Laserphyrin^® and an LED (light emitting diode). We performed sensitivity tests on human malignant mesothelima cell lines, MSTO-211H, NCI-H2052, NCI-H2452, NCI-H28 cells against PDT using LED in vitro. PDT using LED and Laserphyrin^® had strong anti-tumor effect. Furthermore, we transplanted MSTO-211H cells into Balb/c nude mice, and we performed PDT in vivo. PDT using an LED cured the tumor as completely as PDT using laser in vivo.
  We conclude that PDT using LEDs can be useful for malignant mesothelioma in the experiment clinically and we hope to develop LEDs system for the thoracic wall. we will conduct clinical study combining PDT using LEDs and anti-cancer agents for malignant mesothelioma.
• Immunological changes in mesothelioma patients and their experimental detection.

  Megumi Maeda; Yoshie Miura; Yasumitsu Nishimura; Shuko Murakami; Hiroaki Hayashi; Naoko Kumagai; Tamayo Hatayama; Minako Katoh; Naomi Miyahara; Shoko Yamamoto; Kazuya Fukuoka; Takumi Kishimoto; Takashi Nakano; Takemi Otsuki

  Clinical medicine. Circulatory, respiratory and pulmonary medicine 2 11 - 7 1178-1157 2008/03 [Refereed]
   

  It is common knowledge that asbestos exposure causes asbestos-related diseases such as asbestosis, lung cancer and malignant mesothelioma (MM) not only in people who have handled asbestos in the work environment, but also in residents living near factories that handle asbestos. These facts have been an enormous medical and social problem in Japan since the summer of 2005. We focused on the immunological effects of asbestos and silica on the human immune system. In this brief review, we present immunological changes in patients with MM and outline their experimental detection. For example, there is over-expression of bcl-2 in CD4+ peripheral T-cells, high plasma concentrations of interleukin (IL)-10 and transforming growth factor (TGF)-ß, and multiple over-representation of T cell receptor (TcR)-Vß in peripheral CD3+ T-cells found in MM patients. We also detail an experimental long-term exposure T-cell model. Analysis of the immunological effects of asbestos may help our understanding of the biological effects of asbestos.
• Immunological alterations found in mesothelioma patients and supporting experimental evidence.

  Yoshie Miura; Yasumitsu Nishimura; Megumi Maeda; Shuko Murakami; Hiroaki Hayashi; Kazuya Fukuoka; Takumi Kishimoto; Takashi Nakano; Takemi Otsuki

  Environmental health and preventive medicine 13 (2) 55 - 9 1342-078X 2008/03 [Refereed]
   

  It is common knowledge that exposure to asbestos causes asbestos-related diseases, such as asbestosis, lung cancer and malignant mesothelioma, not only in people who have had long-term contact with asbestos in their work environment but also in residents living near factories that handle asbestos. Since the summer of 2005, these revelations turned into a large medical problem and caused and social unrest. We have focused on the immunological effects of both asbestos and silica on the human immune system. In this brief review, we introduce immunological alterations found in patients with malignant mesothelioma and describe the experimental background in which these were found. Analyzing the immunological effects of asbestos may improve our understanding of the biological effects of asbestos.
• 11.間質性肺炎,肺非結核性抗酸菌症の経過中に肺癌を発症した1例(第83回日本呼吸器内視鏡学会近畿支部会)

  田村 邦宣; 福岡 和也; 平山 倫子; 寺田 貴普; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 30 (5) 331 - 331 2008
• O05-03 悪性胸腹中皮腫に対する胸腔鏡下生検の適応と注意点(胸膜中皮腫,第25回日本呼吸器外科学会総会)

  奥村 好邦; 橋本 昌樹; 多久和 輝尚; 近藤 展行; 田中 文啓; 長谷川 誠紀; 福岡 和也; 中野 孝司

  日本呼吸器外科学会雑誌 特定非営利活動法人 日本呼吸器外科学会 22 (3) 419 - 419 2008
• Thoracoscopy Combined with Autofluorescence Imaging and Narrow Band Imaging for the Diagnosis of Malignant Pleural Mesothelioma

  Uesaka Ayuko; Fukuoka Kazuya; Miyake Mitsutomi; Murakami Aki; Yamada Syusai; Tamura Kunihiro; Iida Shin-ichiro; Nobuyama Seiichi; Kuribayashi Kozo; Miyata Shigeru; Takuwa Teruhisa; Matsumoto Seiji; Okumura Yoshitomo; Tanaka Fumihiro; Hasegawa Seiki; Nakano Takashi

  The Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 30 (1) 5 - 12 0287-2137 2008 

  Background and Objective. Thoracoscopy is an essential procedure for the definitive diagnosis of malignant pleural mesothelioma(MPM). However, in some cases of early-stage MPM, it is difficult to detect a lesion even through conventional thoracoscopy. In the present study, to improve the diagnostic accuracy of thoracoscopy on MPM, autofluorescence imaging(AFI) and a narrow band imaging(NBI) system were assessed in combination with the conventional method. Subjects and Methods. Thoracoscopy combined with AFI and NBI was performed on 12 patients with pleural fluid retention, suspected of MPM. Thoracoscopy under local anesthesia and video-assisted thoracoscopic surgery(VATS) were performed on 7 and 5 patients, respectively. Examination was carried out using a flexible bronchoscope(Olympus BF-F260) for AFI and a conventional white light thoracoscope(Olympus LTF-240) for NBI. Results. In 7 of 12 patients, a diagnosis of MPM was made by pleural biopsy using thoracoscopy combined with AFI and NBI. Autofluorescence thoracoscopy showed that nodules suspicious for mesothelioma were clearly visualized as magenta fluorescence, while the intact pleura appeared green in color. In the cases of MPM, thoracoscopy with NBI demonstrated emphasized irregularity of the pleura compared with findings on conventional white light thoracoscopy, and abnormal pink/white nodules with increased vessel growth were easily detected. Conclusion. Thoracoscopy combined with AFI and NBI is a novel tool for the diagnosis of MPM. There is a possibility that this procedure may make it possible to distinguish between pleural lesions due to MPM and the intact pleura more accurately.
• P20-2 気管支内視鏡検査が診断に有用であった抗酸菌感染症の3例(結核その他の感染,ポスター20,第31回日本呼吸器内視鏡学会学術集会)

  山田 秀哉; 福岡 和也; 栗林 康造; 田端 千春; 田村 邦宣; 飯田 慎一郎; 村上 亜紀; 安光 亮洋; 平山 倫子; 寺田 貴普; 中野 孝司; 田中 文啓; 長谷川 誠紀; 坪田 紀明

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 30 S208  2008
• OR5-4 悪性胸膜中皮腫における特殊光内視鏡を導入した胸腔鏡検査の有用性に関する検討(蛍光内視鏡,一般口演5,第31回日本呼吸器内視鏡学会学術集会)

  安光 亮洋; 福岡 和也; 寺田 貴普; 平山 倫子; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 栗林 康造; 田端 千春; 坪田 紀明; 中野 孝司

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 30 S144  2008
• Y3-3 悪性胸膜中皮腫の診断におけるFDG-PETの有用性についての検討(縦隔鏡・PET,要望演題3,第31回日本呼吸器内視鏡学会学術集会)

  栗林 康造; 福岡 和也; 寺田 貴普; 平山 倫子; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 中野 孝司; 坪田 紀明

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 30 S115  2008
• Y2-3 早期悪性胸膜中皮腫の病理診断における遺伝子発現解析の有用性(胸膜疾患に対する診断の開発,要望演題2,第31回日本呼吸器内視鏡学会学術集会)

  福岡 和也; 辻村 亨; 玉置 知子; 安光 亮洋; 平山 倫子; 寺田 貴晋; 村上 亜紀; 山田 秀哉; 田端 千春; 飯田 慎一郎; 田村 邦宣; 栗林 康造; 田中 文啓; 長谷川 誠紀; 坪田 紀明; 中野 孝司

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 30 S113  2008
• W5-1 悪性胸膜中皮腫の臨床診断と治療戦略(悪性中皮腫の診断・治療の進歩,ワークショップ5,第31回日本呼吸器内視鏡学会学術集会)

  中野 孝司; 福岡 和也; 栗林 康造; 村上 亜紀; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 安光 亮洋; 平山 倫子; 坪田 紀明; 長谷川 誠紀; 田中 文啓

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 30 S97  2008
• Two Cases of Intense ^<18>F-fluorodeoxyglucose Uptake Caused by Asbestosis

  Kuribayashi Kozo; Fukuoka Kazuya; Yasumitsu Akihiro; Terada Takayuki; Hirayama Noriko; Murakami Aki; Yamada Syusai; Iida Shinichiro; Tamura Kunihiro; Tabata Chiharu; Nakano Takashi

  The Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 30 (6) 406 - 411 0287-2137 2008 

  Case 1. A 73-year-old man was admitted to our hospital for evaluation of a pulmonary nodule in the right S^<10> segment and #3, #7 mediastinal lymphadenopathy. On ^<18>F-fluorodeoxyglucose positron emission tomography (^<18>FDG-PET), the nodule showed substantial uptake of ^<18>F-fluorodeoxyglucose. Bronchoscopic biopsy did not yield diagnostic material. Mediastinoscopic lymph node biopsy showed fibroblasts and histiocytes. Case 2. A 74-year-old man was admitted to our hospital for evaluation of #3, #7 mediastinal lymphadenopathy. On ^<18>FDG-PET, the nodule showed substantial uptake of ^<18>F-fluorodeoxyglucose. Mediastinoscopic lymph node biopsy showed granuloma formation with multinuclear Langhans giant cells. Conclusion. Asbestosis should be considered as a possibility when interpreting the ^<18>FDG-PET of patients with mediastinal lymphadenopathy.
• [Expression of mesothelin as a potential diagnostic marker in mesothelioma].

  Kuribayashi K; Fukuoka K; Nakajima T; Miyake M; Miyata S; Tamura K; Iida S; Yamada S; Murakami A; Hirano H; Nakano T

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 46 (1) 3 - 9 1343-3490 2008/01 [Refereed]
  
• 悪性中皮腫の克服に向けて 早期悪性胸膜中皮腫 病理診断の問題点と対策

  辻村 亨; 佐藤 鮎子; 鳥井 郁子; 玉置 知子; 吉川 良恵; 福岡 和也; 田中 文啓; 長谷川 誠紀; 中野 孝司

  肺癌 (NPO)日本肺癌学会 47 (5) 448 - 448 0386-9628 2007/10
• [A case of primary lung cancer with cervical tuberculous lymphadenitis].

  Yamada S; Fukuoka K; Miyake M; Miyata S; Nakajima T; Tamura K; Tabata C; Iida S; Kuribayashi K; Uesaka A; Murakami A; Yasumitsu A; Nakano T

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 45 (9) 720 - 725 1343-3490 2007/09 [Refereed]
  
• Immunological effects of silica and asbestos.

  Takemi Otsuki; Megumi Maeda; Shuko Murakami; Hiroaki Hayashi; Yoshie Miura; Masayasu Kusaka; Takashi Nakano; Kazuya Fukuoka; Takumi Kishimoto; Fuminori Hyodoh; Ayako Ueki; Yasumitsu Nishimura

  Cellular & molecular immunology 4 (4) 261 - 8 1672-7681 2007/08 [Refereed]
   

  Silicosis patients (SILs) and patients who have been exposed to asbestos develop not only respiratory diseases but also certain immunological disorders. In particular, SIL sometimes complicates autoimmune diseases such as systemic scleroderma, rheumatoid arthritis (known as Caplan syndrome), and systemic lupus erythematoses. In addition, malignant complications such as lung cancer and malignant mesothelioma often occur in patients exposed to asbestos, and may be involved in the reduction of tumor immunity. Although silica-induced disorders of autoimmunity have been explained as adjuvant-type effects of silica, more precise analyses are needed and should reflect the recent progress in immunomolecular findings. A brief summary of our investigations related to the immunological effects of silica/asbestos is presented. Recent advances in immunomolecular studies led to detailed analyses of the immunological effects of asbestos and silica. Both affect immuno-competent cells and these effects may be associated with the pathophysiological development of complications in silicosis and asbestos-exposed patients such as the occurrence of autoimmune disorders and malignant tumors, respectively. In addition, immunological analyses may lead to the development of new clinical tools for the modification of the pathophysiological aspects of diseases such as the regulation of autoimmunity or tumor immunity using cell-mediated therapies, various cytokines, and molecule-targeting therapies. In particular, as the incidence of asbestos-related malignancies is increasing and such malignancies have been a medical and social problem since the summer of 2005 in Japan, efforts should be focused on developing a cure for these diseases to eliminate nationwide anxiety.
• AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor

  Masayuki Takeda; Tokuzo Arao; Hideyuki Yokote; Teruo Komatsu; Kazuyoshi Yanagihara; Hiroki Sasaki; Yasuhide Yamada; Tomohide Tamura; Kazuya Fukuoka; Hiroshi Kimura; Nagahiro Saijo; Kazuto Nishio

  CLINICAL CANCER RESEARCH AMER ASSOC CANCER RESEARCH 13 (10) 3051 - 3057 1078-0432 2007/05 [Refereed]
   

  Purpose: AZD2171 is an oral, highly potent, and selective vascular endothelial growth factor signaling inhibitor that inhibits all vascular endothelial growth factor receptor tyrosine kinases. The purpose of this study was to investigate the activity of AZD2171 in gastric cancer.Experimental Design: We examined the antitumor effect of AZD2171 on the eight gastric cancer cell lines in vitro and in vivo.Results: AZD2171 directly inhibited the growth of two gastric cancer cell lines (KATO-III and OCUM2M), with an IC50 of 0.15 and 0.37 mu mol/L, respectively, more potently than the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib. Reverse transcription-PCR experiments and immunoblotting revealed that sensitive cell lines dominantly expressed COOH terminus truncated fibroblast growth factor receptor 2 (FGFR2) splicing variants that were constitutively phosphorylated and spontaneously dimerized. AZD2171 completely inhibited the phosphorylation of FGFR2 and downstream signaling proteins (FRS2, AKT, and mitogen-activated protein kinase) in sensitive cell lines at a 10-fold lower concentration (0.1 mu mol/L) than in the other cell lines. An in vitro kinase assay showed that AZD2171 inhibited kinase activity of immunoprecipitated FGFR2 with submicromolar K-i values (similar to 0.05 mu mol/L). Finally, we assessed the antitumor activity of AZD2171 in human gastric tumor xenograft models in mice. Oral administration of AZD2171 (1.5 or 6 mg/kg/d) significantly and dose-dependently inhibited tumor growth in mice bearing KATO-III and OCUM2M tumor xenografts.Conclusions: AZD2171 exerted potent antitumor activity against gastric cancer xenografts overexpressing FGFR2. The results of these preclinical studies indicate that AZD2171 may provide clinical benefit in patients with certain types of gastric cancer.
• 1.最近経験した気管・気管支結核症の1例(第81回 日本呼吸器内視鏡学会近畿支部会)

  安光 亮洋; 栗林 康造; 福岡 和也; 三宅 光富; 宮田 茂; 田端 千春; 田村 邦宣; 飯田 慎一郎; 山田 秀哉; 村上 亜紀; 中野 孝司

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 29 (5) 318 - 318 2007
• 15.局所麻酔下胸腔鏡にて診断された小細胞癌の1例(第80回 日本呼吸器内視鏡学会近畿支部会)

  南 高正; 栗林 康造; 三宅 光富; 宮田 茂; 中嶋 楽典; 田村 邦宣; 飯田 慎一郎; 上板 亜由子; 山田 秀哉; 村上 亜紀; 福岡 和也; 中野 孝司; 松田 育雄; 廣田 誠一

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 29 (1) 64 - 64 2007
• Efficacy of Respiratory Endoscopy on Subjects Requiring Further Detailed Examinations After Initial Asbestos-related Disease Screening

  Fukuoka Kazuya; Uesaka Ayuko; Kuribayashi Kozo; Miyake Mitsutomi; Miyata Shigeru; Nakajima Taisuke; Iida Shin-ichiro; Nobuyama Seiichi; Tamura Kunihiro; Yamada Syusai; Murakami Aki; Takuwa Teruhisa; Matsumoto Seiji; Okumura Yoshitomo; Tanaka Fumihiro; Hasegawa Seiki; Nakano Takashi

  The Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 29 (3) 177 - 185 0287-2137 2007 

  Purpose. We evaluated the efficacy of respiratory endoscopy on subjects requiring further detailed examinations as a result of initial asbestos-related disease screening. Methods. The subjects consisted of 132 participants who underwent asbestos-related disease screening in our hospital between July 2005 and March 2006. According to their history of screening, the participants were classified into the initial screening group and the second screening group. The former consisted of 76 participants without prior screening, while the latter consisted of 56 participants who were referred to our hospital for the detailed examinations as a result of initial screening undergone elsewhere. The participants were examined concerning their history of asbestos exposure, and then underwent chest X-ray followed by chest computed tomography (CT). Respiratory endoscopic examinations were mainly performed in participants with suspected chest malignancies. Results. There were no significant differences in the distribution of age or gender between the two screening groups. In both screening groups, more than 70% of the participants had a history of occupational exposure to asbestos. Radiological abnormalities were observed in 110 (83%) of all participants. Asbestos-related diseases were detected in a total of 90 (68%) cases. The breakdown of the 90 cases by disease was as follows: 60 cases had pleural plaque, 13 pulmonary fibrosis, 5 lung cancer (LC), 4 benign asbestos pleurisy, 4 round atelectasis, 2 diffuse pleural thickening, and 2 malignant pleural mesothelioma (MPM). The disease detection rate of LC and MPM was 3.8% and 1.5%, respectively. Respiratory endoscopic examinations were performed in a total of 15 cases. The breakdown of the 15 cases by examination was as follows: bronchoscopy was performed in 6 cases, thoracoscopy including video-assisted thoracoscopic surgery (VATS) in 8, and mediastinoscopy in 4. Two cases with early LC were diagnosed by videothoracoscopic lung biopsy. A diagnosis of MPM was made by pleural biopsy under VATS. There were no examination-related complications. Conclusion. Respiratory endoscopic examinations should be actively performed in participants with suspected chest malignancies as a result of asbestosrelated disease screening, because the procedure has a high diagnostic rate and can be safely performed.
• OR2-3 診断目的にて外科的呼吸器内視鏡を要したアスベスト関連胸部疾患の検討(一般口演2 胸腔鏡2,抄録集(4),第29回日本呼吸器内視鏡学会学術集会)

  栗林 康造; 上坂 亜由子; 三宅 光富; 宮田 茂; 中嶋 泰典; 田村 邦宣; 延山 誠一; 飯田 慎一郎; 山田 秀哉; 村上 亜紀; 福岡 和也; 中野 孝司; 奥村 好邦; 多久和 輝尚; 松本 成司; 田中 文啓; 長谷川 誠紀

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 28 (3) 171 - 171 2006
• S2-8 中皮腫に対する蛍光及びNarrow Band Imagingをもちいた胸腔鏡検査の試み(シンポジウム2 アスベスト関連疾患に対する呼吸器内視鏡的アプローチ,抄録集(2),第29回日本呼吸器内視鏡学会学術集会)

  上坂 亜由子; 三宅 光富; 村上 亜紀; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 延山 誠一; 中嶋 泰典; 栗林 康造; 宮田 茂; 福岡 和也; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 田中 文啓; 長谷川 誠紀

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 28 (3) 157 - 157 2006
• OR2-5 対側胸膜への腫瘍進展を認めた悪性胸膜中皮腫例の臨床的検討(一般口演2 胸腔鏡2,抄録集(4),第29回日本呼吸器内視鏡学会学術集会)

  三宅 光富; 栗林 康造; 上坂 亜由子; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 延山 誠一; 田村 邦宣; 宮田 茂; 中嶋 泰典; 福岡 和也; 中野 孝司

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 28 (3) 172 - 172 2006
• S2-4 アスベスト検診受診者に対する呼吸器内視鏡検査の適応と有用性に関する検討(シンポジウム2 アスベスト関連疾患に対する呼吸器内視鏡的アプローチ,抄録集(2),第29回日本呼吸器内視鏡学会学術集会)

  福岡 和也; 上坂 亜由子; 村上 亜紀; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 延山 誠一; 中島 泰典; 栗林 康造; 宮田 茂; 三宅 光富; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 田中 文啓; 長谷川 誠紀

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 28 (3) 156 - 156 2006
• 19.有瘻性癌性胸膜炎に対して,Endobronchial Watanabe Spigot(EWS)留置が奏効した肺腺癌の1例(第78回 日本呼吸器内視鏡学会近畿支部会)

  延山 誠一; 宮田 茂; 三宅 光富; 田村 邦宣; 飯田 慎一郎; 栗林 康造; 山田 秀哉; 上坂 亜由子; 村上 亜紀; 大串 晶子; 福岡 和也; 中野 孝司; 奥村 好邦; 松本 成司; 多久和 輝尚; 田中 文啓; 長谷川 誠紀

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 28 (1) 83 - 83 2006
• OP11-2 悪性胸膜中皮腫の術前評価と手術適応について(一般口演11 中皮腫,世界をリードする呼吸器外科医に!,第23回日本呼吸器外科学会総会)

  奥村 好邦; 多久和 輝尚; 松本 成司; 田中 文啓; 栗林 康造; 福岡 和也; 中野 孝司; 長谷川 誠紀

  日本呼吸器外科学会雑誌 特定非営利活動法人 日本呼吸器外科学会 20 (3) 817 - 817 2006
• 15.気管支喘息として治療されていたが,血痰を契機に発見された有茎性気管支内腫瘍の1切除例(第79回 日本呼吸器内視鏡学会近畿支部会,支部会(記録))

  中嶋 泰典; 福岡 和也; 栗林 康造; 宮田 茂; 飯田 慎一郎; 延山 誠一; 田村 邦宣; 上坂 亜由子; 山田 秀哉; 村上 亜紀; 三宅 光富; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 田中 文啓; 長谷川 誠紀; 新長 真由美; 伊藤 敬; 廣田 誠一

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 28 (5) 396 - 396 2006
• Expression of the T cell receptor Vβ repertoire in a human T cell resistant to asbestos-induced apoptosis and peripheral blood T cells from patients with silica and asbestos-related diseases

  Y. Nishimura; Y. Miura; M. Maeda; H. Hayashi; M. Dong; H. Katsuyama; M. Tomita; F. Hyodoh; M. Kusaka; A. Uesaka; K. Kuribayashi; K. Fukuoka; T. Nakano; T. Kishimoto; Takemi Otsuki

  International Journal of Immunopathology and Pharmacology 19 (4) 795 - 805 0394-6320 2006 [Refereed]
   

  To explore the effects of asbestos and silica on the human immune system, an experimental model of low-dose and long-term exposure was established using a human HTLV-1-immortalized polyclonal T cell line, MT-2 (MT-2Org). MT-2 cells were continuously exposed to asbestos at a concentration (10 μg/ml) which does not induce complete cell death during short-term exposure. After acquiring resistance to CB-induced apoptosis (designated MT-2Rst), an immunological comparison was made between the MT-2Org and MT-2Rst lines in terms of T cell receptor-Vβ (TcR-Vβ) expression. MT-2Rst cells showed excess expression of various TcR-Vβ, although TcR-Vβ-overpresenting cells were characterized as undergoing apoptosis due to first contact with CB. Patients with asbestos-related diseases (ARD), such as asbestosis and malignant mesothelioma, were compared with silicosis (SIL) patients as a disease control and with healthy donors (HD). SIL and ARD not only differed in their causative materials, silica and asbestos as mineral silicates, but also in terms of complications; autoimmune disorders in SIL and tumors in ARD. ARD patients showed a restricted overpresentation of TcR-Vβ without clonal expansion, whereas SIL patients revealed significant overpresentation of TcR-Vβ 7.2. These experimental and clinical analyses indicate the superantigenic and dysregulation of autoimmunity-inducing effects of asbestos and silica, respectively. Copyright © by Biolife, s.a.s.
• Molecular detection of SYT-SSX fusion gene transcripts currently represents the most specific and sensitive tool for diagnosing intrathoracic synovial sarcoma

  Kazuya Fukuoka

  INTERNAL MEDICINE JAPAN SOC INTERNAL MEDICINE 45 (15) 881 - 882 0918-2918 2006 [Refereed]
  
• ゲフィチニブ(イレッサ)による皮膚症状

  古林 郁乃; 勝見 祥子; 浅田 秀夫; 宮川 幸子; 福岡 和也; 木村 弘

  日本皮膚科学会雑誌 (公社)日本皮膚科学会 114 (6) 1107 - 1113 0021-499X 2004/05 

  非小細胞肺癌に対する分子標的治療薬である上皮成長因子受容体チロシンキナーゼ阻害薬のゲフィチニブを内服中に皮膚症状を生じた症例について検討した.その結果,ゲフィチニブ250mg/日,内服中に皮膚症状を生じた5症例ではゲフィチニブを隔日内服に減量したところ,皮膚症状は消失または軽快したことから用量依存性であることが確認された.挫創様皮疹・爪郭炎または浸潤性紅斑を生じた3症例の皮膚生検結果では,臨床症状が異なるにもかかわらず組織所見はいずれも表皮または毛包壁のbasal layerとsuprabasal layerに共通して障害が認められた.以上より,表皮ケラチノサイトにおけるepidermal growth factor reseptorを介する情報伝達のゲフィチニブによる阻害作用が皮膚症状の発症に関与している可能性が示唆された
• 9.ホットバイオプシーを用いた腫瘍焼灼によりQOLの改善を認めた甲状腺癌気管内浸潤の1例(第75回日本呼吸器内視鏡学会近畿支部会)

  熊本 牧子; 玉置 伸二; 本津 茂人; 友田 恒一; 福岡 和也; 濱田 薫; 木村 弘(奈良県立医科大学第2内科1); 前田 光一(同総合医療・病態検査学); 善本 英郎(同感染症センター); 小林 武彦; 家根 旦有; 細井 裕司(同耳鼻咽喉科)

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 26 (6) 574 - 574 2004
• W7-4 腎細胞癌気管支内転移に対する内視鏡的治療(ワークショップ7 気管支鏡を用いた治療)

  玉置 伸二; 前田 光一; 福岡 和也; 友田 恒一; 善本 英一郎; 濱田 薫; 木村 弘

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 26 (3) 232 - 232 2004
• Disturbance of respiratory function depends on smoking history and histological type in non-small cell lung cancer

  Hiroshi Kimura; Yuichi Takiguchi; Naoaki Sugimoto; Kazuya Fukuoka; Hiroshi Miyazawa; Mizuto Otsuji; Keiichi Nagao; Takehiko Fujisawa; Takayuki Kuriyama

  Japanese Journal of Lung Cancer Japan Lung Cancer Society 44 (4) 219 - 224 0386-9628 2004 [Refereed]
   

  Objective. When chemotherapy is conducted for the treatment of non-small cell lung cancer (NSCLC), we must pay attention to the degree of impairment of pulmonary function. So far, it is not clear whether the smoking affects pulmonary function in a different manner according to the histological types of lung cancer squamous cell carcinoma and adenocarcinoma of the lung. In order to clarify these issues, we investigated the relation of smoking index (SI), location of cancerous lesions, and pulmonary function in patients with NSCLC. Study design. A total of 307 cases (squamous cell carcinoma 117, adenocarcinoma 190), with bronchial lesions located at sites proximal to the orifice of segmental bronchi (central lesions), or beyond (peripheral lesions) using fiberoptic bronchoscopy, was divided into two groups according to SI. There were 159 cases with an SI of more than 800 (high SI), and 148 less than 400 (low SI). Results. Age and SI were higher in squamous cell carcinoma than in adenocarcinoma, and restrictive and obstructive disturbances and a decrease in DLco and widened alveolar-arterial oxygen difference (AaDO2) were more prominent in squamous cell carcinoma than in adenocarcinoma. Similar results were obtained from analyses in the patients with peripheral lesions. In particular, disturbance of diffusion capacity was more prominent in squamous cell carcinoma than in adenocarcinoma. Moreover, when the subjects were limited to the patients with peripheral lesions, pulmonary functions in the high SI group tended to be more markedly disturbed than in the low SI group. In squamous cell carcinoma, however, V̇25/Ht and DLco did not show a significant difference between high SI and low SI groups with deteriorations of these parameters being observed even in patients with low SI. Conclusion. It is concluded that the disturbance of respiratory function is more prominent in squamous cell carcinoma than in adenocarcinoma. Smoking affects the disturbance of respiratory functions in NSCLC with peripheral lesions. Squamous cell carcinoma shows greater impairment of the peripheral airways and diffusion capacity than adenocarcinoma, even in patients with an SI of less than 400.
• Endobronchial lesions involved in Mycobacterium avium infection

  K Fukuoka; Y Nakano; A Nakajima; S Hontsu; H Kimura

  RESPIRATORY MEDICINE W B SAUNDERS CO LTD 97 (12) 1261 - 1264 0954-6111 2003/12 [Refereed]
   

  Mycobacterium avium (M. avium) has been described traditionally as an opportunistic organism that causes disseminated disease in the human immunodeficiency virus (HIV)-positive population and that acts as a pulmonary pathogen in patients with underlying lung disease such as chronic obstructive pulmonary disease (COPD) or previously diagnosed tuberculosis.' Pulmonary involvement of M. avium may range from asymptomatic colonization of the airway to invasive parenchymal or cavitary disease. However, endobronchial lesions involved in M. avium infection are rare in either immunocompetent or immunosuppressed hosts.(2-6) We report here endobronchial mycobacterial infection in a HIV-negative patient.
• Two cases of endobronchial neurilemmoma and review of the literature in Japan

  K Kasahara; K Fukuoka; M Konishi; K Hamada; K Maeda; K Mikasa; H Kimura

  INTERNAL MEDICINE JAPAN SOC INTERNAL MEDICINE 42 (12) 1215 - 1218 0918-2918 2003/12 [Refereed]
   

  Neurilemmomas are benign tumors which originate from Schwann cells. They rarely occur in the trachea or bronchus. We encountered two cases of endobronchial neurilemmoma and in this context, reviewed 48 cases previously reported in Japan. Neurilemmomas can occur in all regions of the bronchial tree and they often progress into both intraluminal and extraluminal spaces. Incomplete resection results in a local recurrence, despite being rare. As for appropriate therapies, surgery, bronchofiberoptic removal and yttrium aluminum garnet (YAG) laser resection can be chosen depending on the patient's status.
• 進行非小細胞肺癌患者に対するQOL維持を目的とした外来通院集学的緩和療法の検討

  福岡 和也; 本津 茂人; 武田 真幸; 甲斐 吉郎; 小林 真也; 木村 弘

  日本呼吸器学会雑誌 (一社)日本呼吸器学会 41 (増刊) 143 - 143 1343-3490 2003/03
• 肺癌組織における腫瘍関連糖鎖抗原発現プロファイルの検討

  福岡 和也; 本津 茂人; 武田 真幸; 甲斐 吉郎; 小林 真也; 木村 弘

  日本内科学会雑誌 (一社)日本内科学会 92 (Suppl.) 245 - 245 0021-5384 2003/02
• 10.エタノール局所注入と高周波スネアの併用による内視鏡的治療を行った,腎細胞癌気管支内転移の1例(第72回日本気管支学会近畿支部会)

  豊田 幸; 玉置 伸二; 竹中 英昭; 善本 英一郎; 前田 光一; 福岡 和也; 濱田 薫; 木村 弘

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 25 (1) 56 - 56 2003
• 7.左主幹から上区支にかけて, 怒張した気管支粘膜下毛細血管の著名な増生を認めた高齢者小細胞肺癌の1例(第73回日本呼吸器内視鏡学会近畿支部会)

  武田 真幸; 福岡 和也; 奥田 由佳; 玉置 伸二; 善本 英一郎; 竹中 英昭; 濱田 薫; 木村 弘; 前田 光一; 徳山 猛; 北田 裕陸; 東口 隆一

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 25 (6) 485 - 485 2003
• Restoration of p53 gene function in 12-O-tetradecanoylphorbor 13-acetate-resistant human leukemia K562/TPA cells

  J Usuda; M Inomata; H Fukumoto; Y Iwamoto; T Suzuki; HJ Kuh; K Fukuoka; H Kato; N Saijo; K Nishio

  INTERNATIONAL JOURNAL OF ONCOLOGY PROFESSOR D A SPANDIDOS 22 (1) 81 - 86 1019-6439 2003/01 [Refereed]
   

  The human leukemia K562 cell line does not express wild-type p53 protein. Due to the loss of one p53 allele and an insertion mutation in exon 5 of the other allele resulting in a frameshift mutation, K562 cells express a truncated p53 protein of 148 amino acids. A human leukemia phorbol ester-resistant subline, K562/TPA, is cross-resistant to some anticancer agents. A remarkable difference in cell cycle progression at G1/S phase was observed in the synchronised K562/TPA cells as compared with K562 cells. Southern blot and DNA sequence analysis revealed no mutation in exon 5 of the p53 gene in K562/TPA cells. p21(Cip1) expression was also restored in K562/TPA cells confirming that the reversal of this p53 gene mutation restored wild-type p53 function in these cells. This is a unique report describing reversal of p53 gene mutation by drugs. This was associated with the expression of wild-type p53 mRNA and protein in K562/TPA cells. The K562/TPA cell line may provide a very useful tool for the investigation of the relationship between p53 status and chemosensitization.
• [A case of pulmonary arteriovenous malformation treated by transcatheter embolization using coils].

  Takahashi K; Fukuoka K; Konishi M; Takenaka H; Sakamoto M; Okamoto Y; Yoshikawa M; Nishimoto Y; Kikkawa K; Imai T; Yoneda T; Narita N; Kimura H

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 40 (11) 900 - 904 1343-3490 2002/11 [Refereed]
  
• 高度進行肺癌へのQOL維持療法 進行期非小細胞肺癌に対するQOL維持を目指した外来集学的緩和医療の検討

  福岡 和也; 本津 茂人; 甲斐 吉郎; 小林 真也; 木村 弘

  肺癌 (NPO)日本肺癌学会 42 (5) 352 - 352 0386-9628 2002/10
• 局所進行非小細胞肺癌におけるInduction therapyを含む集学的治療法の検討

  福岡 和也; 本津 茂人; 木村 弘; 櫛部 圭司; 高濱 誠; 川口 剛史; 根津 邦基; 谷口 繁樹; 甲斐 吉郎; 小林 真也; 竹澤 祐一

  日本癌治療学会誌 (一社)日本癌治療学会 37 (2) 235 - 235 0021-4671 2002/09
• 先行する核医学検査が診断に有用であった胸部悪性腫瘍症例の検討

  本津 茂人; 福岡 和也; 甲斐 吉郎; 小林 真也; 木村 弘; 今井 照彦

  日本呼吸器学会雑誌 (一社)日本呼吸器学会 40 (増刊) 239 - 239 1343-3490 2002/03
• エイズ関連カリニ肺炎予防のためのペンタミジン吸入療法の有効性と安全性 : 吸引療法の現状と将来(第25回日本気管支学会総会)

  古西 満; 善本 英一郎; 高橋 賢; 笠原 敬; 玉置 伸二; 竹中 英昭; 福岡 和也; 前田 光一; 濱田 薫; 今井 照彦

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 24 (3) 162 - 162 2002
• 7.気管支病変および肺病変にて再燃を認めたHodgkin lymphomaの1例(第70回 日本気管支学会近畿支部会)

  玉置 伸二; 北村 友宏; 平川 遼一; 本津 茂人; 善本 英一郎; 天野 逸人; 竹中 英昭; 坂本 正洋; 前田 光一; 森井 武志; 福岡 和也; 濱田 薫; 木村 弘

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 24 (1) 58 - 58 2002
• Mutational analysis of the β-tubulin gene in lung cancer.

  Tsurutani,J; Komiyama,T; Uejima,H; Tada,H; Negoro,S; Oka,M; Kohno,S; Fukuoka,K; Nakagawa,K

  Lung Cancer 35 (1) 11 - 16 0169-5002 2002 [Refereed]
   

  Recently, several studies have suggested that a major mechanism of resistance to paclitaxel might involve mutations in the β-tubulin gene in tumor cells. To investigate the frequency of β-tubulin mutations in Japanese patients with small and non-small cell lung cancer, direct sequence analysis following reverse transcription-polymerase chain reaction (RT-PCR) of the β-tubulin gene was performed using total RNA from 20 lung cancer cell lines and 22 specimens from lung cancer patients. First-strand cDNA sequence analysis of the 42 samples showed silent mutations at codon 180 of the β-tubulin gene, which encodes the GTP-binding site of the protein, and codons 195 and 217. However, neither missense nor non-sense mutations affecting microtubule dynamics, within or near the GTP-binding site of the β-tubulin gene, were detected. These results indicate that β-tubulin gene mutations might not play a major role in the mechanism of resistance to paclitaxel in Japanese lung cancer patients. Further investigations are needed to clarify the mechanism of drug resistance. © 2002 Elsevier Science Ireland Ltd. All rights reserved.
• 7.特徴的な中枢気道病変を呈し, 心嚢液貯留を認めたサルコイドーシスの1例(第69回 日本気管支学会近畿支部会)

  伊藤 武文; 福岡 和也; 岡本 行功; 坂本 正洋; 竹中 英昭; 善本 英一郎; 濱田 薫; 木村 弘; 今井 照彦; 前田 光一

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 23 (6) 573 - 573 2001
• BALF Findings in HIV-Infected Patients with Pneumocystis Carinii Pneumonia

  Yoshimoto Eiichiro; Konishi Mitsuru; Takahashi Ken; Majima Toshimasa; Murakawa Kouichi; Takenaka Hideaki; Sakamoto Masahiro; Fukuoka Kazuya; Maeda Koichi; Okamoto Yukinori; Hamada Kaoru; Mikasa Keiichi; Imai Teruhiko; Narita Nobuhiro

  The Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 23 (6) 527 - 531 0287-2137 2001 

  We studied the BALF findings in 11 HIV-infected patients with Pneumocystis carinii pneumonia(PCP). Blood examinations revealed that mean counts of CD4 positive T cells were 45/μl and that serum LDH and CRP values had increased. In BALF findings we recognized mean total cell counts had not increased greatly. The findings of BALF revealed an increase in the percentage of the lymphocytes and decrease of the CD4/8 ratio. There was no significant difference in the BALF findings of non-smokers and smokers with PCP. We compared KL-6 concentration of BALF of HIV-infected patients with and without PCP. KL-6 concentration was significantly higher in patients with PCP than without PCP. We recognized a significant relationship between BALF KL-6 concentration and serum LDH value.
• P-45 気管支神経鞘腫を合併した肺扁平上皮癌の1例

  笠原 敬; 福岡 和也; 古西 満; 善本 英一郎; 竹中 英昭; 坂本 正洋; 岡本 行功; 濱田 薫; 成田 亘啓; 今井 照彦; 前田 光一

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 23 (3) 286 - 286 2001
• II-44 気管支鏡検査を契機に診断されたHIV感染症の2例

  前田 光一; 高橋 賢; 善本 英一郎; 坂本 正洋; 竹中 英昭; 福岡 和也; 岡本 行功; 古西 満; 濱田 薫; 成田 亘啓; 今井 照彦

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 22 (3) 210 - 210 2000
• 14. 長期にわたる気道病変を観察できた限局性Wegener肉芽腫の1例(第66回 日本気管支学会近畿支部会)

  甲斐 吉郎; 岡本 行功; 福岡 和也; 善本 英一郎; 竹中 英昭; 坂本 正洋; 前田 光一; 濱田 薫; 成田 亘啓; 今井 照彦

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 22 (4) 319 - 320 2000
• 13.中枢気道狭窄に対して種々の姑息的治療を行った腺様嚢胞癌の1例(第65回 日本気管支学会近畿支部会)

  武田 研一; 前田 光一; 福岡 和也; 岡本 行功; 坂本 正洋; 善本 英一郎; 竹中 英昭; 濱田 薫; 成田 亘啓; 今井 照彦; 吉村 均; 大石 元

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 22 (1) 67 - 67 2000
• P-3 胸部放射線照射併用化学療法後に mucosal bridge を形成した若年者肺癌の一切除例 : mucosal bridge 形成機序の一考察(示説・症例 1)(第 22 回日本気管支学会総会)

  福岡 和也; 緑川 沢樹; 岡本 行功; 前田 光一; 坂本 正洋; 竹中 英昭; 善本 英一郎; 小林 厚; 成田 亘啓; 今井 照彦; 木村 道孝; 高濱 誠; 櫛部 圭司; 根津 邦基; 牧之段 潔

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 21 (3) 233 - 233 1999
• 9. 全身化学療法後に Mucosal Bridge の形成を認めた高齢者小細胞肺癌の 1 例(第 63 回 日本気管支学会近畿支部会)

  甲斐 吉郎; 福岡 和也; 岡本 行功; 前田 光一; 坂本 正洋; 竹中 英昭; 善本 英一郎; 小林 厚; 成田 亘啓; 今井 照彦; 大石 元

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 21 (5) 370 - 370 1999
• 3. BAL でカリニ肺炎とクリプトコッカス肺炎とを同時に診断しえた AIDS の 1 例(第 61 回 日本気管支学会近畿支部会)

  森 啓; 古西 満; 寺本 正治; 竹中 英昭; 坂本 正洋; 福岡 和也; 前田 光一; 岡本 行功; 成田 亘啓; 佐々木 義明; 今井 照彦

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 20 (6) 531 - 531 1998
• Cytokine producing ability of peripheral blood mononuclear cells in the clinical course of pulmonary tuberculosis

  Munehiro Nakaya; Takahiro Yoneda; Atsushi Kobayashi; Yasuhito Onohara; Yukihiro Ikoma; Atsuhiko Fukuoka; Koichi Tomoda; Hideaki Takenaka; Hideo Okamura; Chinaru Yamamoto; Kazuya Fukuoka; Takeshi Tokuyama; Yukinori Okamoto; Masanori Yoshikawa; Katsuhiko Tsukaguchi; Nobuhiro Narita

  Kekkaku 72 (6) 403 - 410 0022-9776 1997/06 [Refereed]
   

  Interferon-γ (IFN-γ) and interleukin-10 (IL-10)-producing ability of peripheral blood plastic-dish adherent cells and non-adherent cells obtained from patients with active pulmonary tuberculosis (N=17) and healthy controls (N=14) upon stimulation with purified protein derivatives (PPD) were assessed. Adherent cells and non-adherent cells were obtained two times from each patient with active pulmonary tuberculosis without any underlying diseases, on admission before the initiation of administrering anti- tuberculous drugs and 2 months later from the negative conversion of Mycobacterium tuberculosis in sputum culture. ELISA was performed to measure IFN-γ and IL-10 levels in culture media of adherent cells and non-adherent cells stimulated with PPD. IFN-γ levels produced by non adherent cells on admission were significantly higher than that of healthy controls (p< 0.001). Elevated IFN-γ levels on admission was reduced after treatment for tuberculosis (p< 0.03), but still remained higher than that in healthy controls. IL-10 levels of non adherent cells of patients were lower than those of healthy controls, although the defference was not significant. IL- 10 levels produced by non adherent cells on admission correlated with the time needed for negative conversion of bacilli in sputum culture (p< 0.05). IL-10 level produced by adherent cells from nutritionally normal patients were significantly higher than that of healthy controls (p< 0.05), and elevated IL-10 level was significantly reduced after therapy (p< 0.05). In the normonourished patients, the time needed for negative conversion of the bacilli in sputum culture of patients kept higher level of L-10 of non- adherent cells (N=5) was significantly longer than that of patients reduced IL-10 level after therapy. These results suggest that IL-10 produced by monocytes may diminish the TH1 responses of patients with pulmonary tuberculosis.
• INVESTIGATION OF SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR IN PATIENTS WITH ACTIVE TUBERCULOSIS

  ONOHARA Yasuhito; TOMODA Koichi; NAKAYA Munehiro; YOSHIKAWA Masanori; TSUKAGUCHI Katsuhiko; TOKUYAMA Takeshi; HU Akihiro; HUKUOKA Kazuya; YAMAMOTO Chinaru; YONEDA Takahiro; NARITA Nobuhiro

  Kekkaku(Tuberculosis) JAPANESE SOCIETY FOR TUBERCULOSIS 71 (7) 435 - 438 0022-9776 1996/07 

  It is assumed that soluble tumor necrosis factor receptor I and II (sTNF-R I, II) play important roles in the regulation of tumor necrosis factor alpha (TNF-α) activity.
  We measured the levels of circulating sTNF-R in patients with active pulmonary tuberculosis (n=31) and the correlation between TNF-α and sTNF-R in serum level was investigeted. We also compared sTNF-R levels before and after the treatment in 7 cases.
  Significant increase of circulating sTNF-R were found in patients with tuberculosis compared with the normal controls (n=28) (p<0.01). Moreover, significnt positive correlations were found between TNF-α and sTNF-RI and II (r=0.520, r=0.553) in serum comparing sTNF-R levels before and after the treatment for patients with tuberculosis, significant fall was found in sTNF-R I, but not in sTNF-R II.
  As a result, it is suggested that sTNF-R regulates TNF-α activity in patients with tuberculosis, and that sTNF-R I levels could be used as one of the indices to evaluate the clinical activity of tuberculosis.
• Analysis of Factors Causing Respiratory Infections during Anticancer Chemotherapy against Lung Cancer.

  Fukuoka Kazuya; Tsukaguchi Nobuhiko; Choh Sumito; Hamada Kaoru; Takenaka Hideaki; Ikoma Yukihiro; Tomoda Kouichi; Yoshikawa Masanori; Yoneda Takahiro; Narita Nobuhiro

  JJLC The Japan Lung Cancer Society 36 (1) 7 - 13 0386-9628 1996 

  In order to elucidate the factors causing respiratory infections (RI) during anticancer chemotherapy, we prospectively analyzed the changes in pharyngeal bacterial floras and the host's defensive potential against infections in lung cancer patients receiving anticancer chemotherapy with the passage of time. Twenty of primary lung cancer patients receiving systemic chemotherapy were selected for this study and 32 treatment courses, including 15 treatment courses with RI (A) and 17 treatment courses without RI (B), could be evaluated.
  In treatment course A, the changes in pharyngeal bacterial floras tended to demonstrate that pathogenic organisms were continuously isolated during, or newly isolated after anticancer chemotherapy. There were significant differences between the two treatment courses, in the frequency of patients with a poor performance status (PS) before anticancer chemotherapy, the nadirs of white blood cell counts and the changing pattern of pharyngeal bacterial floras. Multivariate analysis revealed that the changes in pharyngeal bacterial floras and PS before anticancer chemotherapy are important factors influencing susceptibility to RI during anticancer chemotherapy.
  In conclusion, these results suggested that both the changes in pharyngeal bacterial floras and the deterioration of the host's defensive potential against infections might be responsible for the development of RI during anticancer chemotherapy against lung cancer.
• Clinical benefit of nutritional assessment and support in patients with chronic obstructive pulmonary disease

  T. Yoneda; M. Yoshikawa; A. Fu; T. Tokuyama; Y. Okamoto; K. Fukuoka; C. Yamamoto; E. Okamura; H. Takenaka; K. Tomoda; Y. Onohara; M. Nakaya; A. Kobayashi; K. Tsukaguchi; N. Narita

  Japanese Journal of Thoracic Diseases 34 79 - 85 0301-1542 1996 [Refereed]
   

  Weight loss is common in patients with chronic obstructive pulmonary disease (COPD). Comprehensive nutritional assessment was conducted in two large groups of patients with COPD who were enrolled in the Respiratory failure Research Program sponsored by the Japanese Ministry of Health and Welfare and the Kinki COPD Research Group. The incidences of mild malnutrition (%IBW < 90%) were 74% and 62%, respectively. The incidences of hypoalbuminemia were low: 10.0% and 6.5%, respectively. The incidence of imbalance in plasma amino acids, which was defined as an abnormally low BCAA/AAA ratio, was as high as 93% in patients with COPD and chronic respiratory failure. The %IBW was significantly related to the FEV1 and to the DL(co)/V3. The moderately-malnourished subpopulation was characterized by a greater degree of hyperinflation and hypercapnea: the measured resting energy expenditure (REE) was significantly higher than the values in age- matched healthy controls. REE/REE(pred) was significantly and inversely related to BCAA/AAA and to P(1max). REE was inversely related to FEV1%. REE in the subgroup with severe hyperinflation was significantly higher than REE in those with milder hyperinflation. Among patients with an FEV1% of less than 50%, mortality tended to be higher in those with lower body weight, and this relationship was stronger in patients with an FEV1% of more than 50%. When patients were given a BCAA-enriched enteral formula in addition to their usual diet for 3 months, there was a significant increase in body weight, transferrin level, and P(1max).
• Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes

  Nagahiro Saijo; Kazuto Nishio; Sei Ohta; Hitoshi Arioka; Yasunori Funayama; Kazuya Fukuoka; Hirokazu Kurokawa; Taisuke Nomoto; Tomoyuki Ishida; Nobuyuki Yamamoto; Tomohide Tamura; Tetsu Shinkai; Kenji Eguchi; Yuichiro Ohe; Hideo Kunito; Tomoko Ohtsu; Yasutsuna Sasaki

  Cancer Chemotherapy and Pharmacology, Supplement 38 S11 - S15 0943-9404 1996 [Refereed]
  
• 14. 気管支腔内に凝血塊様の腫瘤を形成した腎癌肺転移の 1 例(症例 (2), 第 50 回日本気管支学会近畿支部会)

  生駒 行拡; 竹中 英昭; 長 澄人; 橋本 和明; 福岡 和也; 成田 亘啓; 川上 万平; 佐々木 進次郎

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 17 (1) 108 - 108 1995
• 9. 早期胃癌術後 9 年目に起こった気管支結腸瘻の 1 剖検例(第 49 回日本気管支学会近畿支部会)

  生駒 行拡; 福岡 和也; 竹中 英昭; 木田 敦子; 橋本 和明; 長 澄人; 成田 亘啓

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 17 (1) 101 - 101 1995
• 15. 気管支鏡にて空洞内部を観察し得た肺非定型抗酸菌症の 1 例(症例 (2), 第 50 回日本気管支学会近畿支部会)

  岡田 徹; 徳山 猛; 友田 恒一; 福岡 和也; 前田 光一; 濱田 薫; 成田 亘啓; 佐々木 義明; 今井 照彦

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 17 (1) 108 - 108 1995
• A Case of Endotracheal Chondroma with Lung Cancer

  Takenaka Hideaki; Choh Sumito; Fukuoka Kazuya; Ikoma Yukihiro; Tsukaguchi Nobuhiko; Tomoda Koichi; Suzuki Yuko; Hamada Kaoru; Narita Nobuhiro

  The Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 17 (6) 501 - 505 0287-2137 1995 

  A 75-year-old male was admitted for further examination of a mass shadow in the right upper lung field on chest X-ray film. Large cell carcinoma was diagnosed by percutaneous needle biopsy. A small smooth-surfaced polypoid tumor was detected unexpectedly on the anterior wall of the lower trachea by bronchoscopy, and was completely removed by biopsy forceps. The biopsy specimen revealed chondroma. We considered this case to be the first report of endotracheal chondroma in Japan.
• 56 気管支鏡下生検材料を用いた肺癌組織に発現する糖鎖抗原の臨床的検討(気管支鏡・腫瘍生検)

  福岡 和也; 濱田 薫; 徳山 猛; 前田 光一; 成田 亘啓; 今井 照彦; 佐々木 義明; 大石 元; 長 澄人; 竹中 英昭; 生駒 行拡

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 17 (3) 260 - 260 1995
• The evaluation of interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) level in peripheral blood of patients with active pulmonary tuberculosis

  Munehiro Nakaya; Takahiro Yoneda; Masanori Yoshikawa; Katsuhiko Tsukaguchi; Takeshi Tokuyama; Akihiro Fu; Yukinori Okamoto; Kazuya Fukuoka; Chinaru Yamamoto; Atsuhiko Fukuoka; Koichi Tomoda; Yasuto Onohara; Nobuhiro Narita; Nagakazu Shimada

  Kekkaku 70 (8) 461 - 466 0022-9776 1995 [Refereed]
   

  We investigated the serum level of IL-8 and TNF-α using ELISA in 16 patients with active pulmonary tuberculosis before administration of antituberculous drugs and in age-, smoking habit-matched 20 healthy controls. The mean level of serum IL-8 in patients with active pulmonary tuberculosis was significantly higher than that in healthy controls (P< 0.001). The mean level of serum TNF-α in tuberculosis patients was also high, while TNF-α was not detectable in the sera of healthy controls. We also examined the relationship between clinical pictures mainly defined by radio graphic findings and the serum levels of IL-8 and TNF-α. The serum IL-8 level of 9 patients with tuberculous cavity is significantly higher than that of 7 patients without cavity. (P< 0.05) We classified the patients with cavities into two subgroups according to the radiographic classification of the Japanese Society of Tuberculosis. Four patients with advanced lesions on chest X-ray showed higher serum IL-8 level than 5 patients with moderate lesions (P< 0.05). On the other hand, there was no correlation between serum TNF-α level and radiographic findings. These results suggest that IL-8 appears to be involved in the formation of tuberculous cavitary lesion. © 1995, JAPANESE SOCIETY FOR TUBERCULOSIS. All rights reserved.
• Studies on production of interleukin-1 β (IL-1β) and granulocyte. Macrophage-colony stimulating factor (GM-CSF) by peripheral blood monocytes from patients with mycobacterium avium-intracellulare complex (MAC) infection

  Koichi Tomoda; Takahiro Yoneda; Katsuhiko Tsukaguchi; Masanori Yoshikawa; Takeshi Tokuyama; Akihiro Fu; Yukinori Okamoto; Kazuya Fukuoka; Chinaru Yamamoto; Munehiro Nakaya; Nobuhiro Narita; Hiromichi Tasaka

  Kekkaku 70 (7) 415 - 421 0022-9776 1995 [Refereed]
   

  Production of Interleukin-1 β(IL-1β) and granulocyte macrophage-colony stimulating factor (GM-CSF) by peripheral blood monocytes (PBMs) from patients with Mycobacterium avium-intracellulare complex (MAC) infection was assesed and the relationship with their clinical course was analyzed. PBMs were obtained from MAC-infected patients in their active stage as well as in the inactive stage and the healthy controls. Spontaneous release of IL-1β by PBMs from patients in the active stage was higher than those by the cells in the inactive stage or the healthy controls. On the other hand, spontaneous GM-CSF release by PBMs from patients in the active stage was higher than the healthy controls. When PBMs were stimulated with MAC-derived purified protein derivatives (PPD-B), increased production of both IL-1β and GM-CSF were obtained for PBMs in their active stage. While these enhanced production upon stimulation with PPD-B related to the persistent infection with MAC, the increased IL-1β production correlated with the exhausted nutritional state. Both IL-1β and GM-CSF produced by PBMs seemed to be closely related with the clinical course of human MAC infection. © 1995, JAPANESE SOCIETY FOR TUBERCULOSIS. All rights reserved.
• Production of tumor necrosis factor alpha and interleukin-6 by peripheral monocytes from patients with atypical mycobacteriosis - Relationship to clinical activity

  K. Tomoda; T. Yoneda; K. Tsukaguchi; M. Yoshikawa; T. Tokuyama; A. Fu; K. Fukuoka; M. Nakaya; N. Narita; H. Tasaka

  Japanese Journal of Thoracic Diseases 33 (6) 618 - 621 0301-1542 1995 [Refereed]
   

  The production of tumor necrosis factor alpha (TNFα) and of interleukin- 6 (IL-6) by peripheral blood monocytes (PBMs) from patients infected with Mycobacterium avium intracellular complex (MAC) were assessed. Spontaneous release of both TNFα and IL-6 were greater during the active stage than during the inactive stage and in healthy controls. When the cells were stimulated with MAC-derived purified protein derivative B (PPD-B), TNFα production by PBMs in the active stage increased and IL-6 production by cells in both the active and inactive stages decreased. Moreover, the in vitro increase in TNFα production after stimulation in the active stage seemed to be related to the persistent MAC infection, which resulted in an exhaustion of nutrition. These results suggest that the ability of PBMs to produce TNFα and IL-6 in vitro is closely related to the clinical stage of MAC infection.
• Studies on mucociliary transport in patients with pulmonary atypical mycobacteriosis - By aerosol inhalation cine-scintigraphy

  K. Tomoda; T. Yoneda; K. Tsukaguchi; M. Yoshikawa; T. Tokuyama; A. Fu; Y. Okamoto; K. Fukuoka; C. Yamamoto; M. Nakaya; N. Narita; Y. Sasaki; T. Imai; H. Ohishi

  Kekkaku 70 (9) 499 - 504 0022-9776 1995 [Refereed]
   

  Mucociliary transport (MCT) was studied in 22 patients with atypical mycobacteriosis (Group 1 : 16 with M. avium-intracellulare complex (MAC), Group II : 6 with M. kansasii) by aerosol inhalation cine-scintigraphy. In most of the patients, the MCT was abnormally slow both in the main bronchus and in the trachea, while in healthy controls the transport of the inhaled aerosol in the bronchus and the trachea were rapid and smooth. In both groups, the tracheal MCT was impaired in two thirds of the patients, while the MCT in the main bronchus was impaired in all except one in Group I and in two thirds in Group II. The results indicate that the grade of bronchial impairment was higher in MAC than in M. kansasii infections. In atypical mycobacteriosis, especially in MAC infections, such impairment of MCT could be closely related to the disruption of local defence mechanisms in the airways.
• A case of tuberculosis of the breast. Review of the literature published during the last 10 years in japan

  Kazuya Fukuoka; Sumito Choh; Kaoru Hamada; Takahiro Yoneda; Nobuhiro Narita

  Kekkaku 70 (2) 111 - 115 0022-9776 1995 [Refereed]
   

  A 58-year-old woman, not having any history of pulmonary tuberculosis, was admitted to our hospital to examine a tender lump in her right breast. A breast echogram disclosed a well-defined hypoechoic mass lesion, indicating a pyogenic breast abscess. The patient underwent incision, drainage and resection of the tumor under local anesthesia. Histological findings of the resected tumor revealed epitheloid cell granulomas with caseous necrosis in mammary glands, suggesting tuberculosis of the breast. After operation, treatment with isoniazid, rifampisin and ethambutol hydrochloride was begun. After one year, she had complete healing without any indication of recurrence. During the last 10 years, 12 cases of tuberculosis of the breast have been reported. Their ages ranged from 28 to 84 years with an average of 42.8 years. Only one cases had a past history of tuberculosis and in the other cases tuberculosis of the breast was considered to be a primary disease. Axillary lymph-nodes involvement and formation of pyogenic breast abscess occurred in each 7 cases. Acid-fast bacilli were demonstrated in 25% of the reported cases. The histological findings of resected specimens and punch biopsy revealed epitheloid cell granulomas with caseous necrosis in 11 of 12 cases. Seven of 11 cases were treated with combination of surgery and antituberculous chemotherapy. © 1995, JAPANESE SOCIETY FOR TUBERCULOSIS. All rights reserved.
• Pulmonary infection due to Mycobacterium szulgai associated with multiple bullous disease of the lung

  K. Mori; M. Yoshikawa; T. Nakamura; K. Tomoda; M. Nakaya; A. Fu; T. Tokuyama; K. Fukuoka; C. Yamamoto; K. Tsukaguchi; T. Yoneda; N. Narita

  Kekkaku 70 (9) 511 - 515 0022-9776 1995 [Refereed]
   

  A 46-years-old male was admitted to our hospital because of productive cough and infiltrates on the chest roentgenogram. The patient had a history of left upper bullectomy ten years prior to the admission. The CT scan of the chest on admission showed infiltrates with cavitation in the left apex and multiple bullae in almost whole lung. Microscopical examination of smears of sputum and bronchoalveolar lavage fluid revealed acid-fast bacilli. They were identified as Mycobacterium szulgai by DNA-DNA hybridization method. The patient was treated with isoniazid, streptomycin and rifampicin. After treatment for about a month, the culture of sputum converted to negative for M. szulgai. After about three months hospitalization, the infiltrates decreased and the cavity wall became thin, and no recurrence sign has been observed after the discharge. There are a few case reports of pulmonary infection due to M. szulgai associated with bullous disease of the lung in Japan.
• Responsiveness of lymphocytes from patients with M. avium-intracellulare complex (MAC) infection to PPDs as measured by IFN-γ production

  K. Tomoda; T. Yoneda; K. Tsukaguchi; M. Yoshikawa; T. Tokuyama; A. Fu; K. Fukuoka; M. Nakaya; N. Narita; H. Tasaka

  Kekkaku 69 (5) 361 - 365 0022-9776 1994 [Refereed]
   

  We investigated the responsiveness of peripheral blood lymphocytes (PBLs) from patients with M. avium-intracellulare complex (MAC) infection to the stimulation with PPDs by measuring their IFN-γ producing ability. PBLs were ohtained from MAC patients at active stage (culture-positive after three-month chemotherapy), those at inactive stage (culture-negative for three months after or during chemotherapy), and healthy donors. PPDs used were PPD-S prepared from M. tuberculosis, PPD-B from M. intracellulare, and PPD-Y from M. kansasii. PBLs from active MAC patients did not produce IFN-γ to a significant extent by stimulation with any of three PPDs, while PBLs from inactive MAC patients showed higher responses to each PPD compared to those from active patients. In inactive MAC patients, the maximal response was observed to PPD-B among three PPDs. On the other hand, PBLs from healthy controls produced different levels of IFN-γ in response to three different PPDs, and their response was most remarkable to PPD-S. These results indicated that the responsiveness of patients' PBLs to PPDs was impaired during active stage of MAC infection and restored on recovery from the disease.
• Lectin Binding to Non-Small Cell Lung Carcinoma

  Kazuya Fukuoka; Takahiro Yoneda; Yoshizumi Kohnoike; Kohichi Tomoda; Masanori Yoshikawa; Hitoshi Katada; Nobuhiro Narita; Teruhiko Imai; Sougo Ioka

  Haigan 34 (2) 161 - 170 0386-9628 1994 [Refereed]
   

  We investigated lectin binding to normal bronchus and lung, metaplastic bronchial epithelium, and 42 cases of primary non-small cell lung carcinoma consisting of 23 squamous cell carcinomas and 19 adenocarcinomas. Fresh frozen sections were stained with 6 fluorescein isothiocyanate (FITC) -conjugated lectins of Dolichos biflorus (DBA), Ulex europaeus (UEA-I), Ricinus communis (RCA-I), Triticum vulgare (WGA), Canavalia ensiformis (ConA), Arachis hypogaea (PNA) and a microphotometer was used for objective evaluation of the fluorescence intensity. UEA-I, RCA-I, WGA, ConA, and PNA with the neuraminidase treatment (PNA · N (+)) were bound to most nontumorous bronchial and lung tissues, metaplastic bronchial epithelium, and lung carcinomas. However, the binding pattern of UEA-I differed from those of RCA-I, WGA, ConA, and PNA · N (+) in terms of localization of its binding sites. DBA was bound to nontumorous and metaplastic bronchial epithelium, bronchial glands, and a part of the bronchiolar epithelium and alveolar septum, but not to alveolar epithelium. The positivity of DBA binding to lung carcinomas was 61.9% (adenocarcinoma, 84.2% squamous cell carcinoma, 43.5%) the positivity of adenocarcinoma being significantly higher than that of squamous cell carcinoma. These results suggest that DBA is an important lectin for the analysis of differences of carbohydrate structures in cell surface membrane between nontumorous bronchus, lung, and the different histological types of non-small cell lung carcinomas. © 1994, The Japan Lung Cancer Society. All rights reserved.
• Relationship Between Nutritional Depletion and Cell-Mediated Immune Function in Active Pulmonary Tuberculosis

  Masanori Yoshikawa; Takahiro Yoneda; Junko Maegawa; Katsuhiko Tsukaguchi; Takeshi Tokuyama; F. U. Akihiro; Kazuya Fukuoka; Koichi Tomoda; Munehiro Nakaya; Atsuhiko Fukuoka; Chinaru Yamamoto; Nobuhiro Narita; Yasuyoshi Enoki; Riichiro Mikami

  Kekkaku 69 (4) 307 - 316 0022-9776 1994 [Refereed]
   

  A survey on the nutritional status and cell-mediated immune function of 47 hospitalized patients with active pulmonary tuberculosis and healthy controls was conducted. In the patients group: 1) Anthropometric measurements, such as %ideal body weight (%IBW), %arm circum ference (%AC), %arm muscle circumference (%AMC) and %triceps skin fold (%TSF), were significantly reduced. 2) Visceral proteins including serum albumin (Alb), transferrin (Tf), prealbumin (PA) and retinol binding protein (RBP) were significantly reduced. 3) The imbalance of plasma amino acids, which was characterized by the depression of Fischer ratio, a molar ratio of branched chain amino acids (BCAA) to aromatic amino acids (AAA), was observed. Fischer ratio was significantly correlated with anthropometric measurements (YDIBW, %AC and %AMC). Delayed-type hypersensitivity to DNCB (2, 4-dinitrochlorobenzene) and iymptiocyte transformation to phytohemagglutinin (PHA) and concanavalin A (Con A) were significantly impaired in the patients group, whereas NK cell activity was higher than that of controls. Alb, PA, RBP and Fischer ratio were significantly lower in the patients with reduced DNCB reaction than in those with normal responses. Lymphocyte transformation was signifcantly correlated with Fischer ratio, and NK cell activity was significantly correlated with Alb, PA, RBP. These data may suggest that the imbalance of plasma amino acids represented by the reduction of Fischer ratio and the depletion of visceral proteins are closely related to the impairment of lymphocyte function in the patients with active pulmonary tuberculosis. Copyright © 1994, The Japan Neurosurgical Society. All rights reserved.
• Clarithromycin in the long-term treatment of primary lung cancer. Possibility of clarithromycin as a biological response modifier

  Keiichi Mikasa; Masayoshi Sawaki; Kaoru Hamada; Mitsuru Konishi; Kouichi Maeda; Shoji Teramoto; Shoji Takeuchi; Kazuya Fukuoka; Masahiro Sakamoto; Masayuki Tsujimoto; Kei Mori; Mikikazu Kunimatsu; Nobuhiro Narita; Eiji Kita; Shuzo Kashiba

  CHEMOTHERAPY 42 (11) 1293 - 1298 0009-3165 1994 [Refereed]
   

  The present authors investigated the utility and mechanism of long-term chemotherapy with erythromycin (EM) in the treatment of chronic lower respiratory tract infections. In parallel, we found that EM-clarithromycin (CAM) possesses properties as a biological response modifier (BRM), stimulating the activities of natural killer cells and producing various cytokines. Given these characteristics of CAM, investigations were performed on the effects of CAM on the survival of lung cancer patients receiving long-term administration of CAM. The subjects were 50 inpatients with primary lung cancer not indicated for surgical operation. They consisted of 43 males and 7 females, 41-82 years of age (64.5±9.8). Patients received concomitant application of radiotherapy with chemotherapy including CDDP after discharge, they were allocated randomly into a CAM administration group and nonadministration group at their initial visit to the outpatient clinic, and subsequent survival times were compared between the two groups. Survival rate data were analyzed using the Kaplan-Meier method and differences between the two groups were compared by the generalized Wilcoxon method and LongranK method. There were no significant differences between the two groups in terms of age, sex, stage, tissue type, basic treatment or efficacy rate. Results indicated that the survival curves of patients with small cell cancer were not significantly different between the two groups, but the 50% survival time of patients with non-small cell cancer was 930 days in the CAM administration group and 299 days in CAM non-administration group, indicating significant prolongation of survival in the CAM administration group (p=0.003). In conclusion, CAM was suggested to have potential as a BRM in eliciting prolongation of survival time in patients with lung cancer. © 1994, Japanese Society of Chemotherapy. All rights reserved.
• 99 中枢気道狭窄による連続性ラ音の検討 : より末梢の狭窄に起因する連続性ラ音との対比検討(気道の病態生理 (II))(第 16 回日本気管支学会総会)

  長 澄人; 濱田 薫; 徳山 猛; 前田 光一; 堅田 均; 成田 亘啓; 佐々木 義明; 今井 照彦; 尾辻 秀章; 飯岡 壮吾; 福岡 和也; 渋谷 惇夫

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 15 (4) 353 - 353 1993
• A Clinical Study on Airway Lesions in Mycoplasma Pneumoniae Pneumonia

  Fukuoka Kazuya; Katada Hitoshi; Cho Sumito; Hamada Kaoru; Maeda Koichi; Mikasa Keiichi; Kohnoike Yoshizumi; Konishi Mitsuru; Watanabe Hiroyuki; Narita Nobuhiro; Imai Teruhiko

  The Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 15 (3) 216 - 223 1993 

  In order to elucidate airway lesions and disorders of mucociliary transport system in Mycoplasma pneumoniae (M. pneumoniae) pneumonia, bronchofiberscopy, broncho-alveolar lavage (BAL), and aerosol inhalation cine-scintigraphy (AICS) were conducted in 6 cases of M. pneumoniae pneumonia. Bronchofiberscopic findings revealed redness and swelling of the bilateral bronchial mucosa in all cases and purulent secretion in 5 of 6 cases. Histological findings of bronchofiberscopic biopsy showed the desquamation and swelling of bronchial epithelial cells, broncho-bronchiolitis and alveolitis. The analysis of broncho-alveolar lavage fluid (BALF) contents demonstrated an increase of total cell counts and proportion of lymphocytes and neutrophils. AICS findings at one month from the onset disclosed that in 3 of 4 cases, either bolus formations or movements were absent, indicating severe impairment of mucociliary clearance. Futhermore, the impairment of mucociliary clearance still remained even 3 months from the onset in one subject. These findings suggested that there were both extensive and severe airway disorders in M. pneumoniae pneumonia.
• A case of von Recklinghausen's disease associated with large cell carcinoma of the lung

  K. Fukuoka; H. Katada; Y. Kohnoike; N. Narita; S. Ioka

  Japanese Journal of Thoracic Diseases 31 (1) 88 - 93 0301-1542 1993 [Refereed]
  
• An Autopsy Case of Lung Cancer with Superior Vena Cava Syndrome, Controlled by a Gianturco Expandable Metallic Stent

  Koichi Tomoda; Kaoru Hamada; Nobuhiro Narita; Kazuya Fukuoka; Keiichi Saitoh; Yoshizumi Kohnoikel

  Japanese Journal of Lung Cancer 33 (2) 261 - 267 0386-9628 1993 [Refereed]
   

  A 66-year-old man was admitted with small cell carcinoma of the lung (T2, N2, MO, stage III A), accompanied by SVC syndrome. With chemo- and radiotherapy, the SVC syndrome temporarily improved, but recurred. Because the SVC syndrome wasthought to be refractory to these therapeutic modalities, a Gianturco expandable metallic stent (EMS) was inserted into the stenotic SVC. Immediately, many symptoms related to SVC syndrome, edema of the face and upper extremities and dyspnea, improved. A month after placement of the EMS he died of pneumonia but without any side effects induced by the EMS. Autopsy demonstrated that there were no thromboses over the EMS, which was covered with white sheets composed of proliferating intima. © 1993, The Japan Lung Cancer Society. All rights reserved.
• A Case of Primary Quadruple Lung Cancer Successfully Treated by Chemotherapy

  Fukuoka Kazuya; Katada Hitoshi; Tsujimoto Masayuki; Cho Sumito; Hamada Kaoru; Mikasa Keiichi; Kohnoike Yoshizumi; Narita Nobuhiro; Imai Teruhiko; Ioka Sougo

  The Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 14 (4) 339 - 345 1992 

  A 70-year-old man, heavy smoker, consulted his family doctor because of cough and sputum. He was subsequently admitted to our hospital as chest X-ray film showed a tumor shadow in the left hilum and cytological examination of the sputum proved positive. Bronchofiberscopic findings on admission revealed a nodular tumor with superficial infiltration at the orifice of left B^<1-2> and at the bifurcation between the right middle and lower bronchi, thickening of the right upper trifurcation and complete occlusion of left B^6 by a tumor. Apart from the lesion in left B^6, the other three lesions were consistent with endoscopic hilar early lung cancer. Histopathological findings demonstrated squamous cell carcinoma, one was carcinoma in situ. As the four lesions were mutually isolated and there were no metastase to lymph nodes or distant organs, this was considered to be a case of primary quadruple lung cancer. After bronchial arterial infusion and systemic chemotherapy using CDDP, VDS and MMC, bronchofiberscopic findings revealed no cancerous tissue remaining, indicating the effectiveness of chemotherapy for quadruple lung cancer. Subsequently radiotherapy of the tumor in left S^6 was performed in addition to the chemotherapy. The patient has survived for three years since treatment, with no apparent recurrence of lung cancer.
• 3 Cases of Summer-Type Hypersensitivity Pneumonia in which Time-Related Changes in Bronchoalveolar Lavage were Observed Over a Period of 2 to 3 Years

  Katada Hitoshi; Nishikawa Kiyoshi; Imai Teruhiko; Konoike Yoshizumi; Fukuoka Kazuya; Hamada Kaoru; Cho Sumito; Kasuga Hirotomo; Ito Shinsaku; Narita Nobuhiro; Mikami Riichiro

  The Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 14 (1) 75 - 84 1992 

  Time-related changes in bronchoalveolar lavage were observed in three cases of summer-type hypersensitivity pneumonia over a period of 2 to 3 years. When symptoms were present, the total cell count, lymphocyte and neutrophil ratio increased, while the CD4/CD8 ratio decreased. In winter, spring and symptomless summer, the total cell count, neutrophil ratio and CD4/CD8 all tended to normalize, but the lymphocyte ratio still remained high. A case undergoing steroid therapy showed a recovery of lymphocyte ratio as well as other parameters, but the lymphocyte ratio showed abnormal values after cessation of steroid therapy. House removal and/or reconstruction of their residence suppressed symptom recurrence, causing slow improvement of the CD4/CD8 and a decrease in the fungal antibody titer, but those still remained the lymphocyte ratio high.
• A Case of Lung Cancer Developed Severe Disorder of Ventilation and Perfusion of the Lung by Residual Bronchial Stenosis after Operation

  Fukuoka Kazuya; Katada Hitoshi; Cho Sumito; Hamada Kaoru; Fujimura Masashi; Kohnoike Yoshizumi; Sawaki Masayoshi; Narita Nobuhiro; Imai Teruhiko; Watanabe Hiroyuki; Ohishi Hazime; Ioka Sougo; Kitamura Souichirou

  The Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 14 (1) 31 - 37 1992 

  A 57-year-old man had undergone right upper lobectomy and S^6a partial segmental resection for squamous cell carcinoma that developed in B^3b and had been complicated with pulmonary tuberculosis. Seven months after the operation, he was readmitted complaining of persistent cough and dyspnea on exertion. The chest roentgenogram showed severe loss of volume of the right middle lobe and compensatory overinflation of the right lower lobe. Bronchofiberscopy of the right bronchus revealed stenosis of the truncus intermedius and the middle lobe bronchus and protrusions in the orifice of the basal segmental bronchus. As bronchography, pulmonary arteriography, ventilation and perfusion scintigraphy and aerosol inhalation scintigraphy suggested that the residual bronchial stenosis widely disturbed the ventilation and perfusion of the right lung, he underwent pneumonectomy. The pathological investigation of the resected lung revealed that the protrusions of the bronchial wall were composed of folded bronchial cartilage. It was considered that in this case, stenosis and protrusions of the residual bronchus developed by bending of the bronchus and folding of the bronchial wall caused by movement and reexpansion of the residual lung after right upper lobectomy and S^6a partial segmental resection.
• 20. 中心型三重早期肺扁平上皮癌の 1 例(第 43 回日本気管支学会近畿支部会)

  塚口 信彦; 福岡 和也; 梅村 康義; 濱田 薫; 長 澄人; 成田 亘啓

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 14 (6) 621 - 621 1992
• An Autopsy Case of Adenocarcinoma of the Lung with Cutaneous Lymphangitic Carcinomatosis

  Kazuya Fukuoka; Michiaki Shiozaki; Mitsuru Konishi; Kaoru Hamada; Sumito Cho; Nobuhiro Narita

  Haigan 32 (2) 271 - 277 0386-9628 1992 [Refereed]
   

  A 72-year-old woman was admitted to our hospital with exertional dyspnea (Hugh-Jones III). Chest X-ray films showed right pleural effusion and pleural biopsy revealed pleural carcinomatosis (adenocarcinoma). Despite the intrathoracic administration of MMC and OK-432, an encapsulated pleural effusion remained and pulmonary lymphangitic carcinomatosis developed. Subsequently, a subcutaneous tumor that showed cancer cell infiltration became palpable at the site where the intrathoracic catheter had been inserted, and diffuse subcutaneous swelling extended over the right side of the trunk with right axillary lymphadenopathy. CT scans of the chest and abdomen showed a network of high density lesions in the subcutaneous tissue of the trunk. These physical and CT findings suggested diffuse subcutaneous infiltration of adenocarcinoma. Although systemic chemotherapy with CBDCA and VP-16 was performed, she died of respiratory failure. Autopsy findings revealed that the tumor was a poorly differentiated adenocarcinoma that originated from the right lower lobe, and both direct tumor infiltration from the pleura and the chest wall into the subcutaneous tissue and cutaneous lymphangitic carcinomatosis caused the diffuse subcutaneous swelling. © 1992, The Japan Lung Cancer Society. All rights Reserved.
• A randomized controlled postoperative adjuvant chemotherapy trial of MMC+tegafur and MMC+UFT for adenocarcinoma of the lung-First study.:Trial of NIMC+Tegafur and MMC+UFT for Adenocarcinoma of the Lung-First Study

  Teramatsu Takashi

  JJLC The Japan Lung Cancer Society 31 (2) 193 - 200 0386-9628 1991 

  A joint study was carried out in western Japan by 30 institutions (Society of Adjuvant Chemotherapy for Lung Cancer Surgery in West Japan) to examine the survival period, disease-free period, and side effects of postoperative adjuvant chemotherapy.Absolutely or relatively curatively resected patients were randomized to a group treated with MMC+ Tegafur (Group A) or one treated with MMC+UFT (Group B) and results were compared. Of 224 patients 80.8% were eligible for this study.
  No difference was observed in background factors, medication, 3-year survival rate, and 3-year disease-free rate between the two groups. The results were better in Group B in relatively curatively resected cases and Stage III patients, and significantly better in patients with N2 lesions than in Group A.
• Intratumoral Injection of Absolute Ethanol for Tracheobronchial Stenosis by Tumor

  Hamada Kaoru; Cho Sumito; Fujimura Masashi; Fukuoka Kazuya; Katada Hitoshi; Sawaki Masayoshi; Narita Nobuhiro; Watanabe Hiroyuki; Imai Teruhiko; Oishi Hajime; Higashiguchi Ryuuichi; Nishiura Kimiaki

  The Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 13 (3) 249 - 258 1991 

  Intratumoral injection of absolute (99.5%) ethanol via a flexible bronchofiberscope was attempted on 10 cases with tracheobronchial stenosis or obstruction by neoplasia. Out of 7 cases with lung cancer, ethanol injections were effective in 1 case, and temporarily effective in 3 cases, while they were ineffective in the others. Though the results were ineffective in pulmonary metastasis, effects were obtained in a case of tracheal cancer and one of tracheal papillomatosis was improved. In some cases, radio- or chemotherapy were performed in combination with ethanol injection. There were no complications except for mild cough. This method was effective against polypoid proliferative tumors but ineffective for superficial or submucosally infiltrating tumor. However, even in effective cases, long term prognosis was not so good. Though it is palliative, intratumoral ethanol injection can be useful for bronchoscopic treatment from the standpoint of the patient's quality of life.
• The Heat Probe Method in Bronchoscopic Treatment

  Hamada Kaoru; Cho Sumito; Fujimura Masashi; Fukuoka Kazuya; Katada Hitoshi; Sawaki Masayoshi; Narita Nobuhiro; Watanabe Hiroyuki; Imai Teruhiko; Ooishi Hajime

  The Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 13 (4) 349 - 357 1991 

  The heat probe method is commonly used endoscopically for gastrointestinal bleeding. The authors studied the effects of heat coagulation on normal tracheal tissue and tried clinically to halt bronchial bleeding in case of lung cancer and to treat tracheal cancer. In the membranous portion of the trachea, almost all of the fibrocartilage plates showed injury with 90J heating, but without peribronchial tissue damage. On the cartilage of the trachea, 150J heating could not change cartilage tissue histologically. Five cases with bronchial bleeding caused by biopsy in case of lung cancer were treated with heat probe. One case of tracheal cancer was treated with it and severe inflmmatory changes of the mucosa were seen a week after heating. Healing changes were seen two weeks after heating, but histologically cancer remained. The heat probe was considered to be useful for bronchoscopic treatment of bleeding from carcinoma and does not cause severe complication.
• 11. 気管切開部の肉芽性腫瘤に対する純エタノール局注療法の試み(第 40 回近畿気管支鏡懇話会)

  濱田 薫; 長 澄人; 福岡 和也; 堅田 均; 成田 亘啓; 今井 照彦; 渡辺 裕之; 大石 元; 松田 成器

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 13 (1) 101 - 101 1991
• 10. 救急処置としての気管内挿管により脱落させたポリープ型気管癌の 1 例(第 40 回近畿気管支鏡懇話会)

  川崎 恭; 丸谷 正実; 濱田 薫; 長 澄人; 藤村 昌史; 小山 泰弘; 鴻池 義純; 福岡 和也; 佐々木 義明; 塚口 勝彦; 堅田 均; 成田 亘啓; 今井 照彦; 渡辺 裕之; 大石 元

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 13 (1) 101 - 101 1991
• 4 気管支狭窄音の音響学的性状および伝播特性に関する検討 : 内視鏡所見との対比において(画像・音響)

  長 澄人; 塩谷 直久; 小山 泰弘; 浜田 薫; 藤村 昌史; 福岡 和也; 堅田 均; 成田 亘啓; 今井 照彦; 渡辺 裕之; 大石 元; 渋谷 惇夫

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 12 83 - 83 1990
• 156 内視鏡的治療 : エタノール局注療法(気道病変に対する内視鏡的治療 (2))

  濱田 薫; 長 澄人; 藤村 昌史; 福岡 和也; 堅田 均; 澤木 政好; 成田 亘啓; 渡辺 裕之; 今井 照彦; 大石 元; 東口 隆一; 西浦 公章

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 12 121 - 121 1990
• 155 ヒート・プローブの気管支鏡への応用(気道病変に対する内視鏡的治療 (2))

  濱田 薫; 長 澄人; 藤村 昌史; 福岡 和也; 堅田 均; 澤木 政好; 成田 亘啓; 渡辺 裕之; 今井 照彦; 大石 元

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 12 121 - 121 1990
• 9. 右上葉切除後, 喘鳴を伴う呼吸困難を訴え気管支の偏位と広範な狭窄を認めた 1 例(第 39 回近畿気管支鏡懇話会)

  福岡 和也; 堅田 均; 長 澄人; 濱田 薫; 藤村 昌史; 鴻池 義純; 澤木 政好; 成田 亘啓; 大塚 浩史; 東条 尚; 飯岡 壮吾; 北村 惣一郎; 今井 照彦; 渡辺 裕之; 大石 元

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 12 (4) 447 - 447 1990
• 11. 連続性ラ音が診断の契機となった扁平上皮癌の 1 例(第 38 回近畿気管支鏡懇話会)

  長 澄人; 福岡 和也; 夫 彰啓; 濱田 薫; 藤村 冒史; 菅原 聡; 鴻池 義純; 堅田 均; 成田 亘啓; 今井 照彦; 渡辺 裕之; 大石 元

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 12 (3) 336 - 337 1990
• 8. 化学療法が奏効した四重多発肺癌の内視鏡所見(第 37 回近畿気管支鏡懇話会)

  福岡 和也; 堅田 均; 藤村 昌史; 長 澄人; 濱田 薫; 辻本 正之; 杉村 祐子; 鴻池 義純; 澤木 政好; 成田 亘啓; 今井 照彦; 大石 元; 飯岡 壮吾; 東条 尚; 北村 惣一郎

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 11 (6) 617 - 618 1989
• 5. マイコプラズマ肺炎の病態の検討 : 気管支所見を中心として(第 35 回 近畿気管支鏡懇話会)

  福岡 和也; 堅田 均; 藤村 昌史; 長 澄人; 夫 彰啓; 三笠 桂一; 鴻池 義純; 水本 保子; 古西 満; 渡辺 裕之; 前田 光一; 中尾 宰子; 小林 秀明; 澤木 政好; 成田 亘啓; 今井 照彦; 大石 元

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 11 (2) 209 - 209 1989
• P-5 マイコプラズマ肺炎における気道病変の検討(示説 1)

  福岡 和也; 堅田 均; 藤村 昌史; 長 澄人; 三笠 桂一; 古西 満; 鴻池 義純; 水本 保子; 渡辺 裕之; 澤木 政好; 成田 亘啓; 今井 照彦; 大石 元

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 11 124 - 124 1989
• P-84 気管支鏡検査における非定型抗酸菌汚染について(示説 8)

  藤村 昌史; 堅田 均; 福岡 和也; 長 澄人; 三笠 桂一; 澤木 政好; 成田 亘啓; 今井 照彦; 大石 元; 増谷 喬之; 播金 収

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 11 143 - 143 1989
• A case of multiple small pulmonary arteriovenous fistulas with chronic hepatitis and abdominal vessel abnormalities

  K. Fukuoka; K. Kasuga; S. Morikawa; H. Watanabe; K. Mikasa; H. Ka tada; M. Sawaki; N. Narita; T. Imai; H. Oishi; H. Otsuzi; H. Uchid a

  Japanese Journal of Thoracic Diseases 27 (11) 1362 - 1366 0301-1542 1989 [Refereed]
  
• An Autopsy Case of Combined Lung Mesenchymal Chondrosarcoma and Squamous Cell Carcinoma Associated with Multiple Neurofibromatosis

  Kazuya Fukuoka; Hitoshi Katada; Hiromichi Kitada; Nobuhtro Narita; Masahiro Tsutsumi; Yoichi Konishi

  haigan 29 (4) 391 - 396 0386-9628 1989 [Refereed]
   

  A 80-year-old male had complained of cough and general fatigue. The chest roentogenogram showed a mass shadow in right S3. Fiberoptic bronchoscopy revealed a white necrotic polypoid tumor obstructing the orifice of right B3. Right upper lobectomy and lymph node dissection was performed. Histological examination of the resected specimen showed that the tumor was composed of mesenchymal chondrosarcoma and moderately differentiated squamous cell carcinoma. Since these two were separate, this case was considered double lung carcinoma. In spite of postoperative chemotherapy, he died of metastatic brain tumor, pneumonia and DIC after six months. Autopsy revealed multiple skin neurofibromatous lesions, and that the mesenchymal chondrosarcoma did not originate from bones or soft tissue. Metastases to the cerebrum, small intestine and mesenteric lymph nodes were recognized. We reported a rare double lung carcinoma associated with multiple neurofibromatosis. © 1989, The Japan Lung Cancer Society. All rights reserved.
• 8. 声帯白板症を合併した肺小細胞癌の 1 例(第 34 回 近畿気管支鏡懇話会)

  山中 貴世; 藤村 昌史; 福岡 和也; 鴻池 義純; 堅田 均; 成田 亘啓; 今井 照彦; 大石 元; 宮原 裕; 松永 喬

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 10 (4) 454 - 454 1988
• 6. 閉塞性肺炎を伴う肺癌が疑われ, 右 B^6 の気管支閉塞を呈した食道気管支瘻の 1 例(第 33 回 近畿気管支鏡懇話会)

  吉田 英里; 堅田 均; 吉岡 真理子; 福岡 和也; 夫 彰啓; 北田 裕陸; 成田 亘啓; 今井 照彦; 西浦 公章; 浜田 信夫; 東条 尚; 飯岡 壮吾

  気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 10 (2) 225 - 226 1988
• Sulbactam·ampicillin in respiratory tract infections

  Keiichi Mikasa; Masayoshi Sawaki; Mikikazu Kunimatsu; Masashi Fujimura; Kazuya Fukuoka; Koichi Maeda; Nobuhiro Narita

  CHEMOTHERAPY 36 214 - 218 0009-3165 1988 [Refereed]
   

  We assessed the clinical efficacy of sulbactam·ampicillin (SBT·ABPC) in a study of 19 patients with respiratory tract infections. The drug was administered by intravenous infusion in a dose of 1.5g twice a day. Those detected included H.influenzae in 10 patients, S.pneumoniae in 8, B.catarrhalis in 2, H.parahaemolyticus in 2, K.pneumoniae in 1 and Peptostreptococcus in 1. In 5 patients the organisms detected by transtracheal aspiration together with other organisms. 1) Efficacy was judged to be excellent in 2 patients, good in 16 and poor in 1, the efficacy rate being 94.7%. 2) The organisms were all eradicated except H.influenzae (1 strain) and K.pneumoniae (1 strain). 3) Nausea as a side effect was observed in 1 patient, but no abnormal laboratory findings were observed. From these findings, we believe this drug to be useful in the treatment of respiratory tract infections. © 1988, Japanese Society of Chemotherapy. All rights reserved.

Books etc

• 患者さんのための肺がんガイドブック : 悪性胸膜中皮腫・胸腺腫瘍含む

  日本肺癌学会 (Contributor第8章 悪性胸膜中皮腫)金原出版 2021/11 9784307204491 203p
• Textbook of Medical Oncology, 3rd Edition

  Japanese Society of Medical Oncology (Joint workMesothelioma (Pleura, Peritoneum, etc))Nankodo 2020/07 9784524225422
• 1から学ぶ医師主導臨床研究の基本ーがん研究推進のために知っておきたい最新情報ー

  福岡 和也 (Single work)株式会社A・M・S 2018/02 9784990455286

MISC

• 肺癌に対する遺伝子パネル検査の実際と出口戦略の検討

  高濱隆幸; 高濱隆幸; 米阪仁雄; 米阪仁雄; 谷崎潤子; 田中薫; 鈴木慎一郎; 金村宙昌; 磯本晃佑; 白石直樹; 坂井和子; 福岡和也; 福岡和也; 福岡和也; 西尾和人; 中川和彦; 中川和彦; 林秀敏  日本肺癌学会学術集会号  64th (CD-ROM)-  2023
• 原発不明癌に対するNivolumab(ONO-4538)の有効性を検討する第II相試験

  谷崎 潤子; 鈴木 慎一郎; 金村 宙昌; 岩朝 勤; 川上 尚人; 田中 薫; 吉田 健史; 米阪 仁雄; 伊藤 彰彦; 坂井 和子; 木寺 康裕; 福岡 和也; 千葉 康敬; 西尾 和人; 中川 和彦; 林 秀敏  近畿大学医学雑誌  46-  (3-4)  20A  -20A  2021/12
• コロナ下の近畿大学病院遺伝子診療部における状況

  西郷和真; 池川敦子; 木戸滋子; 川上尚人; 武田真幸; 岩朝勤; 巽純子; 福岡和也; 西尾和人; 田村和朗; 中川和彦; 松村謙臣  日本遺伝カウンセリング学会誌  41-  (4)  2021
• NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary.

  Junko Tanizaki; Kan Yonemori; Kohei Akiyoshi; Hironobu Minami; Hiroki Ueda; Yuichi Takiguchi; Chihiro Nakayama Kondoh; Yoshihiko Segawa; Shin Takahashi; Yasuo Iwamoto; Yasuhiro Kidera; Kazuya Fukuoka; Yasushi Nakamura; Yasutaka Chiba; Kazuto Nishio; Kazuhiko Nakagawa; Hidetoshi Hayashi  JOURNAL OF CLINICAL ONCOLOGY  38-  (15)  2020/05
• A phase II study on the efficacy of Nivolumab in Japanese patients with cancer of unknown primary (CUP) (NivoCUP)

  Junko Tanizaki; Hidetoshi Hayashi; Hironobu Minami; Makoto Arai; Shin Takahashi; Yoshihiko Segawa; Yukinori Ozaki; Hiroki Ueda; Kohei Akiyoshi; Yasuo Iwamoto; Kan Yonemori; Yasuhiro Kidera; Kazuya Fukuoka; Kazuto Nishio; Kazuhiko Nakagawa  ANNALS OF ONCOLOGY  29-  2018/10
• 肺癌個別化医療に向けた取り組み

  武田 真幸; 坂井 和子; 林 秀敏; 田中 薫; 高濱 隆幸; 原谷 浩司; 福岡 和也; 中川 和彦; 西尾 和人  日本癌治療学会学術集会抄録集  56回-  O2  -2  2018/10
• Afatinib投与によって、原発巣にpathological CRが得られたEGFR遺伝子変異陽性(del.19)肺腺癌の1例

  岡田 あすか; 福岡 和也; 西尾 和人; 高橋 慶一; 片山 公実子; 小口 展生; 村上 伸介; 竹中 英昭; 長 澄人; 鈴木 啓史; 西村 元宏  肺癌  56-  (6)  856  -856  2016/11
• Immune-related response kinetics in patient with melanoma receiving nivolumab, programmed cell death 1 (PD-1) inhibitor

  Hiroyasu Kaneda; Satomi Nishida; Tsutomu Iwasa; Toshio Shimizu; Kazuya Fukuoka; Kazuhiko Nakagawa  ANNALS OF ONCOLOGY  26-  126  -126  2015/11
• 手引き書 呼吸器内視鏡診療を安全に行うために

  浅野 文祐; 大崎 能伸; 藤野 昇三; 千場 博; 佐藤 滋樹; 笹田 真滋; 各務 博; 鈴木 栄一; 岡田 克典; 青江 基; 福岡 和也; 日本呼吸器内視鏡学会安全対策委員会  気管支学  35-  (3)  1  -48  2013/05
• CLINICAL SIGNIFICANCE OF PLEURAL EFFUSION MESOTHELIN IN MALIGNANT PLEURAL MESOTHELIOMA

  S. Yamada; C. Tabata; T. Nakano; K. Fukuoka  ANNALS OF ONCOLOGY  23-  147  -147  2012/10
• 悪性中皮腫の血清診断における可溶性メソテリン関連ペプチド(SMRP:Soluble Mesothelin-related Peptides)の有用性に関する多施設共同試験

  福岡 和也; 関戸 好孝; 樋田 豊明; 河原 邦光; 太田 三徳; 松村 晃秀; 岡田 守人; 岸本 卓巳; 中野 喜久雄; 中野 孝司  医学と薬学  68-  (1)  177  -183  2012/07
• Comparison of prognostic impact between metabolic and radiologic response after induction chemotherapy for resectable malignant pleural mesothelioma: A multicenter study

  Yasuhiro Tsutani; Teruhisa Takuwa; Yoshihiro Miyata; Kazuya Fukuoka; Seiki Hasegawa; Takashi Nakano; Morihito Okada  JOURNAL OF CLINICAL ONCOLOGY  30-  (15)  2012/05
• Circulating tumor cell (CTC) as a significant clinical marker in epithelioid-type malignant pleural mesothelioma (MPM).

  Kazue Yoneda; Fumihiro Tanaka; Shunichi Fukuda; Hayato Orui; Masaki Hashimoto; Teruhisa Takuwa; Yoshitomo Okumura; Seiji Matsumoto; Nobuyuki Kondo; Ayuko Sato; Tohru Tsujimura; Noriaki Tsubota; Kazuya Fukuoka; Takashi Nakano; Seiki Hasegawa  JOURNAL OF CLINICAL ONCOLOGY  30-  (15)  2012/05
• 悪性胸膜中皮腫切除例に対するPETを用いた術前化学療法の効果判定

  宮田義浩; 津谷康大; 多久和輝尚; 伊富貴雄太; 見前隆洋; 吉屋智晴; 福岡和也; 長谷川誠紀; 中野孝司; 岡田守人  肺癌  52-  (5)  2012
• Trimodality therapy for malignant pleural mesothelioma

  福岡 和也  Clinical oncology  7-  (6)  578  -584  2011/06
• EVALUATION OF THE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER

  Asuka Okada; Kazuya Fukuoka; Hisaya Okuwa; Hitomi Kamiya; Miki Honda; Eriko Masachika; Taiichiro Otsuki; Risa Maeda; Noriko Hirayama; Takayuki Terada; Aki Murakami; Syusai Yamada; Kuninobu Tamura; Chiharu Tabata; Takashi Nakano  JOURNAL OF THORACIC ONCOLOGY  6-  (6)  S1202  -S1203  2011/06
• PERFORMANCE OF A COMBINATION OF SERUM BIOMARKERS, INCLUDING SOLUBLE MESOTHELIN-RELATED PEPTIDE (SMRP), IN DIAGNOSING MALIGNANT MESOTHELIOMA

  Asuka Okada; Kazuya Fukuoka; Syusai Yamada; Taiichiro Otsuki; Eriko Masachika; Hitomi Kamiya; Miki Honda; Hisaya Okuwa; Yoshitaka Nogi; Kouji Mikami; Risa Maeda; Kuninobu Tamura; Chiharu Tabata; Takashi Nakano  JOURNAL OF THORACIC ONCOLOGY  6-  (6)  S1051  -S1052  2011/06
• HISTONE DEACETYLASE ACTIVITY IN PERIPHERAL BLOOD OF PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA

  Asuka Okada; Takashi Nakano; Kuninobu Tamura; Taiichiro Otsuki; Hisaya Okuwa; Hitomi Kamiya; Eriko Masachika; Miki Honda; Kouji Mikami; Yoshitaka Nogi; Chiharu Tabata; Risa Maeda; Kazuya Fukuoka  JOURNAL OF THORACIC ONCOLOGY  6-  (6)  S1356  -S1356  2011/06
• 科学技術振興調整費「アスベスト関連疾患への総括的取り組み」班研究 成果報告 班研究の概要と登録事業、中皮腫細胞特性ならびにアスベストの免疫影響について

  大槻 剛巳; 中野 孝司; 長谷川 誠紀; 岡田 守人; 辻村 亨; 関戸 好孝; 豊國 伸哉; 西本 寛; 福岡 和也; 田中 文啓; 熊谷 直子; 前田 恵; 松崎 秀紀; 李 順姫; 西村 泰光; 科学技術振興調整費平成18-22年度「アスベスト関連疾患への総括的取り組み」研究班  日本衛生学雑誌  66-  (3)  543  -552  2011/05
• Pleural Effusion VEGF Levels As A Prognostic Factor Of Malignant Pleural Mesothelioma

  N. Hirayama; C. Tabata; R. Tabata; R. Maeda; A. Yasumitsu; S. Yamada; K. Kuribayashi; K. Fukuoka; T. Nakano  AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE  183-  2011
• Endbronchial Ultrasound-Transbronchial Fine Needle Aspiration (EBUS-TBNA) as a Modern Cold Standard for Clinical N2 (c-N2) Lung Cancer Patients

  Masaki Hashimto; Teruhisa Takuwa; Yoshitomo Okumura; Hayato Orui; Kazu Shiomi; Seiji Matsumoto; Nobuyuki Kondo; Fumihiro Tanaka; Noriaki Tsubota; Kazuya Fukuoka; Takashi Nakano; Seiki Hasegawa  JOURNAL OF THORACIC ONCOLOGY  5-  (12)  S413  -S413  2010/12
• 科学技術振興調整費「アスベスト関連疾患への総括的取り組み」班 悪性中皮腫集学的治療に関する安全性確認試験ならびに基礎研究の進捗状況

  大槻 剛巳; 中野 孝司; 長谷川 誠紀; 岡田 守人; 辻村 享; 関戸 好孝; 豊國 伸哉; 西本 寛; 福岡 和也; 田中 文啓  日本職業・災害医学会会誌  58-  (臨増)  別179  -別179  2010/10
• From the Special Session of the "Special Coordination Funds for Promoting Science and Technology (H18-13-3-1)" Entitled "Malignant Mesothelioma" in the 55^ Annual Meeting of the Japanese Society of Occupational Medicine and Traumatology : Brief Overview and Approaches from the Basic Science

  OTSUKI Takemi; NAKANO Takashi; HASEGAWA Seiki; OKADA Morihito; TSUJIMURA Tohru; SEKIDO Yoshitaka; TOYOKUNI Shinya; NISHIMOTO Hiroshi; FUKUOKA Kazuya; TANAKA Fumihiro  Japanese journal of occupational medicine and traumatology  58-  (1)  1  -8  2010/01
• Pemetrexed, a multitargeted antifolate active against malignant pleural mesothelioma

  福岡 和也  最新医学  64-  (12)  2616  -2620  2009/12
• 科学技術振興調整費「アスベスト関連疾患への総括的取り組み」班 悪性中皮腫集学的治療に関する安全性確認試験の進捗状況

  大槻 剛巳; 長谷川 誠紀; 田中 文啓; 岡田 守人; 福岡 和也; 辻村 亨; 西本 寛; 関戸 好孝; 豊國 伸哉; 中野 孝司; 科学技術振興調整費; アスベスト関連疾患への総括的取り組み  日本職業・災害医学会会誌  57-  (臨増)  別148  -別148  2009/10
• 科学技術振興調整費「アスベスト関連疾患への総括的取り組み」班 登録事業の現状と、基礎研究よりアスベストの免疫系への影響について

  大槻 剛巳; 西本 寛; 前田 恵; 熊谷 直子; 林 宏明; 西村 泰光; 長谷川 誠紀; 田中 文啓; 岡田 守人; 福岡 和也; 辻村 亨; 関戸 好孝; 豊國 伸哉; 岸本 卓巳; 中野 孝司; 科学技術振興調整費; アスベスト関連疾患への総括的取り組み  日本職業・災害医学会会誌  57-  (臨増)  別149  -別149  2009/10
• Irinotecan in combination with gemcitabine as second-line chemotherapy in patients with malignant pleural mesothelioma previously treated with pemetrexed-cisplatin regimen: a phase 2 study

  Kazuya Fukuoka; Takashi Nakano; Kozo Kuribayashi; Shin-ichiro Iida; Kunihiro Tamura; Chiharu Tabata  JOURNAL OF THORACIC ONCOLOGY  4-  (9)  S771  -S771  2009/09
• Can soluble mesothelin-related peptide (SMRP) in pleural effusion be a useful biomarker for an early diagnosis of malignant pleural mesothelioma?

  Kazuya Fukuoka; Syusai Yamada; Kozo Kuribayashi; Takashi Nakano  JOURNAL OF THORACIC ONCOLOGY  4-  (9)  S757  -S757  2009/09
• Arsenic trioxide induces apoptosis of human malignant mesothelioma cells through induction of reactive oxygen species

  Kazuya Fukuoka; Asuka Okada; Ryoji Eguchi; Yoshihiro Fujimori; Masakazu Muramoto; Kozo Kuribayashi; Noriaki Tsubota; Takashi Nakano; Noriko Hirayama  JOURNAL OF THORACIC ONCOLOGY  4-  (9)  S760  -S760  2009/09
• Narrow band imaging in medical thoracoscopy: a new technology for the detection of early-stage malignant pleural mesothelioma

  Kazuya Fukuoka; Akihiro Yasumitsu; Takayuki Terada; Noriko Hirayama; Kunihiro Tamura; Takashi Nakano  JOURNAL OF THORACIC ONCOLOGY  4-  (9)  S475  -S475  2009/09
• Issues and their resolution in the pathological diagnosis of malignant pleural mesothelioma in the early stage

  Tohru Tsujimura; Ayuko Sato; Ikuko Torii; Tomoko Hashimoto-Tamaoki; Yoshie Yoshikawa; Kazuya Fukuoka; Fumihiro Tanaka; Seiki Hasegawa; Takashi Nakano  Japanese Journal of Lung Cancer  49-  (4)  376  -379  2009/08
• Clinical trials for unresectable malignant pleural mesothelioma

  Kazuya Fukuoka; Takashi Nakano  Japanese Journal of Lung Cancer  49-  (4)  397  -402  2009/08
• A multiinstitutional feasibility study of trimodality therapy for resectable malignant mesothelioma

  Fumihiro Tanaka; Seiki Hasegawa; Morihito Okada; Takeharu Yamanaka; Kazuya Fukuoka; Toshinori Soejima; Norihiko Kamikonya; Kouki Inai; Tohru Tsujimura; Takashi Nakano  Japanese Journal of Lung Cancer  49-  (4)  403  -408  2009/08
• Soluble mesothelin-related peptides (SMRP) as a biomarker for malignant pleural mesothelioma

  Tomonori Hirashima; Kazuya Fukuoka; Toyoaki Hida; Kunimitsu Kawahara; Takumi Kishimoto; Akihide Matsumura; Kikuo Nakano; Morihito Okada; Takashi Nakano  Japanese Journal of Lung Cancer  49-  (4)  380  -385  2009/08
• Perspectives on multimodality therapy for malignant pleural mesothelioma

  Fumihiro Tanaka; Masaki Hashimoto; Teruhisa Takuwa; Seiji Matsumoto; Nobuyuki Kondo; Yoshitomo Okumura; Aki Murakami; Syusai Yamada; Kunihiro Tamura; Shinichiro Iida; Kozo Kuribayashi; Mitsudomi Miyake; Kazuya Fukuoka; Noriaki Tsubota; Norihiko Kamikonya; Masayuki Fujiwara; Tohru Tsujimura; Seiki Hasegawa; Takashi Nakano  Japanese Journal of Lung Cancer  49-  (4)  392  -396  2009/08
• Anti-cancer drug: Alimta

  福岡 和也  Clinical oncology  3-  (4)  464  -469  2009/04
• Solitary fibrous tumor (SFT)

  福岡和也  呼吸器症候群  452  -454  2009
• 35.化学療法後限局性再発し,放射線照射が有効であったびまん性悪性胸膜中皮腫の1例(第88回日本肺癌学会関西支部会,関西支部,支部活動)

  寺田 貴普; 栗林 康造; 安光 亮洋; 平山 倫子; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 福岡 和也; 中野 孝司  肺癌  48-  (6)  781  -782  2008/10
• 20.ゲフィチニブ投与中に肺結核を発症した肺腺癌の1例(第88回日本肺癌学会関西支部会,関西支部,支部活動)

  坂根 理矢; 栗林 康造; 池田 久美子; 平山 倫子; 寺田 貴普; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 福岡 和也; 中野 孝司; 坪田 紀明  肺癌  48-  (6)  779  -779  2008/10
• 7.腹腔内転移の診断にFDG-PETが有用であった非小細胞肺癌の2例(第88回日本肺癌学会関西支部会,関西支部,支部活動)

  安光 亮洋; 福岡 和也; 寺田 貴普; 平山 倫子; 村上 亜紀; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明; 中野 孝司  肺癌  48-  (6)  777  -777  2008/10
• 32.腹膜中皮腫24例におけるアスベスト関連胸膜肺病変の検討(第88回日本肺癌学会関西支部会,関西支部,支部活動)

  寺田 貴普; 栗林 康造; 安光 亮洋; 平山 倫子; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 福岡 和也; 中野 孝司  肺癌  48-  (6)  781  -781  2008/10
• P-665 アスベスト曝露症例における実験的な影響の観察を踏まえた免疫担当細胞の変化(悪性中皮腫3,第49回日本肺癌学会総会号)

  大槻 剛巳; 前田 恵; 村上 周子; 熊谷 直子; 林 宏明; 栗林 康造; 福岡 和也; 岸本 卓巳; 中野 孝司; 西村 泰光  肺癌  48-  (5)  656  -656  2008/10
• P-668 悪性胸膜中皮腫における胸水中platelet-derived growth factor (PDGF)測定の意義(悪性中皮腫3,第49回日本肺癌学会総会号)

  田村 邦宣; 福岡 和也; 平山 倫子; 寺田 貴普; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明  肺癌  48-  (5)  656  -656  2008/10
• P-432 悪性胸膜中皮腫(MPM)に対するカルボプラチン(CBDCA)+ペメトレキセド(MTA)併用療法のpilot study(化学療法3,第49回日本肺癌学会総会号)

  飯田 慎一郎; 福岡 和也; 寺田 貴普; 平山 倫子; 安光 亮洋; 村上 亜紀; 山田 秀哉; 田村 邦宣; 田端 千春; 栗林 康造; 坪田 紀明; 中野 孝司  肺癌  48-  (5)  597  -597  2008/10
• SS-5 悪性胸膜中皮腫に対する集学的治療の多施設共同臨床試験 : 科学技術振興調整費(悪性胸膜中皮腫の治療戦略-欧州と我が国の臨床試験の現状と対策-,第49回日本肺癌学会総会号)

  長谷川 誠紀; 田中 文啓; 山中 竹春; 岡田 守人; 副島 俊典; 辻村 亨; 上紺屋 憲彦; 福岡 和也; 中野 孝司  肺癌  48-  (5)  442  -442  2008/10
• WS15-2 悪性胸膜中皮種における胸水中可溶型メソテリン(SMRP)の診断的意義に関する検討(悪性胸膜中皮腫,第49回日本肺癌学会総会号)

  山田 秀哉; 福岡 和也; 栗林 康造; 田端 千春; 田村 邦宣; 飯田 慎一郎; 村上 亜紀; 安光 亮洋; 寺田 貴普; 平山 倫子; 中野 孝司; 坪田 紀明  肺癌  48-  (5)  437  -437  2008/10
• O-99 末梢循環血液中血管内皮細胞(CEC)を指標とした悪性胸膜中皮腫の診断(胸膜中皮種・アスベスト関連肺癌,第49回日本肺癌学会総会号)

  田中 文啓; 米田 和恵; 橋本 昌樹; 多久和 輝尚; 松本 成司; 近藤 展行; 奥村 好邦; 長谷川 誠紀; 辻村 亨; 坪田 紀明; 安光 亮洋; 村上 亜紀; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 田端 千春; 栗林 康造; 福岡 和也; 中野 孝司  肺癌  48-  (5)  469  -469  2008/10
• O-102 悪性胸膜中皮腫治療における外科医の役割 : 確定診断と病期診断,手術治療について(胸膜中皮種・アスベスト関連肺癌,第49回日本肺癌学会総会号)

  奥村 好邦; 橋本 昌樹; 多久和 輝尚; 近藤 展行; 田中 文啓; 長谷川 誠紀; 栗林 康造; 福岡 和也; 中野 孝司; 坪田 紀明  肺癌  48-  (5)  470  -470  2008/10
• O-101 悪性胸膜中皮腫における経時的FDG-PETの有用性についての検討(胸膜中皮種・アスベスト関連肺癌,第49回日本肺癌学会総会号)

  安光 亮洋; 福岡 和也; 平山 倫子; 寺田 貴普; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 栗林 康造; 坪田 紀明; 中野 孝司  肺癌  48-  (5)  470  -470  2008/10
• S2-3 早期中皮腫の発見と診断 : ビデオ補助胸腔鏡と胸水細胞診(中皮腫の克服を目指して-基礎と臨床の最前線-,グローバル時代の細胞診,第47回日本臨床細胞学会秋期大会)

  長谷川 誠紀; 田中 文啓; 福岡 和也; 中野 孝司; 辻村 亨  日本臨床細胞学会雑誌  47-  (2)  370  -370  2008/09
• S2-11 悪性胸膜中皮腫 : 我が国における多施設共同臨床試験と中皮腫登録の現状(中皮腫の克服を目指して-基礎と臨床の最前線-,グローバル時代の細胞診,第47回日本臨床細胞学会秋期大会)

  福岡 和也; 田中 文啓; 辻村 亨; 西本 寛; 長谷川 誠紀; 中野 孝司  日本臨床細胞学会雑誌  47-  (2)  375  -375  2008/09
• 21.同一家系内に発症した悪性胸膜中皮腫の2例(第87回日本肺癌学会関西支部会,関西支部,支部活動)

  村上 亜紀; 安光 亮洋; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 栗林 康造; 福岡 和也; 中野 孝司; 多久和 輝尚; 奥村 好邦; 田中 文啓; 長谷川 誠紀; 新長 真由美; 羽尾 裕之; 廣田 誠一; 井上 哲郎; 田口 善夫  肺癌  48-  (2)  148  -148  2008/04
• 48.興味ある胸腔鏡所見を呈した悪性胸腹中皮腫の1例(第87回日本肺癌学会関西支部会,関西支部,支部活動)

  田村 邦宣; 福岡 和也; 平山 倫子; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明; 近藤 展行; 多久和 輝尚; 奥村 好邦; 田中 文啓; 長谷川 誠紀; 小野寺 正征; 辻村 亨  肺癌  48-  (2)  152  -153  2008/04
• 49.浸潤型胸腺腫と悪性中皮腫との鑑別に苦慮した胸部悪性腫瘍の1例(第87回日本肺癌学会関西支部会,関西支部,支部活動)

  飯田 慎一郎; 安光 亮洋; 村上 亜紀; 山田 秀哉; 田村 邦宜; 田端 千春; 栗林 康造; 福岡 和也; 中野 孝司; 坪田 紀明; 多久和 輝尚; 松本 成司; 近藤 展行; 奥村 好邦; 田中 文啓; 長谷川 誠紀; 小野寺 正征; 辻村 亨  肺癌  48-  (2)  153  -153  2008/04
• P-334 アスベスト曝露症例末梢血CD3+T細胞におけるT細胞受容体Vβ発現の検討と実験系における検証(一般演題(ポスター)35 免疫・サイトカイン,第48回日本肺癌学会総会号)

  大槻 剛巳; 前田 恵; 村上 周子; 林 宏明; 福岡 和也; 栗林 康造; 岸本 卓巳; 草加 勝康; 中野 孝司; 西村 泰光  肺癌  47-  (5)  608  -608  2007/10
• P-333 悪性中皮腫患者NK細胞の細胞傷害性及びNK活性化レセプターNKp46発現量の低下(一般演題(ポスター)35 免疫・サイトカイン,第48回日本肺癌学会総会号)

  西村 泰光; 前田 恵; 村上 周子; 林 宏明; 三浦 由恵; 福岡 和也; 中野 孝司; 大槻 剛巳  肺癌  47-  (5)  608  -608  2007/10
• P-206 悪性胸膜中皮腫に対するセカンドライン療法 : ゲムシタビン+塩酸イリノテカン併用療法のpilot study(一般演題(ポスター)22 胸膜中皮腫1,第48回日本肺癌学会総会号)

  飯田 慎一郎; 安光 亮洋; 村上 亜紀; 山田 秀哉; 田村 邦宣; 田端 千春; 栗林 康造; 宮田 茂; 三宅 光富; 福岡 和也; 坪田 紀明; 中野 孝司  肺癌  47-  (5)  576  -576  2007/10
• O-156 all-trans retinoic acid(ATRA)による放射性肺障害抑制作用(一般演題(口演)26 放射線療法,第48回日本肺癌学会総会号)

  田端 千春; 栗林 康造; 三宅 光富; 田村 邦宣; 飯田 慎一郎; 山田 秀哉; 村上 亜紀; 安光 亮洋; 福岡 和也; 中野 孝司  肺癌  47-  (5)  517  -517  2007/10
• O-149 悪性中皮腫の血清診断マーカーとしての血清オステオポンチンの検討(一般演題(口演)25 腫瘍マーカー,第48回日本肺癌学会総会号)

  山田 秀哉; 福岡 和也; 安光 亮洋; 村上 亜紀; 栗林 康造; 飯田 慎一郎; 田村 邦宣; 田端 千春; 宮田 茂; 三宅 光富; 中野 孝司; 坪田 紀明  肺癌  47-  (5)  516  -516  2007/10
• SP3-4 切除可能悪性胸膜中皮腫に対するペメトレキセドを含む集学的治療に関する妥当性試験(特別企画 悪性胸膜中皮腫-治療戦略と中皮腫登録の現状と課題-,第48回日本肺癌学会総会号)

  田中 文啓; 長谷川 誠紀; 岡田 守人; 副島 俊典; 上紺屋 憲彦; 山中 竹春; 福岡 和也; 中野 孝治  肺癌  47-  (5)  473  -473  2007/10
• SP3-2 切除不能悪性胸膜中皮腫に対する臨床試験(特別企画 悪性胸膜中皮腫-治療戦略と中皮腫登録の現状と課題-,第48回日本肺癌学会総会号)

  福岡 和也  肺癌  47-  (5)  472  -472  2007/10
• O-45 悪性胸膜中皮腫の胸壁漫潤巣に対する局所放射線治療の有用性に関する検討(一般演題(口演)8 胸膜中皮腫2,第48回日本肺癌学会総会号)

  安光 亮洋; 栗林 康造; 三宅 光富; 宮田 茂; 田端 千春; 田村 邦宣; 飯田 慎一郎; 山田 秀哉; 村上 亜紀; 冨士原 将之; 福岡 和也; 坪田 紀明; 中野 孝司  肺癌  47-  (5)  490  -490  2007/10
• O-47 既治療悪性胸膜中皮腫に対するPemetrexed+Cisplatin併用療法の治療経験(一般演題(口演)8 胸膜中皮腫2,第48回日本肺癌学会総会号)

  栗林 康造; 福岡 和也; 安光 亮洋; 三宅 光富; 宮田 茂; 田端 千春; 田村 邦宣; 飯田 慎一郎; 山田 秀哉; 村上 亜紀; 坪田 紀明; 中野 孝司  肺癌  47-  (5)  490  -490  2007/10
• O-46 未治療悪性胸膜中皮腫に対するペメトレキセド+シスプラチン併用療法の有効性と安全性の検討(一般演題(口演)8 胸膜中皮腫2,第48回日本肺癌学会総会号)

  福岡 和也; 栗林 康造; 三宅 光富; 田村 邦宣; 飯田 慎一郎; 田端 千春; 安光 亮洋; 村上 亜紀; 山田 秀哉; 宮田 茂; 坪田 紀明; 中野 孝司  肺癌  47-  (5)  490  -490  2007/10
• P-213 悪性胸膜中皮腫におけるEGFR遺伝子変異(一般演題(ポスター)22 胸膜中皮腫1,第48回日本肺癌学会総会号)

  多久和 輝尚; 田中 文啓; 松本 成司; 奥村 好邦; 近藤 典行; 長谷川 誠紀; 橋本 昌樹; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 栗林 康造; 三宅 光富; 福岡 和也; 中野 孝司; 辻村 亨; 坪田 紀明  肺癌  47-  (5)  578  -578  2007/10
• WS11-1 悪性中皮腫症例末梢血CD4+T細胞におけるBcl-2高発現と実験的検証(ワークショップ 悪性中皮腫,第48回日本肺癌学会総会号)

  大槻 剛巳; 三浦 由恵; 前田 恵; 林 宏明; 村上 周子; 福岡 和也; 栗林 康造; 岸本 卓巳; 中野 孝司; 西村 泰光  肺癌  47-  (5)  467  -467  2007/10
• S5-7 胸膜中皮腫に対する集学的治療に向けて(シンポジウム 悪性中皮腫の克服に向けて,第48回日本肺癌学会総会号)

  田中 文啓; 橋本 昌樹; 多久和 輝尚; 松本 成司; 奥村 好邦; 近藤 展行; 長谷川 誠紀; 村上 亜紀; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 栗林 康造; 三宅 光富; 福岡 和也; 中野 孝司; 辻村 亨; 坪田 紀明  肺癌  47-  (5)  449  -449  2007/10
• WS11-5 悪性胸膜中皮腫の術前評価と手術適応の検討(ワークショップ 悪性中皮腫,第48回日本肺癌学会総会号)

  近藤 展行; 橋本 昌樹; 多久和 輝尚; 松本 成司; 奥村 好邦; 田中 文啓; 長谷川 誠紀; 村上 亜紀; 山田 秀哉; 宮田 茂; 田村 邦宣; 飯田 慎一郎; 栗林 康造; 三宅 光富; 福岡 和也; 中野 孝司; 坪田 紀明  肺癌  47-  (5)  468  -468  2007/10
• P-71 術後pN2と診断された肺癌(c-N0-1)切除例におけるFDG-PETによる縦隔リンパ節転移の検討(一般演題(ポスター) 転移,第48回日本肺癌学会総会)

  田村 邦宣; 福岡 和也; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田端 千春; 栗林 康造; 宮田 茂; 三宅 光富; 坪田 紀明; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 近藤 展行; 田中 文啓; 長谷川 誠紀  肺癌  47-  (5)  542  -542  2007/10
• P-530 アスベスト環境曝露を受けた同一家系内に発症した中皮腫の検討(一般演題(ポスター) 胸膜中皮腫2,第48回日本肺癌学会総会号)

  村上 亜紀; 安光 亮洋; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 栗林 康造; 宮田 茂; 三宅 光富; 福岡 和也; 坪田 紀明; 中野 孝司  肺癌  47-  (5)  657  -657  2007/10
• 30.悪性中皮腫における血清オステオポンチン濃度の検討(第86回日本肺癌学会関西支部会)

  山田 秀哉; 福岡 和也; 安光 亮洋; 村上 亜紀; 栗林 康造; 飯田 慎一郎; 田村 邦宣; 田端 千春; 宮田 茂; 三宅 光富; 中野 孝司  肺癌  47-  (4)  401  -401  2007/08
• 31. 偽中皮腫性発育を示した肺原発と考えられる印環細胞癌の1例(第85回 日本肺癌学会関西支部会,支部活動)

  永井 孝憲; 中嶋 泰典; 村上 亜紀; 山田 秀哉; 上坂 亜由子; 飯田 慎一郎; 田村 邦宣; 栗林 康造; 宮田 茂; 三宅 光富; 福岡 和也; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 田中 文啓; 長谷川 誠紀; 新長 真由美; 廣田 誠一  肺癌  47-  (2)  195  -195  2007/04
• 30. 中皮腫登録制度と悪性胸膜中皮腫に対する多施設共同臨床試験(科学技術振興調整費)(第85回 日本肺癌学会関西支部会,支部活動)

  中野 孝司; 福岡 和也; 長谷川 誠紀; 田中 文啓; 中野 孝司; 坪田 紀明; 辻村 亨; 岡田 守人; 三村 剛史; 西本 寛  肺癌  47-  (2)  195  -195  2007/04
• P-526 高齢者もしくはPS不良例のIII期NSCLCに対するVNR少量毎週投与及びTRTの同時併用療法の有効性と安全性の検討(低肺機能・高齢者肺癌2, 第47回日本肺癌学会総会)

  武田 真幸; 福岡 和也; 小林 厚; 小林 真也; 本津 茂人; 木村 弘  肺癌  46-  (5)  657  -657  2006/11
• P-607 化学療法にて good PRが得られた悪性胸膜中皮腫の4例(胸膜中皮腫3, 第47回日本肺癌学会総会)

  宮田 茂; 福岡 和也; 上坂 亜由子; 村上 亜紀; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 延山 誠一; 中嶋 泰典; 栗林 康造; 三宅 光富; 中野 孝司  肺癌  46-  (5)  677  -677  2006/11
• P-204 石綿関連職種に合併した原発性肺癌の検討(肺病変合併肺癌1, 第47回日本肺癌学会総会)

  村上 亜紀; 三宅 光富; 山田 秀哉; 上坂 亜由子; 飯田 慎一郎; 延山 誠一; 田村 邦宣; 中嶋 泰典; 栗林 康造; 宮田 茂; 福岡 和也; 中野 孝司; 廣田 誠一; 廣田 誠一  肺癌  46-  (5)  576  -576  2006/11
• P-258 悪性胸膜中皮腫における対側胸膜進展形態の臨床的検討(胸膜中皮腫1, 第47回日本肺癌学会総会)

  三宅 光富; 栗林 康造; 上坂 亜由子; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 延山 誠一; 田村 邦宣; 中嶋 泰典; 宮田 茂; 福岡 和也; 中野 孝司  肺癌  46-  (5)  590  -590  2006/11
• P-251 悪性胸膜中皮腫に対するCDDP+CPT-11+DXR併用化学療法の Pilot phase II study(胸膜中皮腫1, 第47回日本肺癌学会総会)

  福岡 和也; 上坂 亜由子; 栗林 康造; 三宅 光富; 宮田 茂; 中嶋 泰典; 飯田 慎一郎; 延山 誠一; 田村 邦宣; 山田 秀哉; 村上 亜紀; 中野 孝司  肺癌  46-  (5)  588  -588  2006/11
• P-431 当科におけるアスベスト検診にて発見された肺癌・中皮腫症例に関する検討(集団検診, 第47回日本肺癌学会総会)

  上坂 亜由子; 福岡 和也; 栗林 康造; 村上 亜紀; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 延山 誠一; 中嶋 泰典; 三宅 光富; 宮田 茂; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 田中 文啓; 長谷川 誠紀  肺癌  46-  (5)  633  -633  2006/11
• SP1-2 悪性胸膜中皮腫に対する多施設共同臨床試験の提案(悪性胸膜中皮腫治療の state of the art, 第47回日本肺癌学会総会)

  中野 孝司; 福岡 和也; 長谷川 誠紀; 田中 文啓  肺癌  46-  (5)  483  -483  2006/11
• O-11 悪性胸膜中皮腫化学療法奏効例の背景因子の解析(中皮腫, 第47回日本肺癌学会総会)

  栗林 康造; 三宅 光富; 宮田 茂; 中嶋 泰典; 田村 邦宣; 延山 誠一; 飯田 慎一郎; 上坂 亜由子; 山田 秀哉; 村上 亜紀; 福岡 和也; 中野 孝司  肺癌  46-  (5)  489  -489  2006/11
• S4-3 悪性中皮腫診断における血清バイオマーカーの有用性(悪性胸膜中皮腫の診断と治療, 第47回日本肺癌学会総会)

  福岡 和也; 上坂 亜由子; 栗林 康造; 三宅 光富; 宮田 茂; 中嶋 泰典; 飯田 慎一郎; 延山 誠一; 田村 邦宣; 山田 秀哉; 村上 亜紀; 中野 孝司  肺癌  46-  (5)  449  -449  2006/11
• P-45 中皮腫に対する蛍光観察 (AFI) 及び狭帯域観察 (NBI) を用いた胸腔鏡検査の試み(内視鏡・ステント1, 第47回日本肺癌学会総会)

  上坂 亜由子; 三宅 光富; 福岡 和也; 宮田 茂; 栗林 康造; 中嶋 泰典; 延山 誠一; 飯田 慎一郎; 田村 邦宣; 山田 秀哉; 村上 亜紀; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 田中 文啓; 長谷川 誠紀  肺癌  46-  (5)  537  -537  2006/11
• 41. 小細胞肺癌完全寛解後に,同側肺に異時性の扁平上皮癌を発症した1例(第84回 日本肺癌学会関西支部会,関西支部,支部活動)

  宮田 茂; 福岡 和也; 村上 亜紀; 山田 秀哉; 上坂 亜由子; 田村 邦宣; 延山 誠一; 飯田 慎一郎; 中嶋 泰典; 栗林 康造; 三宅 光富; 中野 孝司; 後藤 功  肺癌  46-  (4)  389  -390  2006/08
• 2. 骨格筋転移を契機に発見された肺癌の1例(第84回 日本肺癌学会関西支部会,関西支部,支部活動)

  山田 秀哉; 田村 邦宣; 村上 亜紀; 上坂 亜由子; 栗林 康造; 飯田 慎一郎; 延山 誠一; 中嶋 泰典; 宮田 茂; 三宅 光富; 福岡 和也; 中野 孝司; 新長 真由美; 廣田 誠一  肺癌  46-  (4)  383  -383  2006/08
• A case of pulmonary eosinophilic granuloma that remitted after cessation of smoking

  UESAKA Ayuko; MATSUDA Yoshinobu; YAMAGUCHI Atsushige; ASAI Mitsuko; YAMADA Syusai; FUKUOKA Kazuya; NAKANO Takashi  日本呼吸器学会雑誌 = The journal of the Japanese Respiratory Society  44-  (7)  528  -531  2006/07
• 10.CDDP+CPT-11+DXRの3剤 併用化学療法にてCRが得られた悪性胸膜中皮腫の1例(第83回 日本肺癌学会関西支部会,関西支部,支部活動)

  上坂 亜由子; 山田 秀哉; 村上 亜紀; 延山 誠一; 飯田 慎一郎; 田村 邦宣; 栗林 康造; 宮田 茂; 三宅 光富; 福岡 和也; 中野 孝司; 竹中 雅彦; 陣 祥子; 松田 良信  肺癌  46-  (2)  180  -180  2006/04
• 23.当科におけるゲフィチニブ長期内服例の臨床的検討(第83回 日本肺癌学会関西支部会,関西支部,支部活動)

  小林 厚; 小林 真也; 武田 真幸; 木村 弘; 福岡 和也  肺癌  46-  (2)  182  -182  2006/04
• 38.アスベスト検診にて発見された悪性胸膜中皮腫の1例(第83回 日本肺癌学会関西支部会,関西支部,支部活動)

  飯田 慎一郎; 村上 亜紀; 山田 秀哉; 上坂 亜由子; 延山 誠一; 田村 邦宣; 栗林 康造; 宮田 茂; 三宅 光富; 福岡 和也; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 田中 文啓; 長谷川 誠紀  肺癌  46-  (2)  185  -185  2006/04
• FDG-PETは肺癌と炎症性肺病変との鑑別に有用か?(5 画像診断・PET, 第46回 日本肺癌学会総会)

  小林 厚; 福岡 和也; 小林 真也; 本津 茂人; 武田 真幸; 木村 弘; 高濱 誠; 東条 尚; 坂本 雅彦  肺癌  45-  (5)  539  -539  2005/11
• 腎障害併発胸部悪性腫瘍患者における塩酸イリノテカン投与後の薬物動態(8 抗癌剤・薬理動態, 第46回 日本肺癌学会総会)

  宮田 茂; 山田 秀哉; 上坂 亜由子; 村上 亜紀; 延山 誠一; 飯田 慎一郎; 栗林 康造; 三宅 光富; 福岡 和也; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 長谷川 誠紀  肺癌  45-  (5)  548  -548  2005/11
• 悪性中皮腫の診断における中皮腫抗体の有用性についての検討(悪性胸膜中皮腫-臨床と病理-, 第46回 日本肺癌学会総会)

  栗林 康造; 平野 博嗣; 三宅 光富; 宮田 茂; 延山 誠一; 飯田 慎一郎; 上坂 亜由子; 山田 秀哉; 村上 亜紀; 多久和 輝尚; 松本 成司; 奥村 好邦; 福岡 和也; 長谷川 誠紀; 中野 孝司  肺癌  45-  (5)  475  -475  2005/11
• 胸膜中皮腫にFDG-PETスキャンは有用か?(悪性胸膜中皮腫-臨床と病理-, 第46回 日本肺癌学会総会)

  福岡 和也; 栗林 康造; 三宅 光富; 宮田 茂; 延山 誠一; 飯田 慎一郎; 上坂 亜由子; 山田 秀哉; 村上 亜紀; 中野 孝司; 奥村 好邦; 長谷川 誠紀  肺癌  45-  (5)  474  -474  2005/11
• 膠原病に合併した中皮腫の臨床病理学的検討(23 胸膜中皮腫1, 第46回 日本肺癌学会総会)

  上坂 亜由子; 村上 亜紀; 山田 秀哉; 延山 誠一; 飯田 慎一郎; 栗林 康造; 三宅 光富; 宮田 茂; 福岡 和也; 中野 孝司  肺癌  45-  (5)  581  -581  2005/11
• 悪性胸膜中皮腫に対する Methotrexate+Irinotecan+Doxorubicin 療法の Pilot phase II study(24 胸膜中皮腫2, 第46回 日本肺癌学会総会)

  栗林 康造; 三宅 光富; 宮田 茂; 延山 誠一; 飯田 慎一郎; 上坂 亜由子; 山田 秀哉; 村上 亜紀; 福岡 和也; 中野 孝司  肺癌  45-  (5)  583  -583  2005/11
• 悪性胸膜中皮腫における血清NSE値の検討(57 胸膜中皮腫3, 第46回日本肺癌学会総会)

  飯田 慎一郎; 村上 亜紀; 山田 秀哉; 上坂 亜由子; 延山 誠一; 栗林 康造; 三宅 光富; 宮田 茂; 福岡 和也; 中野 孝司  肺癌  45-  (5)  658  -658  2005/11
• 心外膜原発悪性中皮種の2剖検例(57 胸膜中皮腫3, 第46回日本肺癌学会総会)

  三宅 光富; 村上 亜紀; 奥窪 琢; 山田 秀哉; 栗林 康造; 上坂 亜由子; 延山 誠一; 飯田 慎一郎; 宮田 茂; 福岡 和也; 中野 孝司; 中正 恵二; 平野 博嗣  肺癌  45-  (5)  659  -659  2005/11
• 10. 原発不明癌を疑われたが, 気管支鏡検査にて広汎な気管支粘膜下浸潤を認めた肺腺癌の1例(第82回 日本肺癌学会関西支部会, 支部活動)

  寺西 融; 小林 厚; 福岡 和也; 本津 茂人; 米田 和之; 児山 紀子; 牧之 段潔; 玉置 伸二; 友田 恒一; 濱田 薫; 木村 弘; 善本 英一郎; 前田 光一  肺癌  45-  (6)  766  -766  2005/10
• 気管内転移による気道狭窄を呈した,肺カルチノイド腫瘍の1例

  新熊 悟; 玉置 伸二; 児山 紀子; 牧之段 潔; 米田 和之; 友田 恒一; 福岡 和也; 濱田 薫; 木村 弘; 善本 英一郎; 前田 光一  気管支学  27-  (5)  417  -417  2005/07
• 55. 免疫組織化学的にADH産生を確認し得たSIADH合併小細胞肺癌の2例(第81回日本肺癌学会関西支部会, 支部活動)

  本津 茂人; 福岡 和也; 武田 真幸; 小林 真也; 木村 弘; 辰巳 晃子; 和中 明生; 小林 厚  肺癌  45-  (1)  99  -99  2005/02
• 42. 長期にわたり無気肺と考えられFDG-PETを契機に診断された肺腺癌の1切除例(第80回日本肺癌学会関西支部会)(支部活動)

  岩井 一哲; 本津 茂人; 福岡 篤彦; 牧之段 潔; 友田 恒一; 福岡 和也; 濱田 薫; 木村 弘; 高濱 誠; 櫛部 圭司; 谷口 繁樹; 今井 照彦  肺癌  44-  (6)  722  -722  2004/10
• P11-27 切除不能肺腺癌におけるゲフィチニブの抗腫瘍効果と血中腫瘍マーカーとの関連性(ポスター総括11 : 基礎 分子標的1(トランスレーショナルリサーチ))

  福岡 和也; 武田 真幸; 本津 茂人; 小林 真也; 木村 弘  肺癌  44-  (5)  643  -643  2004/10
• P1-31 I期非小細胞肺癌切除例における細胞周期調節因子発現の検討 : FDG-PETとの関連性を中心にして(ポスター総括1 : 診断1 FDG-PET診断)

  武田 真幸; 福岡 和也; 本津 茂人; 小池 真也; 木村 弘; 高濱 誠; 櫛部 圭司  肺癌  44-  (5)  391  -391  2004/10
• P6-9 SIADHを呈した小細胞肺癌の臨床的検討(ポスター総括6 : 内科1 小細胞肺癌)

  本津 茂人; 福岡 和也; 武田 真幸; 小林 真也; 木村 弘  肺癌  44-  (5)  511  -511  2004/10
• 気管支炎症性ポリープを伴った慢性壊死性肺アスペルギルス症の1例

  岡林 里枝; 前田 光一; 神野 正敏; 藤本 隆; 松村 雅彦; 藤本 眞一; 中村 忍; 玉置 伸二; 友田 恒一; 福岡 和也; 濱田 薫; 木村 弘; 善本 英一郎; 三笠 桂一  気管支学  26-  (6)  575  -575  2004/09
• 63. 縦隔リンパ節および脳に転移巣を認めた原発不明の低分化癌の1例(第79回日本肺癌学会関西支部会)

  宇野 健司; 福岡 和也; 福岡 篤彦; 武田 真幸; 濱田 薫; 木村 弘; 野々村 昭孝  肺癌  44-  (2)  144  -144  2004/04
• 51. 塩酸アムルビシンが奏効したSIADH合併小細胞肺癌の1例(第79回日本肺癌学会関西支部会)

  早川 正樹; 福岡 和也; 福岡 篤彦; 武田 真幸; 濱田 薫; 木村 弘; 中村 契; 高濱 誠; 櫛部 圭司; 谷口 繁樹  肺癌  44-  (2)  142  -142  2004/04
• 16.腫瘍塊を自己喀出した腎細胞癌気管支内転移の1例(第74回 日本呼吸器内視鏡学会近畿支部会)

  宇野 健司; 三宅 牧人; 田中 基幹; 植村 天受; 平尾 佳彦; 福岡 和也; 玉置 伸二; 善本 英一郎; 友田 恒一; 竹中 英昭; 濱田 薫; 木村 弘; 前田 光一  気管支学  26-  (1)  97  -97  2004
• ゲフィチニブ投与非小細胞肺癌患者における皮膚障害の臨床病理学的検討

  福岡 和也; 本津 茂人; 小林 真也; 武田 真幸; 木村 弘; 古林 郁乃; 浅田 秀夫; 宮川 幸子  肺癌  43-  (5)  590  -590  2003/10
• 62.多発性胸壁腫瘤で発見され,剖検にて気管支壁内への浸潤が明らかとなった悪性胸膜中皮腫の1例(第78回日本肺癌学会関西支部会)

  藤田 幸男; 福岡 和也; 福岡 篤彦; 宇野 健司; 武田 真幸; 濱田 薫; 木村 弘; 堤 雅弘; 國安 弘基; 西本 優子  肺癌  43-  (6)  772  -772  2003/10
• 63.悪性リンパ腫との鑑別を要した神経内分泌成分を伴った原発不明の低分化癌の1例(第78回日本肺癌学会関西支部会)

  水野 陽花; 福岡 和也; 福岡 篤彦; 大屋 修一; 武田 真幸; 濱田 薫; 木村 弘; 山本 泰弘  肺癌  43-  (6)  772  -772  2003/10
• 肺癌術後胸郭内再発症例に対するFDG-PEフスキャンの有用性の検討

  武田 真幸; 福岡 和也; 本津 茂人; 小林 真也; 木村 弘; 高濱 誠; 櫛部 圭司; 谷口 繁樹; 今井 照彦; 坂本 雅彦  肺癌  43-  (5)  529  -529  2003/10
• 22. 無治療で約3年間生存し得た高齢者小細胞肺癌の1例(第77回日本肺癌学会関西支部会)(支部活動)

  宇野 建司; 福岡 和也; 玉置 伸二; 本津 茂人; 武田 真幸; 濱田 薫; 木村 弘  肺癌  43-  (2)  161  -161  2003/04
• 6. 口蓋扁桃を含む多臓器への転移を来した小細胞肺癌の1例(第77回日本肺癌学会関西支部会)(支部活動)

  藤田 幸男; 福岡 和也; 福岡 篤彦; 本津 茂人; 武田 真幸; 濱田 薫; 木村 弘  肺癌  43-  (2)  158  -158  2003/04
• Restoration of p53 gene function in 12-O-tetradecanoylphorbor 13-acetate-resistant human leukemia K562/TPA cells

  J Usuda; M Inomata; H Fukumoto; Y Iwamoto; T Suzuki; HJ Kuh; K Fukuoka; H Kato; N Saijo; K Nishio  INTERNATIONAL JOURNAL OF ONCOLOGY  22-  (1)  81  -86  2003/01
• 局所進行非小細胞肺癌におけるInduction Therapyを含む集学的治療法の検討

  福岡 和也; 本津 茂人; 木村 弘; 櫛部 圭司; 高濱 誠; 川口 剛史; 根津 邦基; 甲斐 吉郎; 小林 真也; 竹澤 祐一  肺癌  42-  (5)  369  -369  2002/10
• 23. 脊髄内転移を来した特発性間質性肺炎合併小細胞肺癌の1例(第76回 日本肺癌学会関西支部会)(関西支部)(支部活動)

  甲斐 吉郎; 芳野 詠子; 福岡 和也; 伊藤 武文; 本津 茂人; 濱田 薫; 木村 弘; 藤田 千絵; 高群 美和; 上野 聡; 寺本 正治; 今井 照彦  肺癌  42-  (6)  661  -661  2002/10
• 22. 嚢胞形成性視床転移を来した小細胞肺癌の1例(第76回 日本肺癌学会関西支部会)(関西支部)(支部活動)

  田村 緑; 福岡 篤彦; 福岡 和也; 竹中 英昭; 本津 茂人; 濱田 薫; 木村 弘; 飯田 淳一; 榊 寿右  肺癌  42-  (6)  660  -661  2002/10
• 24. Lambert-Eaton myasthenic syndrome(LEMS)を合併した小細胞肺癌の1例(第76回 日本肺癌学会関西支部会)(関西支部)(支部活動)

  平川 遼一; 福岡 和也; 玉置 伸二; 本津 茂人; 濱田 薫; 木村 弘; 藤田 千絵; 高群 美和; 上野 聡  肺癌  42-  (6)  661  -661  2002/10
• Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells

  K Fukuoka; H Arioka; Y Iwamoto; H Fukumoto; H Kurokawa; T Ishida; A Tomonari; T Suzuki; J Usuda; F Kanzawa; H Kimura; N Saijo; K Nishio  CANCER CHEMOTHERAPY AND PHARMACOLOGY  49-  (5)  385  -390  2002/05
• 12.術前の腹部造影CTが診断に有用であった肺腺癌の空腸転移の1例(第75回 日本肺癌学会関西支部会)

  芳野 詠子; 福岡 和也; 本津 茂人; 濱田 薫; 木村 弘  肺癌  42-  (2)  149  -149  2002/04
• 16.血中カルシトニン値の上昇を認めた肺性肥大性骨関節症を合併した肺腺癌の1例(第75回 日本肺癌学会関西支部会)

  宮本 謙一; 福岡 和也; 本津 茂人; 福岡 篤彦; 木村 弘; 中島 啓  肺癌  42-  (2)  150  -150  2002/04
• Enhancement of in vivo antitumor activity of a novel antimitotic 1-phenylpropenone derivative, AM-132, by tumor necrosis factor-alpha or interleukin-6 (vol 92, pg 768, 2001)

  Y Tatsumi; H Arioka; S Ikeda; H Fukumoto; K Miyamoto; K Fukuoka; Y Ohe; N Saijo; K Nishio  JAPANESE JOURNAL OF CANCER RESEARCH  92-  (12)  1355  -1355  2001/12
• Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells

  K Fukuoka; H Arioka; Y Iwamoto; H Fukumoto; H Kurokawa; T Ishida; A Tomonari; T Suzuki; J Usuda; F Kanzawa; N Saijo; K Nishio  LUNG CANCER  34-  (3)  451  -460  2001/12
• 73.胃転移が契機となり発見された肺扁平上皮癌の1剖検例(第74回日本肺癌学会関西支部会)

  高橋 賢; 福岡 和也; 本津 茂人; 小林 真也; 濱田 薫; 米田 尚弘; 木村 弘; 川口 剛史; 根津 邦基; 谷口 繁樹; 北東 大督; 高山 智燮; 中島 祥介; 中江 大  肺癌  41-  (6)  725  -725  2001/10
• 6.感覚性ニューロパチーを合併した肺小細胞癌の1例(第74回日本肺癌学会関西支部会)

  本津 茂人; 福岡 和也; 小林 真也; 濱田 薫; 米田 弘; 木村 弘; 川原 誠; 熊澤 昌洋; 上野 聡  肺癌  41-  (6)  714  -714  2001/10
• G-12 胃転移を来した肺扁平上皮癌の1剖検例 : 当科における肺癌消化管転移の検討

  高橋 賢; 福岡 和也; 本津 茂人; 濱田 薫; 木村 弘  肺癌  41-  (5)  488  -488  2001/09
• PD-42 切除不能III期非小細胞肺癌に対するパクリタキセル+カルボプラチンと胸部放射線照射同時併用療法の検討

  福岡 和也; 本津 茂人; 木村 弘  肺癌  41-  (5)  447  -447  2001/09
• P-178 当科における肺癌に伴う腫瘍随伴症候群の臨床的検討

  本津 茂人; 福岡 和也; 木村 弘  肺癌  41-  (5)  567  -567  2001/09
• 非小細胞肺癌に対するビノレルビンの放射線増感効果の基礎的検討と臨床応用

  福岡 和也; 本津 茂人; 木村 弘; 西尾 和人; 西條 長宏  肺癌  41-  (5)  531  -531  2001/09
• Enhancement of in vivo antitumor activity of a novel antimitotic 1-phenylpropenone derivative, AM-132, by tumor necrosis factor-alpha or interleukin-6

  Y Tatsumi; H Arioka; S Ikeda; H Fukumoto; K Miyamoto; K Fukuoka; Y Ohe; N Saijo; K Nishio  JAPANESE JOURNAL OF CANCER RESEARCH  92-  (7)  768  -777  2001/07
• Enhancement of in vivo antitumor activity of a novel antimitotic 1-phenylpropenone derivative, AM-132, by tumor necrosis factor-alpha or interleukin-6

  Y Tatsumi; H Arioka; S Ikeda; H Fukumoto; K Miyamoto; K Fukuoka; Y Ohe; N Saijo; K Nishio  JAPANESE JOURNAL OF CANCER RESEARCH  92-  (7)  768  -777  2001/07
• 35. SLEを合併した肺腺癌の1切除例

  宮本 謙一; 福岡 和也; 善本 英一郎; 小林 真也; 濱田 薫; 米田 尚弘; 成田 亘啓; 安川 元章; 櫛部 圭司; 根津 邦基; 谷口 繁樹; 森 啓; 甲斐 吉郎; 竹澤 祐一; 山田 雄三  肺癌  41-  (2)  175  -175  2001/04
• 57. 血中ProGRP値が治療効果の指標となったlarge cell neuroendocrine carcinomaの1例

  山本 佳史; 福岡 和也; 緑川 沢樹; 中村 孝人; 古西 満; 小林 真也; 濱田 薫; 米田 尚弘; 成田 亘啓; 安川 元章; 川口 剛史; 櫛部 圭司; 根津 邦基; 谷口 繁樹  肺癌  41-  (2)  178  -179  2001/04
• A Case of Rapidly Progressed Human Chorionic Gonadotropin Producing Squamous Cell Carcinoma of the Lung

  眞島 利匡; 福岡 和也; 緑川 沢樹  日本胸部臨床  60-  (2)  168  -172  2001/02
• Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells

  K Fukuoka; J Usuda; Y Iwamoto; H Fukumoto; T Nakamura; T Yoneda; N Narita; N Saijo; K Nishio  INVESTIGATIONAL NEW DRUGS  19-  (3)  219  -227  2001
• Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells

  K Fukuoka; J Usuda; Y Iwamoto; H Fukumoto; T Nakamura; T Yoneda; N Narita; N Saijo; K Nishio  INVESTIGATIONAL NEW DRUGS  19-  (3)  219  -227  2001
• Mechanism of action of aragusterol A (YTA0040), a potent anti-tumor marine steroid targeting the G(1) phase of the cell cycle

  K Fukuoka; T Yamagishi; T Ichihara; S Nakaike; K Iguchi; Y Yamada; H Fukumoto; T Yoneda; K Samata; H Ikeya; K Nanaumi; N Hirayama; N Narita; N Saijo; K Nishio  INTERNATIONAL JOURNAL OF CANCER  88-  (5)  810  -819  2000/12
• Mechanism of action of aragusterol A (YTA0040), a potent anti-tumor marine steroid targeting the G(1) phase of the cell cycle

  K Fukuoka; T Yamagishi; T Ichihara; S Nakaike; K Iguchi; Y Yamada; H Fukumoto; T Yoneda; K Samata; H Ikeya; K Nanaumi; N Hirayama; N Narita; N Saijo; K Nishio  INTERNATIONAL JOURNAL OF CANCER  88-  (5)  810  -819  2000/12
• 40.胸部放射線照射同時併用化学療法(weekly Paclitaxel+Carboplatin)の経過中に間質性肺炎を発症し死亡した腺扁平上皮癌の1剖検例(第72回日本肺癌学会関西支部会)

  本津 茂人; 福岡 和也; 善本 英一郎; 小林 真也; 濱田 薫; 米田 尚弘; 成田 亘啓; 村田 奈保; 中江 大; 小西 陽一  肺癌  40-  (6)  682  -682  2000/10
• 27.Lambert-Eaton myasthenic syndrome(LEMS)を合併した小細胞肺癌の1例(第72回日本肺癌学会関西支部会)

  中野 優子; 福岡 和也; 小林 真也; 濱田 薫; 米田 尚弘; 成田 亘啓; 後藤 泰史; 田丸 司; 上野 聡  肺癌  40-  (6)  680  -680  2000/10
• E-2 切除不能局所進行性非小細胞肺癌に対するパクリタキセル+カルボプラチンと胸部放射線照射同時併用のpilot study

  福岡 和也; 小林 真也; 米田 尚弘; 成田 亘啓  肺癌  40-  (5)  430  -430  2000/09
• I-72 肺性肥大性骨関節症を合併した原発性肺悪性腫瘍の二例

  福岡 和也; 武田 研一; 小林 真也; 濱田 薫; 米田 尚弘; 成田 亘啓; 櫛部 圭司; 川口 剛史; 谷口 繁樹  肺癌  40-  (5)  543  -543  2000/09
• 61.癌性胸膜炎で発症し, 剖検にて胆管細胞癌の胸膜浸潤と診断された1例(第71回日本肺癌学会関西支部会)

  小林 真也; 福岡 和也; 米田 和之; 濱田 薫; 米田 尚弘; 成田 亘啓; 楠岡 修; 堤 雅弘; 小西 陽一  肺癌  40-  (2)  162  -162  2000/04
• 24.肋骨への骨形成性転移が発見の契機となった肺扁平上皮癌の1例(第71回日本肺癌学会関西支部会)

  本津 茂人; 福岡 和也; 米田 和之; 金山 清二; 小林 真也; 濱田 薫; 米田 尚弘; 成田 亘啓  肺癌  40-  (2)  156  -157  2000/04
• Ectopic p16(INK4) expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells

  K Fukuoka; K Nishio; H Fukumoto; H Arioka; H Kurokawa; T Ishida; Y Iwamoto; A Tomonari; T Suzuki; J Usuda; N Narita; N Saijo  INTERNATIONAL JOURNAL OF CANCER  86-  (2)  197  -203  2000/04
• Ectopic p16(INK4) expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells

  K Fukuoka; K Nishio; H Fukumoto; H Arioka; H Kurokawa; T Ishida; Y Iwamoto; A Tomonari; T Suzuki; J Usuda; N Narita; N Saijo  INTERNATIONAL JOURNAL OF CANCER  86-  (2)  197  -203  2000/04
• Molecular determinants of UCN-01-induced growth inhibition in human lung cancer cells

  J Usuda; N Saijo; K Fukuoka; H Fukumoto; HJ Kuh; T Nakamura; Y Koh; T Suzuki; F Koizumi; T Tamura; H Kato; K Nishio  INTERNATIONAL JOURNAL OF CANCER  85-  (2)  275  -280  2000/01
• Molecular determinants of UCN-01-induced growth inhibition in human lung cancer cells

  J Usuda; N Saijo; K Fukuoka; H Fukumoto; HJ Kuh; T Nakamura; Y Koh; T Suzuki; F Koizumi; T Tamura; H Kato; K Nishio  INTERNATIONAL JOURNAL OF CANCER  85-  (2)  275  -280  2000/01
• 10.HCG産生肺癌の1例 : 第70回日本肺癌学会関西支部会

  眞島 利匡; 福岡 和也; 緑川 沢樹; 坂本 正洋; 三笠 桂一; 米田 尚弘; 成田 亘啓  肺癌  39-  (6)  916  -916  1999/10
• P-42 非小細胞肺癌に対するClarithromycinの投与(示説,サイトカイン・腫瘍免疫,第40回日本肺癌学会総会号)

  眞島 利匡; 坂本 正洋; 三笠 桂一; 濱田 薫; 古西 満; 前田 光一; 福岡 和也; 善本 英一郎; 村川 幸市; 高橋 賢; 喜多 英二; 成田 亘啓  肺癌  39-  (5)  667  -667  1999/09
• P-43 切除不能非小細胞肺癌患者におけるclarithromycinの有用性 : 長期生存例の検討(示説,サイトカイン・腫瘍免疫,第40回日本肺癌学会総会号)

  坂本 正洋; 三笠 桂一; 眞島 利匡; 濱田 薫; 古西 満; 前田 光一; 福岡 和也; 善本 英一郎; 村川 幸市; 高橋 賢; 喜多 英二; 成田 亘啓  肺癌  39-  (5)  667  -667  1999/09
• I-18 上大静脈症候群合併肺癌患者に対するQOL向上を目指したクリティカルパスの導入(QOL等,第40回日本肺癌学会総会号)

  福岡 和也; 中野 優子; 西本 優子; 幕谷 士郎; 今井 照彦; 大石 元; 打田 日出夫; 網本 学; 小林 真也; 米田 尚弘; 成田 亘啓  肺癌  39-  (5)  644  -644  1999/09
• 新規スルホンアミド系抗癌剤E7070の作用機序の検討

  福岡 和也; 臼田 実男; 福本 久郎; 中村 貴; 西條 長宏; 成田 亘啓; 西尾 和人  日本癌学会総会記事  58回-  680  -680  1999/08
• Effect of a chimeric anti-ganglioside GM2 antibody on ganglioside GM2-expressing human solid tumors in vivo

  H Fukumoto; K Nishio; S Ohta; N Hanai; K Fukuoka; Y Ohe; K Sugihara; T Kodama; N Saijo  INTERNATIONAL JOURNAL OF CANCER  82-  (5)  759  -764  1999/08
• Effect of a chimeric anti-ganglioside GM2 antibody on ganglioside GM2-expressing human solid tumors in vivo

  H Fukumoto; K Nishio; S Ohta; N Hanai; K Fukuoka; Y Ohe; K Sugihara; T Kodama; N Saijo  INTERNATIONAL JOURNAL OF CANCER  82-  (5)  759  -764  1999/08
• In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model

  F Kanzawa; K Nishio; K Fukuoka; T Sunami; N Saijo  CANCER CHEMOTHERAPY AND PHARMACOLOGY  43-  (5)  353  -363  1999/05
• Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells

  T Sunami; K Nishio; F Kanzawa; K Fukuoka; S Kudoh; J Yoshikawa; N Saijo  CANCER CHEMOTHERAPY AND PHARMACOLOGY  43-  (5)  394  -401  1999/05
• Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells

  T Sunami; K Nishio; F Kanzawa; K Fukuoka; S Kudoh; J Yoshikawa; N Saijo  CANCER CHEMOTHERAPY AND PHARMACOLOGY  43-  (5)  394  -401  1999/05
• In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model

  F Kanzawa; K Nishio; K Fukuoka; T Sunami; N Saijo  CANCER CHEMOTHERAPY AND PHARMACOLOGY  43-  (5)  353  -363  1999/05
• 39.気管・気管支内ステント挿入および胸部放射線照射により5年間生存中の腺様嚢胞癌の1例 : 第69回日本肺癌学会関西支部会

  小川 修平; 福岡 和也; 牧之 段潔; 寺元 正治; 三笠 桂一; 岡本 行功; 前田 光一; 坂本 正洋; 竹中 英昭; 善本 英一郎; 成田 亘啓; 佐々木 義明  肺癌  39-  (2)  216  -216  1999/04
• Mitogen-activated protein kinase antisense oligonucleotide inhibits the growth of human lung cancer cells

  K Nishio; K Fukuoka; H Fukumoto; T Sunami; Y Iwamoto; T Suzuki; J Usuda; N Saijo  INTERNATIONAL JOURNAL OF ONCOLOGY  14-  (3)  461  -469  1999/03
• Mitogen-activated protein kinase antisense oligonucleotide inhibits the growth of human lung cancer cells

  K Nishio; K Fukuoka; H Fukumoto; T Sunami; Y Iwamoto; T Suzuki; J Usuda; N Saijo  INTERNATIONAL JOURNAL OF ONCOLOGY  14-  (3)  461  -469  1999/03
• Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells

  H Arioka; K Nishio; T Ishida; H Fukumoto; K Fukuoka; T Nomoto; H Kurokawa; H Yokote; S Abe; N Saijo  JAPANESE JOURNAL OF CANCER RESEARCH  90-  (1)  108  -115  1999/01
• Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells

  H Arioka; K Nishio; T Ishida; H Fukumoto; K Fukuoka; T Nomoto; H Kurokawa; H Yokote; S Abe; N Saijo  JAPANESE JOURNAL OF CANCER RESEARCH  90-  (1)  108  -115  1999/01
• The C-terminal domain of p53 catalyzes DNA-renaturation and strand exchange toward annealing between intact ssDNAs and toward eliminating damaged ssDNA from duplex formation through preferential recognition of damaged DNA by a duocarmycin

  H Yokote; K Nishio; H Arioka; H Kurokawa; K Fukuoka; H Fukumoto; T Ishida; T Terada; T Itakura; N Saijo  MUTATION RESEARCH-DNA REPAIR  409-  (3)  147  -162  1998/12
• The C-terminal domain of p53 catalyzes DNA-renaturation and strand exchange toward annealing between intact ssDNAs and toward eliminating damaged ssDNA from duplex formation through preferential recognition of damaged DNA by a duocarmycin

  H Yokote; K Nishio; H Arioka; H Kurokawa; K Fukuoka; H Fukumoto; T Ishida; T Terada; T Itakura; N Saijo  MUTATION RESEARCH-DNA REPAIR  409-  (3)  147  -162  1998/12
• 肺癌脳転移に対するγナイフ症例の検討

  植田 勝廣; 三笠 桂一; 福岡 和也; 坂本 正洋; 古西 満; 前田 光一; 辻本 正之; 真島 利匡; 成田 亘啓; 都築 俊英  肺癌  38-  (5)  543  -543  1998/09
• マウス肺癌モデルでの抗癌剤及びclarithromycinの各種サイトカイン産生に与える影響

  植田 勝廣; 三笠 桂一; 濱田 薫; 坂本 正洋; 眞島 利匡; 古西 満; 前田 光一; 善本 英一郎; 福岡 和也; 成田 亘啓; 喜多 英二  肺癌  38-  (5)  466  -466  1998/09
• 新規ATP Binding Cassette(ABC)トランスポーターSMRP/MRP5のクローニングとその機能の解析

  西尾 和人; 鈴木 俊宏; 須波 俊彦; 臼田 実男; 福岡 和也; 岩本 康男; 成 清一郎; 西條 長宏  肺癌  38-  (5)  442  -442  1998/09
• 細胞周期制御因子に対する新規抗がん剤の感受性耐性要因

  臼田 実男; 福岡 和也; 岩本 康男; 須波 敏彦; 加藤 治文; 西條 長宏; 西尾 和人  肺癌  38-  (5)  443  -443  1998/09
• 新規抗腫瘍性ステロイド化合物アラグステロールA(YTA0040)の肺癌細胞に対する抗腫瘍効果の検討

  福岡 和也; 臼田 実男; 岩本 康男; 成田 亘啓; 西條 長宏; 西尾 和人  肺癌  38-  (5)  564  -564  1998/09
• UCN-01によるヒト末梢血リンパ球のFas発現を介したアポトーシス誘導作用

  須波 敏彦; 西尾 和人; 福岡 和也; 岩本 康男; 臼田 実男; 成瀬 一郎; 田村 友秀; 西條 長宏  肺癌  38-  (5)  567  -567  1998/09
• 44.亜急性感覚障害,自律神経障害を初発症状とした抗Hu抗体陽性肺腺癌の1例 : 第68回日本肺癌学会関西支部会

  上森 栄和; 坂本 正洋; 福岡 和也; 前田 光一; 古西 満; 三笠 桂一; 成田 亘啓; 尾崎 京子; 田丸 司; 村田 顕也; 高柳 哲也; 田中 恵子; 犬塚 貴  肺癌  38-  (4)  388  -388  1998/08
• 新抗癌剤の評価と展望 UCN-01の感受性を規定する細胞内因子

  臼田 実男; 西尾 和人; 福岡 和也; 福本 久郎; 岩本 康男; 鈴木 俊宏; 加藤 治文; 西條 長宏  日本癌治療学会誌  33-  (3)  93  -93  1998/08
• 新規抗腫瘍性ステロイド化合物アラグステロールA(YTA0040)の作用機序の検討

  福岡 和也; 臼田 実男; 山岸 武弘; 市原 智子; 中池 司郎; 井口 和男; 山田 泰司; 成田 亘啓; 西條 長宏; 西尾 和人  日本癌学会総会記事  57回-  643  -643  1998/08
• Small Cell Lung Cancer Associated with Nephrotic Syndrome: Remission FTER Chemotherapy

  TOMODA Koichi; HAMADA Kaoru; FUKUOKA Kazuya; TSUKAGUCHI Katsuhiko; TSUJIMOTO Masayuki; MIKASA Keiichi; CHOH Umito; YONEDA Takahiro; NARITA Nobuhiro  日本呼吸器学会雑誌 = The journal of the Japanese Respiratory Society  36-  (6)  541  -544  1998/06
• Increased expression of sialyl Lewis(x) antigen is associated with distant metastasis in lung cancer patients: Immunohistochemical study on bronchofiberscopic biopsy specimens

  K Fukuoka; N Narita; N Saijo  LUNG CANCER  20-  (2)  109  -116  1998/05
• Increased expression of sialyl Lewis(x) antigen is associated with distant metastasis in lung cancer patients: Immunohistochemical study on bronchofiberscopic biopsy specimens

  K Fukuoka; N Narita; N Saijo  LUNG CANCER  20-  (2)  109  -116  1998/05
• UCN-01 accumulates functional p53 into the nucleus in a phorbolester resistant leukemia cell line as a basis of cyclin-dependent kinase inhibition

  J Usuda; K Nishio; K Fukuoka; H Fukumoto; Y Iwamoto; S Naruse; T Suzuki; H Kato; N Saijo  ANNALS OF ONCOLOGY  9-  111  -111  1998
• The role of MAP kinase in the taxane-induced cytotoxicity. in " Cytoskeleton and G-proteins in The Regulation of Cancer" H

  Hokkaido University School of Medicine, Sapporo, Japan,  172-179-  1998
• The role of MAP kinase in the taxane-induced cytotoxicity. (共著)

  Hokkaido University School of Medicine Medical Library Series : "Cytoskeleton and G-proteins in The Regulation of Cancer"Sapporo, Kokoku Printing Co. Ltd  37-  172  -179  1998
• In vitro enhancement of antitumor activity of a water-soluble duocarmycin derivative, KW-2189, by caffeine-mediated DNA-repair inhibition in human lung cancer cells

  H Ogasawara; K Nishio; T Ishida; H Arioka; K Fukuoka; N Saijo  JAPANESE JOURNAL OF CANCER RESEARCH  88-  (11)  1033  -1037  1997/11
• In vitro enhancement of antitumor activity of a water-soluble duocarmycin derivative, KW-2189, by caffeine-mediated DNA-repair inhibition in human lung cancer cells

  H Ogasawara; K Nishio; T Ishida; H Arioka; K Fukuoka; N Saijo  JAPANESE JOURNAL OF CANCER RESEARCH  88-  (11)  1033  -1037  1997/11
• G-28 微小管の脱重合を促進するがん関連蛋白質オンコプロテイン18の肺がん細胞における発現と抗がん剤感受性

  西尾 誠人; 福岡 和也; 福本 久郎; 有岡 仁; 岩本 泰男; 臼田 実男; 友成 章; 須波 敏彦; 成清 一郎; 鈴木 俊宏; 西條 長宏  肺癌  37-  (5)  691  -691  1997/10
• G-24 シスブラチンによるγ-グルタミルシステイン合成酵素ヘビーサブユニット遺伝子の転写活性の増強に関与するプロモーター領域の検討

  友成 章; 西尾 和人; 福本 久郎; 福岡 和也; 岩本 康男; 成清 一郎; 臼田 実男; 鈴木 俊宏; 須波 敏彦; 板倉 光夫; 西條 長宏  肺癌  37-  (5)  690  -690  1997/10
• E-55 肺癌細胞に対するvinorelbineの放射線増感作用の検討

  福岡 和也; 西尾 和人; 宮澤 文彦; 福本 久郎; 友成 章; 岩本 康男; 臼田 実男; 須波 敏彦; 成清 一郎; 成田 亘啓; 西條 長宏  肺癌  37-  (5)  664  -664  1997/10
• P-142 新規微小管作用薬E7010にたいする耐性機構の検討

  岩本 康男; 西尾 和人; 福岡 和也; 友成 章; 福本 久郎; 臼田 実男; 須波 敏彦; 吉松 賢太郎; 山木戸 道郎; 西條 長宏  肺癌  37-  (5)  740  -740  1997/10
• P-143 新規抗癌剤TAS-103と他種抗癌剤のin vitro併用効果の検討

  須波 敏彦; 宮澤 文彦; 臼田 実男; 岩本 康男; 福岡 和也; 西尾 和人; 西條 長宏  肺癌  37-  (5)  740  -740  1997/10
• p16(INK4) expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors

  K Fukuoka; J Adachi; K Nishio; H Arioka; H Kurokawa; H Fukumoto; T Ishida; T Nomoto; H Yokote; A Tomonari; N Narita; J Yokota; N Saijo  JAPANESE JOURNAL OF CANCER RESEARCH  88-  (10)  1009  -1016  1997/10
• Circumvention of glutathione-mediated mitomycin C resistance by a novel mitomycin C analogue, KW-2149

  T Ishida; K Nishio; H Kurokawa; H Arioka; H Fukumoto; K Fukuoka; T Nomoto; H Yokote; S Hasegawa; N Saijo  INTERNATIONAL JOURNAL OF CANCER  72-  (5)  865  -870  1997/09
• Circumvention of glutathione-mediated mitomycin C resistance by a novel mitomycin C analogue, KW-2149

  T Ishida; K Nishio; H Kurokawa; H Arioka; H Fukumoto; K Fukuoka; T Nomoto; H Yokote; S Hasegawa; N Saijo  INTERNATIONAL JOURNAL OF CANCER  72-  (5)  865  -870  1997/09
• Proximal 5'-flanking sequence of the human gamma-glutamylcysteine synthetase heavy subunit gene is involved in cisplatin-induced transcriptional up-regulation in a lung cancer cell line SBC-3

  A Tomonari; K Nishio; H Kurokawa; H Fukumoto; K Fukuoka; Y Iwamoto; J Usuda; T Suzuki; M Itakura; N Saijo  BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS  236-  (3)  616  -621  1997/07
• Proximal 5'-flanking sequence of the human gamma-glutamylcysteine synthetase heavy subunit gene is involved in cisplatin-induced transcriptional up-regulation in a lung cancer cell line SBC-3

  A Tomonari; K Nishio; H Kurokawa; H Fukumoto; K Fukuoka; Y Iwamoto; J Usuda; T Suzuki; M Itakura; N Saijo  BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS  236-  (3)  616  -621  1997/07
• Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC-3

  F Kanzawa; K Nishio; K Fukuoka; M Fukuda; T Kunimoto; N Saijo  INTERNATIONAL JOURNAL OF CANCER  71-  (3)  311  -319  1997/05
• Interferon-gamma-inducing factor gene transfection into Lewis lung carcinoma cells reduces tumorigenicity in vivo

  H Fukumoto; M Nishio; K Nishio; Y Heike; H Arioka; H Kurokawa; T Ishida; K Fukuoka; T Nomoto; Y Ohe; N Saijo  JAPANESE JOURNAL OF CANCER RESEARCH  88-  (5)  501  -505  1997/05
• Interferon-gamma-inducing factor gene transfection into Lewis lung carcinoma cells reduces tumorigenicity in vivo

  H Fukumoto; M Nishio; K Nishio; Y Heike; H Arioka; H Kurokawa; T Ishida; K Fukuoka; T Nomoto; Y Ohe; N Saijo  JAPANESE JOURNAL OF CANCER RESEARCH  88-  (5)  501  -505  1997/05
• Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC-3

  F Kanzawa; K Nishio; K Fukuoka; M Fukuda; T Kunimoto; N Saijo  INTERNATIONAL JOURNAL OF CANCER  71-  (3)  311  -319  1997/05
• Identification of cis-acting DNA elements of the human gamma-glutamylcysteine synthetase heavy subunit gene

  A Tomonari; K Nishio; H Kurokawa; H Arioka; T Ishida; H Fukumoto; K Fukuoka; T Nomoto; Y Iwamoto; Y Hieke; M Itakura; N Saijo  BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS  232-  (2)  522  -527  1997/03
• Identification of cis-acting DNA elements of the human gamma-glutamylcysteine synthetase heavy subunit gene

  A Tomonari; K Nishio; H Kurokawa; H Arioka; T Ishida; H Fukumoto; K Fukuoka; T Nomoto; Y Iwamoto; Y Hieke; M Itakura; N Saijo  BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS  232-  (2)  522  -527  1997/03
• Effect of glutathione depletion on cisplatin resistance in cancer cells transfected with the gamma-glutamylcysteine synthetase gene

  H Kurokawa; K Nishio; T Ishida; H Arioka; K Fukuoka; T Nomoto; H Fukumoto; H Yokote; N Saijo  JAPANESE JOURNAL OF CANCER RESEARCH  88-  (2)  108  -110  1997/02
• Effect of glutathione depletion on cisplatin resistance in cancer cells transfected with the gamma-glutamylcysteine synthetase gene

  H Kurokawa; K Nishio; T Ishida; H Arioka; K Fukuoka; T Nomoto; H Fukumoto; H Yokote; N Saijo  JAPANESE JOURNAL OF CANCER RESEARCH  88-  (2)  108  -110  1997/02
• Recent Advance in Cancer Treatment and Biology. γ-Glutamylcysteine Synthetase and Chemosensitivity.

  西尾和人; 黒川博一; 石田智之; 福岡和也; 西条長宏  癌と化学療法  24-  (4)  1997
• Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phenanthridinium hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines

  F Kanzawa; K Nishio; T Ishida; M Fukuda; H Kurokawa; H Fukumoto; Y Nomoto; K Fukuoka; K Bojanowski; N Saijo  BRITISH JOURNAL OF CANCER  76-  (5)  571  -581  1997
• Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phenanthridinium hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines

  F Kanzawa; K Nishio; T Ishida; M Fukuda; H Kurokawa; H Fukumoto; Y Nomoto; K Fukuoka; K Bojanowski; N Saijo  BRITISH JOURNAL OF CANCER  76-  (5)  571  -581  1997
• Significant survival benefit of clarithromycin treatment for patients with unresectable lung cancer

  MIKASA Keiichi; SAWAKI Masayoshi; KITA Eiji; HAMADA Kaoru; SAKAMOTO Masahiro; KONISHI Mitsuru; MAEDA Koichi; TERAMOTO Shoji; TSUJIMOTO Masayuki; MORI Kei; UEDA Katsuhiro; FUKUOKA Kazuya; SEGAWA Kotaro; KATAOKA Tateshi; NARITA Nobuhiro  日本化学療法学会雜誌 = Japanese journal of chemotherapy  44-  (12)  883  -889  1996/12
• Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines

  K Nishio; T Ishida; H Arioka; H Kurokawa; K Fukuoka; T Nomoto; H Fukumoto; H Yokote; N Saijo  ANTICANCER RESEARCH  16-  (6B)  3387  -3395  1996/11
• Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines

  K Nishio; T Ishida; H Arioka; H Kurokawa; K Fukuoka; T Nomoto; H Fukumoto; H Yokote; N Saijo  ANTICANCER RESEARCH  16-  (6B)  3387  -3395  1996/11
• A topoisomerase II inhibitor, NK109, induces DNA single- and double-strand breaks and apoptosis

  M Fukuda; M Inomata; K Nishio; K Fukuoka; F Kanzawa; H Arioka; T Ishida; H Fukumoto; H Kurokawa; M Oka; N Saijo  JAPANESE JOURNAL OF CANCER RESEARCH  87-  (10)  1086  -1091  1996/10
• A topoisomerase II inhibitor, NK109, induces DNA single- and double-strand breaks and apoptosis

  M Fukuda; M Inomata; K Nishio; K Fukuoka; F Kanzawa; H Arioka; T Ishida; H Fukumoto; H Kurokawa; M Oka; N Saijo  JAPANESE JOURNAL OF CANCER RESEARCH  87-  (10)  1086  -1091  1996/10
• ワークショップ7 : 間質性肺炎と肺癌 : 当科における石綿関連肺癌の臨床的検討

  濱田 薫; 徳山 猛; 米田 尚弘; 岡本 行功; 森川 暁; 春日 宏友; 三笠 桂一; 田村 猛夏; 宮崎 隆治; 鴻池 義純; 福岡 和也; 成田 亘啓  肺癌  36-  (5)  506  -506  1996/09
• 原発性肺癌に対するclarithromycinの延命効果の検討

  三笠 桂一; 澤木 政好; 喜多 英二; 浜田 薫; 坂本 正洋; 古西 満; 前田 光一; 寺本 正治; 辻本 正之; 森 啓; 植田 勝廣; 福岡 和也; 瀬川 耕太郎; 片岡 達治; 成田 亘啓  肺癌  36-  (5)  527  -527  1996/09
• 癌性胸膜炎における胸水中TNFα.sTNF-R(I)の検討

  友田 恒一; 福岡 和也; 長 澄人; 竹中 英昭; 仲谷 宗裕; 小林 厚; 鈴木 夕子; 薄葉 恵史; 鴻池 義純; 米田 尚弘; 成田 亘啓  肺癌  36-  (5)  672  -672  1996/09
• GX-Xポンプを介するシスプラチン耐性と細胞内グルタチオンの関連

  黒川 博一; 西尾 和人; 石田 智之; 有岡 仁; 福本 久郎; 福岡 和也; 野本 泰介; 友成 章; 横手 秀行; 岩本 康男; 鈴木 俊宏; 平家 勇司; 西條 長宏  肺癌  36-  (5)  624  -624  1996/09
• p16^導入非小細胞肺癌細胞における各種抗癌剤感受性の検討

  福岡 和也; 安達 淳一; 西尾 和人; 有岡 仁; 黒川 博一; 福本 久郎; 石田 智之; 野本 泰介; 横手 秀行; 友成 章; 鈴木 俊宏; 岩本 康男; 成田 亘啓; 横田 淳; 西條 長宏  肺癌  36-  (5)  623  -623  1996/09
• 多剤耐性癌細胞株のトポイソメラーゼI阻害剤に対する感受性とトポイソメラーゼI活性

  野本 泰介; 西尾 和人; 石田 智之; 有岡 仁; 黒川 博一; 福本 久郎; 福岡 和也; 横手 秀行; 友成 章; 岩本 康男; 鈴木 俊宏; 西條 長宏  肺癌  36-  (5)  623  -623  1996/09
• TAS-103;新規DNAトポイソメラーゼI、II阻害剤

  石田 智之; 西尾 和人; 有岡 仁; 黒川 博一; 福本 久郎; 福岡 和也; 野本 泰介; 友成 章; 横手 秀行; 岩本 康男; 鈴木 俊宏; 西條 長宏  肺癌  36-  (5)  691  -691  1996/09
• 27.最近経験した悪性中皮腫症の4例 : 血中シフラ,TPAの腫瘍マーカーとしての有用性

  眞島 利匡; 徳山 猛; 濱田 薫; 岡本 行功; 福岡 和也; 辻本 正之; 酢谷 喜世子; 薄葉 恵史; 稲田 浩; 米田 尚弘; 成田 亘啓  肺癌  36-  (2)  187  -187  1996/04
• 抗癌剤とアポト-シス

  福岡 和也; 西条 長宏  日本臨床  54-  (1)  250  -258  1996/01
• Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes

  N Saijo; K Nishio; S Ohta; H Arioka; Y Funayama; K Fukuoka; H Kurokawa; T Nomoto; T Ishida; N Yamamoto; T Tamura; T Shinkai; K Eguchi; Y Ohe; H Kunito; T Ohtsu; Y Sasaki  CANCER CHEMOTHERAPY AND PHARMACOLOGY  38-  S11  -S15  1996
• Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes

  N Saijo; K Nishio; S Ohta; H Arioka; Y Funayama; K Fukuoka; H Kurokawa; T Nomoto; T Ishida; N Yamamoto; T Tamura; T Shinkai; K Eguchi; Y Ohe; H Kunito; T Ohtsu; Y Sasaki  CANCER CHEMOTHERAPY AND PHARMACOLOGY  38-  S11  -S15  1996
• Phorbol ester and okadaic acid-resistant cells: The crossroads of signal transduction and drug resistance

  N Saijo; K Nishio; Y Takeda; H Arioka; T Ishida; T Nomoto; K Fukuoka; H Kurokawa; H Fukumoto  AMERICAN JOURNAL OF MEDICINE  99-  S35  -S39  1995/12
• Phorbol ester and okadaic acid-resistant cells: The crossroads of signal transduction and drug resistance

  N Saijo; K Nishio; Y Takeda; H Arioka; T Ishida; T Nomoto; K Fukuoka; H Kurokawa; H Fukumoto  AMERICAN JOURNAL OF MEDICINE  99-  S35  -S39  1995/12
• 8.肺癌化学療法中に出現した肺動脈血栓症の1例(第62回日本肺癌学会関西支部会)

  井前 徳久; 鈴木 夕子; 福岡 和也; 前田 光一; 森井 武志; 徳山 猛; 濱田 薫; 三笠 桂一; 成田 亘啓  肺癌  35-  (6)  826  -826  1995/10
• Docetaxel(Taxotere^lt;[◯!R]>)耐性ヒト肺癌細胞株の樹立 : 抗癌剤感受性, 耐性1

  有岡 仁; 舩山 康則; 西尾 和人; 石田 智之; 福本 久郎; 黒川 博一; 佐田 誠; 福田 実; 福岡 和也; 野本 泰介; 平家勇司; 西條 長安  肺癌  35-  (5)  571  -571  1995/09
• γ-グルタミルシステインシンテターゼ遺伝子導入細胞におけるマイトマイシンC誘導体(KW-2149)の感受性 : 抗癌剤感受性, 耐性2

  石田 智之; 西尾 和人; 有岡 仁; 黒川 博一; 福本 久郎; 福田 実; 福岡 和也; 野本 泰介; 西篠 長宏  肺癌  35-  (5)  573  -573  1995/09
• シスプラチン碓肺癌細胞におけるGS-Xポンプ : 抗癌剤感受性, 耐性1

  黒川 博一; 西尾 和人; 石田 智之; 有岡 仁; 福本 久郎; 野本 泰介; 福岡 和也; 三浦 傳; 西條 長宏  肺癌  35-  (5)  572  -572  1995/09
• Paclitaxelの微小管関連蛋白質およびMitogen activated protein kinaseに対する作用の検討 : 抗癌剤感受性, 耐性2

  福岡 和也; 西尾 和人; 有岡 仁; 石田 智之; 黒川 博一; 福本 久郎; 野本 泰介; 西條 長宏  肺癌  35-  (5)  572  -572  1995/09
• 新規抗癌剤NK-109のヒト肺小細胞癌株に対するDNA切断活性とアポトーシス : 抗癌剤感受性2

  福田 実; 猪俣 素子; 西尾 和人; 官澤 文彦; 有岡 仁; 石田 智之; 福本 久郎; 黒川 博一; 福岡 和也; 野本 泰介; 岡 三喜男; 西條 長宏  肺癌  35-  (5)  619  -619  1995/09
• ガングリオシドGM2のヒト癌抗癌剤耐性細胞における過剰発現と抗GM2キメラ抗体を用いた耐性克服 : 抗癌剤感受性2

  福本 久郎; 西尾 和人; 平家 勇司; 有岡 仁; 石田 智之; 黒川 博一; 野本 泰介; 福岡 和也; 山本 信之; 大江 裕一郎; 西條 長宏  肺癌  35-  (5)  620  -620  1995/09
• Bcl-2関連遺伝子導入による抗がん剤感受性の変化 : 肺癌におけるアポトーシス関連遺伝子bcl-2発現の意義

  西尾 和人; 有岡 仁; 石田 智之; 黒川 博一; 福岡 和也; 野本 泰介; 福本 久郎; 西條 長宏  肺癌  35-  (5)  535  -535  1995/09
• KW2189およびCPT-11のcarboxyl esteraseによる細胞内代謝と感受性の検討 : 抗癌剤感受性, 耐性2

  野本 泰介; 西尾 和人; 小笠原 勇人; 有岡 仁; 石田 智之; 黒川 博一; 福本 久郎; 福岡 和也; 官澤 文彦; 西篠 長宏  肺癌  35-  (5)  573  -573  1995/09
• 乳腺結核の1例

  福岡和也  結核  7-  111  -115  1995
• 肺気腫合併肺癌の臨床的検討 : 肺癌合併時の肺機能を中心に : 併存肺病変・合併症

  林 宏明; 米田 尚弘; 福岡 和也; 吉川 雅則; 夫 彰啓; 徳山 猛; 山本 智生; 竹中 英昭; 友田 恒一; 仲谷 宗裕; 成田 亘啓  肺癌  34-  (5)  676  -676  1994/10
• 肺癌患者に聴取された連続ラ音の音響学的性状に関する検討 : 重複癌・合併症他

  長 澄人; 竹中 英昭; 生駒 行拡; 福岡 和也; 成田 亘啓  肺癌  34-  (5)  816  -816  1994/10
• 肺癌患者における栄養学的予後指数(Prgnostic Nutritional Index, PNl)の検討 : 予後因子(4)

  竹中 英昭; 福岡 和也; 長 澄人; 生駒 行拡; 吉川 雅則; 夫 彰啓; 徳山 猛; 山本 智生; 友田 恒一; 福岡 篤彦; 仲谷 宗裕; 林 宏明; 米田 尚弘; 成田 亘啓  肺癌  34-  (5)  708  -708  1994/10
• 原発性肺癌における糖鎖抗原の免疫組織化学的検討 : 腫瘍マーカー

  福岡 和也; 米田 尚弘; 長 澄人; 濱田 薫; 竹中 英昭; 生駒 行拡; 塚口 信彦; 吉川 雅則; 徳山 猛; 夫 彰啓; 山本 智生; 友田 恒一; 仲谷 宗裕; 成田 亘啓  肺癌  34-  (5)  778  -778  1994/10
• 原発性肺癌に対するClarithromycin(CAM)長期投与の試み : Biological response modifierとしてのCAMの可能性 : 集学的治療と副作用

  三笠 桂一; 澤木 政好; 喜多 英二; 濱田 薫; 古西 満; 前田 光一; 寺本 正治; 竹内 章治; 福岡 和也; 坂本 正洋; 辻本 正之; 森 啓; 国松 幹和; 成田 亘啓  肺癌  34-  (5)  625  -625  1994/10
• P-223 肺癌化学療法時の咽頭細菌叢の変動と呼吸器感染症発症との関連性についての検討

  福岡 和也; 塚口 信彦; 長 澄人; 濱田 薫; 鴻池 義純; 友田 恒一; 米田 尚弘; 成田 亘啓  肺癌  33-  (5)  760  -760  1993/10
• 49.Desmoplastic mesotheliomaの1症例 : 第58回日本肺癌学会関西支部会 : 関西支部

  松澤 邦明; 浜田 薫; 徳山 猛; 三笠 桂一; 田村 猛夏; 古西 満; 前田 光一; 福岡 和也; 澤木 政好; 成田 亘啓; 澤端 章好; 櫛部 圭司; 根津 邦基; 飯岡 壮吾; 北村 惣一郎  肺癌  33-  (3)  449  -449  1993/06
• C-72 肺癌化学療法時のG-CSF投与時期に関する検討

  鴻池 義純; 夫 彰啓; 竹内 章治; 三笠 桂一; 濱田 薫; 長 澄人; 北村 和道; 福岡 和也; 龍神 良忠; 前川 純子; 成田 亘啓  肺癌  32-  (5)  651  -651  1992/10
• E-35 肺癌化学療法時の心理変化に対するエチゾラムの効果

  古西 満; 三笠 桂一; 福岡 和也; 前田 光一; 友田 恒一; 佐々木 義明; 鴻池 義純; 澤木 政好; 成田 亘啓  肺癌  32-  (5)  683  -683  1992/10
• A Case of Pulmonary Atypical Mycobacteriosis Combined with Small Cell Lung Cancer

  Fukuoka Kazuya; Kohnoike Yoshizumi; Narita Nobuhiro; Kushibe Keishi; Ioka Sougo; Shirai Fumio  Japanese Journal of Lung Cancer  32-  (3)  389  -395  1992/06
• A Randomized Controlled Postoperative Adjuvant Chemotherapy Trial of MMC+Tegafur and MMC+UFT for Adenocarcinoma of the Lung-First Study (Second Report) :

  Nobuyoshi Shimizu et al  Japanese Journal of Lung Cancer  31-  (7)  1011  -1019  1991/12
• 67.若年者胸腺癌の1例 : 第55回日本肺癌学会関西支部会

  友田 恒一; 古西 満; 西川 潔; 森井 武志; 福岡 和也; 長 澄人; 濱田 薫; 鳩池 義純; 成田 亘啓; 大澤 政彦; 青笹 克之  肺癌  31-  (6)  979  -979  1991/10
• 58.多彩な組織亜型を呈した肺腺癌の1剖検例 : 第55回日本肺癌学会関西支部会

  玉置 伸二; 岡村 英生; 佐々木 義明; 長 澄人; 福岡 和也; 濱田 薫; 鴻池 義純; 成田 亘啓; 近藤 哲; 堤 雅弘; 丸山 博司; 小西 陽一  肺癌  31-  (6)  978  -978  1991/10
• 61.左房内心粘液腫を合併した肺扁平上皮癌の1剖検例 : 第55回日本肺癌学会関西支部会

  八木 秀男; 森井 武志; 鴻池 義純; 徳山 猛; 濱田 薫; 長 澄人; 福岡 和也; 吉川 雅則; 成田 亘啓; 日浅 義雄  肺癌  31-  (6)  978  -978  1991/10
• 57.びまん性皮下浸潤を呈した肺腺癌の1剖検例 : 第55回日本肺癌学会関西支部会

  福岡 和也; 塩崎 道明; 板橋 司; 久保田 靖; 古西 満; 濱田 薫; 長 澄人; 鴻池 義純; 成田 亘啓; 小路 徹二; 森井 外吉  肺癌  31-  (6)  977  -978  1991/10
• B-34 肺癌化学療法時における心理変化の検討

  古西 満; 三笠 桂一; 佐々木 義明; 福岡 和也; 前田 光一; 友田 恒一; 鴻池 義純; 澤木 政好; 成田 亘啓  肺癌  31-  (5)  655  -655  1991/10
• 第54回日本肺癌学会関西支部会 : 5.松果体転移を伴った肺扁平上皮癌の1剖検例

  斉藤 圭一; 古西 満; 鴻池 義純; 福岡 和也; 濱田 薫; 長 澄人; 澤木 政好; 成田 亘成; 小西 登; 青笹 克之  肺癌  31-  (3)  441  -441  1991/06
• 第53回日本肺癌学会関西支部会 : 17.心タンポナーデで発症した珪肺合併肺癌の1例

  天野 逸人; 長 澄人; 古西 満; 福岡 和也; 濱田 薫; 鴻池 義純; 澤木 政好; 宮崎 隆治; 成田 亘啓; 日浅 義雄; 吉川 雅則; 竹下 修治  肺癌  30-  (7)  1079  -1079  1990/12
• 第53回日本肺癌学会関西支部会 : 22.化学療法,放射線療法後のSVC症候群にステント挿入が有効であった肺小細胞癌の1例

  友田 恒一; 斎藤 圭一; 阿児 博文; 古西 満; 福岡 和也; 長 澄人; 濱田 薫; 鴻池 義純; 澤木 政好; 成田 亘啓; 吉岡 哲也; 尾辻 秀章; 折田 日出夫  肺癌  30-  (7)  1079  -1080  1990/12
• 第53回日本肺癌学会関西支部会 : 67.血中および胸水中CEA高値を認めた石綿肺合併胸膜型肺癌の1例

  塚口 信彦; 濱田 薫; 長 澄人; 福岡 和也; 鴻池 義純; 田村 猛夏; 春日 宏友; 澤木 政好; 成田 亘啓; 沢田 泉; 東条 尚; 飯岡 壮吾; 北村 惣一郎; 宮崎 隆治  肺癌  30-  (7)  1086  -1087  1990/12
• P-96 肺癌患者合併呼吸器感染症の臨床的検討

  古西 満; 福岡 和也; 鴻池 義純; 澤木 政好; 三笠 桂一; 竹内 章治; 佐々木 義明; 濱田 薫; 国松 幹和; 成田 亘啓  肺癌  30-  (5)  750  -750  1990/10
• 335 当科における石棉肺合併肺癌の臨床疫学的検討

  鴻池 義純; 福岡 和也; 阿児 博文; 春日 宏友; 森川 暁; 濱田 薫; 長 澄人; 田村 猛夏; 米田 尚弘; 堅田 均; 宮崎 隆治; 成田 亘啓  肺癌  30-  (5)  706  -706  1990/10
• 3.肺癌組織におけるレクチン結合性の検討 : 臨床病態との関連を中心として(第52回日本肺癌学会関西支部会)

  福岡 和也; 米田 尚弘; 鴻池 義純; 澤木 政好; 成田 亘啓; 飯岡 壮吾; 北村 惣一郎; 小西 陽一  肺癌  30-  (4)  595  -595  1990/08
• 54.血胸にて発見された骨肉腫の一例(第52回日本肺癌学会関西支部会)

  小林 秀明; 古西 満; 福岡 和也; 濱田 薫; 鴻池 義純; 澤木 政好; 成田 亘啓; 櫛部 圭司; 飯岡 壮吾; 北村 惣一郎; 宮内 義純; 三井 宣夫; 玉井 進  肺癌  30-  (4)  603  -603  1990/08
• 71.多発性小腸転移巣穿孔により死亡した肺扁平上皮癌の一剖検例(第52回日本肺癌学会関西支部会)

  中尾 宰子; 古西 満; 福岡 和也; 鴻池 義純; 澤木 政好; 成田 亘啓; 榮本 弘行; 丸山 博司; 小西 陽一  肺癌  30-  (4)  606  -606  1990/08
• 727. Clinical study on lung cancer with asbestosis : 1. clinico-epidemiological study(DUST・PNEUMOCONIOSIS,FREE COMMUNICATION,Proceedings of the 62nd Annual Meeting of Japan Association of Industrial Health(Formerly Annual Meeting of Japan Society of Industrial Medicine))

  Morikawa S.  Japanese journal of industrial health  31-  (7)  719  -719  1989/12
• 第51回日本肺癌学会関西支部会 : 5.非定型抗酸菌症に合併した肺小細胞癌の一切除例

  福岡 和也; 鴻池 義純; 堅田 均; 澤木 政好; 成田 亘啓; 櫛部 圭司; 東条 栄; 飯岡 壮吾; 北村 惣一郎; 白井 史朗  肺癌  29-  (7)  811  -812  1989/12
• 第51回日本肺癌学会関西支部会 : 18.CDDPを含む化学療法後の味覚異常に対する亜鉛投与の試み

  福岡 和也; 堅田 均; 三笠 桂一; 古西 満; 前田 光一; 辻本 正之; 中尾 宰子; 鴻池 義純; 澤木 政好; 成田 亘啓  肺癌  29-  (7)  814  -814  1989/12
• 第51回日本肺癌学会関西支部会 : 42.原発性肺4重複癌の1例

  辻本 正之; 福岡 和也; 鴻池 義純; 藤村 昌史; 杉村 裕子; 堅田 均; 澤木 政好; 成田 亘啓; 今井 照彦; 大石 元; 飯岡 壮荘; 北村 惣一郎  肺癌  29-  (7)  818  -818  1989/12
• 肺癌化学療法下の成分栄養剤経口投与の検討

  江川 信一; 米田 尚弘; 塚口 勝彦; 吉川 雅則; 鴻池 義純; 福岡 和也; 成田 亘啓  肺癌  29-  (5)  597  -597  1989/10
• 肺癌化学療法におけるQuality Of Life(QOL)評価の試み

  浜崎 直樹; 古西 満; 福岡 和也; 坂本 正洋; 友田 恒一; 佐々木 義明; 三笠 桂一; 堅田 均; 澤木 政好; 成田 亘啓  肺癌  29-  (5)  496  -496  1989/10
• 特発性間質性肺炎合併肺癌自験例の検討 : "定型例"と"非定型例"とによる相違を中心として

  福岡 和也; 春日 宏友; 中尾 宰子; 森川 暁; 阿児 博文; 長 澄人; 渡辺 裕之; 鴻池 義純; 米田 尚弘; 堅田 均; 澤木 政好; 成田 亘啓; 今井 照彦; 大石 元  肺癌  29-  (5)  502  -502  1989/10
• 肺癌患者における細胞性免疫能と栄養障害(第3報) : IL-2産生能は内臓蛋白・亜鉛と関連する

  米田 尚弘; 吉川 雅則; 塚口 勝彦; 江川 信一; 鴻池 義純; 福岡 和也; 成田 亘啓  肺癌  29-  (5)  563  -563  1989/10
• 肺癌に伴う細胞診陰性胸水の検討

  鴻池 義純; 福岡 和也; 江川 信一; 米田 尚弘; 堅田 均; 西川 潔; 澤木 政好; 成田 亘啓  肺癌  29-  (5)  506  -506  1989/10
• 87.皮膚筋炎に肺重複癌を合併した一剖検例(第50回日本肺癌学会関西支部会)

  岡村 英生; 福岡 和也; 古西 満; 三笠 桂一; 鴻池 義純; 堅田 均; 澤木 政好; 成田 亘啓; 村上 宣也; 生駒 一憲; 高柳 哲也; 杉本 充彦; 今井 俊介; 日浅 義雄  肺癌  29-  (4)  422  -422  1989/08
• 33.空洞を伴う多発性肺内転移を示した原発性肺癌の2例(第50回日本肺癌学会関西支部会)

  竹中 英昭; 福岡 和也; 前田 光一; 鴻池 義純; 古西 満; 三笠 桂一; 堅田 均; 沢木 政好; 成田 亘啓; 今井 照彦; 大石 元  肺癌  29-  (4)  414  -414  1989/08
• 49.塩酸モルヒネにてコントロール不良な癌性疼痛に対する塩酸ブプレノルフィン持続皮下注入の有効性について(第50回日本肺癌学会関西支部会)

  坂本 正洋; 堅田 均; 三笠 桂一; 鴻池 義純; 古西 満; 福岡 和也; 澤木 政好; 成田 亘啓  肺癌  29-  (4)  416  -416  1989/08
• 25.右小脳半球に孤立性嚢胞形成性転移をきたした肺扁平上皮癌の一例(第49回日本肺癌学会関西支部会)

  福岡 和也; 堅田 均; 鴻池 義純; 澤木 政好; 成田 亘啓; 今井 照彦; 永田 清; 金 良根; 京井 喜久男; 内海 庄三郎  肺癌  29-  (1)  98  -99  1989/02
• 67.肺小細胞癌寛解6年後に同一部位に再発, 骨転移巣は腺扁平上皮癌であった1例(第49回日本肺癌学会関西支部会)

  下山 丈人; 堅田 均; 鴻池 義純; 福岡 和也; 阿児 博文; 森川 暁; 澤木 政好; 成田 亘啓  肺癌  29-  (1)  105  -105  1989/02
• 40.脳神経症状を主とするGuillain-Barre症候群を合併した肺扁平上皮癌の一例(第49回日本肺癌学会関西支部会)

  吉田 英里; 堅田 均; 吉岡 真理子; 阿児 博文; 福岡 和也; 鴻池 義純; 澤木 政好; 成田 亘啓; 柳本 真一; 高柳 哲也  肺癌  29-  (1)  101  -101  1989/02
• 73.多発性嚢胞を伴った気管扁平上皮癌と末梢腺癌の肺多発癌の一例(第49回日本肺癌学会関西支部会)

  吉川 雅則; 堅田 均; 米田 尚弘; 福岡 和也; 鴻池 義純; 澤木 政好; 成田 亘啓; 今井 照彦  肺癌  29-  (1)  106  -106  1989/02
• 125 各種レクチンを用いた肺癌の免疫組織学的検討

  福岡 和也; 米田 尚弘; 澤木 政好; 成田 亘啓; 飯岡 壮吾; 東条 尚; 北村 惣一郎  肺癌  28-  (5)  588  -588  1988/09
• 31 肺癌における^<123>I-IMP肺シンチグラフィの有用性について

  今井 照彦; 大石 元; 吉村 均; 堅田 均; 鴻池 義純; 福岡 和也; 沢木 政好; 成田 亘啓; 東条 尚; 飯岡 壮吾  肺癌  28-  (5)  564  -564  1988/09
• 12 切除肺癌の高分解能X線CT像と伸展固定標本軟X線像ならびに病理像との対比検討

  畠山 雅行; 西村 幸洋; 玉田 俊明; 佐藤 典子; 久保田 靖; 尾辻 秀章; 打田 日出夫; 今井 照彦; 吉村 均; 大石 元; 福岡 和也; 鴻池 義純; 堅田 均; 成田 亘啓; 東条 尚; 飯岡 壮吾; 北村 惣一郎; 小西 陽一  肺癌  28-  (5)  559  -559  1988/09
• 61 癌性胸水中のLeu-19^+リンパ球の検討

  鴻池 義純; 西川 潔; 福岡 和也; 堅田 均; 成田 亘啓  肺癌  28-  (5)  572  -572  1988/09
• 3. 進行肺癌患者における味覚異常の検討(第48回日本肺癌学会関西支部会)

  前田 光一; 堅田 均; 三笠 桂一; 福岡 和也; 辻本 正之; 吉田 英里; 今井 照彦; 成田 亘啓  肺癌  28-  (3)  414  -414  1988/06
• 1. 末期肺癌患者の疼痛治療における自他覚的評価(第48回日本肺癌学会関西支部会)

  福岡 和也; 堅田 均; 三笠 桂一; 佐々木 義明; 古西 満; 渡辺 裕之; 前田 光一; 吉田 英里; 成田 亘啓  肺癌  28-  (3)  414  -414  1988/06
• 104 レクチンを用いた腫瘍マーカーの検討(第3報) : 肺癌細胞診への臨床応用

  米田 尚弘; 鴻池 義純; 福岡 和也; 堅田 均; 成田 亘啓  肺癌  27-  (5)  482  -482  1987/09
• 示-151 腫瘍熱を呈しナプロキセン有効な肺癌患者のPGE_2の検討

  堅田 均; 渡辺 裕之; 三笠 桂一; 鴻池 義純; 西川 潔; 吉岡 真理子; 吉田 恵里; 福岡 和也; 前田 光一; 成田 亘啓  肺癌  27-  (5)  611  -611  1987/09
• Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells.(共著)

  Lung Cancer (IASLC)  (in press)-

Awards & Honors

• 2008/10 第46回日本癌治療学会総会 優秀演題賞
   悪性胸膜中皮腫に対する胸膜肺全摘除術前導入化学療法の現状と展望 

  受賞者: 福岡 和也
• 2007/06 学校法人 兵庫医科大学 平成18年度第4学年次 学生が選ぶベストティーチャー賞
   

  受賞者: 福岡 和也
• 2006/12 第47回日本肺癌学会総会 優秀ポスター賞
   悪性胸膜中皮腫に対するCDDP+CPT-11+DXR併用化学療法のPilot phase II study 受賞者 福岡 和也 

  受賞者: 福岡 和也

Research Grants & Projects

• Based on the experience of 8,000 cases multiomics analysis, research on patient reduction of whole genome analysis

  日本医療研究開発機構(AMED)：革新的がん医療実用化研究事業

  Date (from‐to) : 2021/04 -2023/03
• Development of an education program utilizing hands-on training to train experts with outstanding knowledge and skills on lung cancer biomarker testing

  Pfizer：Pfizer Global Medical Grants

  Date (from‐to) : 2020/10 -2022/08 

  Author : Chikara Hirase; Yasuhiro Kidera; HIroto Shimano; Kazuto Nishio; Kazuko Sakai; Masayuki Takeda
• Development of remote learning method utilizing AR (Augmented Reality) in the field of university and graduate school education

  Kindai University：令和２年度“オール近大”新型コロナウイルス感染症 対策支援プロジェクト

  Date (from‐to) : 2020/07 -2021/02 

  Author : Kazuto Nishio; Yoshihiro Yamaguchi
• Development of a novel treatment targeting cancer stem cells for malignant pleural mesothelioma

  Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

  Date (from‐to) : 2015/04 -2018/03 

  Author : FUKUOKA Kazuya

   

  Malignant pleural mesothelioma (MPM) is an aggressive and highly-refractory tumor caused by asbestos exposure. To date, the standard treatment for MPM remains to be established. In the present study, to explore the gene mutations for the targets of molecular targeted therapy against MPM, we performed the gene expression analyses using next-generation sequencer. Of the gene mutations which were commonly identified in both MPM cell lines and pleural tumor tissues, NOTCH1, FBXW7, TSC1, and BRCA2 might be novel targets for molecular targeted therapy. NOTCH1 and FBXW7 are involved in survival and proliferation of cancer stem cells (CSCs). TSC1 and BRCA2 are causing genes of other genetic malignancies, on which existing molecular targeted agents show the anti-tumor activities. The present study indicated that these genes and CSCs can be applied for the promising targets of novel molecular targeted therapy against MPM.
• Research on the Establishment of Multidisciplinary Treatment Methods for Resectable Malignant Pleural Mesothelioma

  厚生労働省：厚生労働科学研究費補助金(厚生科研費)

  Date (from‐to) : 2011/04 -2014/03
• Comprehensive Approach to Asbestos-Related Diseases

  科学技術振興機構(JST)：科学技術戦略推進費（旧：科学技術振興調整費）

  Date (from‐to) : 2006/04 -2011/03
• Detection of frequent genomic deletions in malignant mesothelioma cells

  Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

  Date (from‐to) : 2008 -2010 

  Author : TAMAOKI Tomoko; TSUJIMURA Toru; NAKANO Takashi; FUKUOKA Kazuya; MORINAGA Tomonori; YOSHIKAWA Reigetsu; SAITO Yuko; YOSHIKAWA Yoshie

   

  Malignant mesothelioma(MM) is an asbestos-related tumor. Array-based CGH was performed using MM primary-cultured cells established in Hyogo College of Medicine(HCM). In HCM-MM cell samples, frequent deletions were detected in 1p, 3p21, 4q, 9p21, 16p13 and 22q. We also used ATCC and Riken MM cells. All 21 MM cells showed homozygous deletions in the 9p21 region carrying the CDKN2A/p16 and CDKN2B/p15 genes. Homozygous or heterozygous deletions in the 22q region carrying the NF2 gene were detected in 80% of HCC-MM cells, and deletions in 3p21.1-21.31 in 50%. We focused on the 3p21 region because it was specific to the epithelioid type. Since 3p21.1 and 3p21.31 regions contain Semaphorin family genes that inhibit VEGF activity, we analyzed gene expression profiles and found that lower expression of several SEMA genes and higher expression of VEGFA in epithelioid MMs than in Met5a, a normal mesothelial cell line, suggesting that VEGFA biological activity may be higher in epithelioid MMs. Genome alterations of BAP1, located in 3p21.1, was detected in 15 of 16 epithelioid MMs ; biallelic deletions or monoallelic deletions with or without mutations. Immunostaining with anti-BAP1 antibody showed negative nuclear staining in most of epithelioid MMs. These BAP1 mutations and deletions were somatic, since no germinal mutations were detected. These results showed that BAP1 mutation plays a significant role in the pathogenesis of epithelioid MMs.
• 肺癌に対する分子標的治療に関する基礎的研究
• Study on Expression of Carbohydrate Autigens on Lung Cancer Tissue
• Basic Research on Target-based therapy for Lung Cancer
• Clinical Research on Chemotherapy and Radiotherapy for Lung Cancer

Other link

researchmap

https://researchmap.jp/kazu0125